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Summary  V 
Summary 
Cancer is one of the top causes of mortality and morbidity despite our medical 
advances, thus new therapeutic concepts are needed. Solid tumors are composed of 
malignant cells within a tumor stroma. This microenvironment has become focus of 
ongoing cancer therapy research. Engineered versions of mesenchymal stem cells 
(MSCs) using suicide genes are a new approach under development for the therapy 
of solid tumors. 
MSCs are multipotent progenitor cells residing in many tissues including the bone 
marrow and play an important role in tissue homeostasis as well as wound healing. 
The signals produced by a solid tumor resemble those from chronic non-healing 
wounds. Thus, MSCs show a natural tropism for solid cancers and act as progenitors 
for many of the cell types that make up the tumor stroma. These characteristics have 
been exploited in a Trojan horse-like approach to deliver exogenously administered 
MSCs carrying anticancer agents (e.g. suicide genes) into the tumor environment. 
After homing into the tumor, MSCs are activated by tumor signals. These signals can 
also be used to selectively activate specific gene promoters to focus the gene trans-
cription of suicide genes to the tumor leaving other tissues relatively unaffected. To 
date, the RANTES/CCL5 promoter has been the most effective tumor-specific 
promoter. The general approach, which uses the herpes simplex virus thymidine 
kinase (HSV-TK) in combination with ganciclovir as a suicide gene system, has 
advanced to clinical trials for progressed gastrointestinal tumors.  
Our laboratory has recently developed a new MSC-based approach using the 
thyroidal sodium iodide symporter (NIS), which shows enhanced therapeutic 
efficiency through the active uptake of radionuclides and can also be used for dia-
gnostic purposes. The use of this gene system for non-thyroidal tumors requires pro-
tection of the thyroid gland from uptake of radionuclides by thyroid hormone pre-
treatment, which reduces NIS surface expression on thyroidal cells. In vivo experi-
ments have not shown adverse effects of this treatment, however the effects of this 
biology on MSC cells have not been examined in detail. Thyroid hormones affect 
cells long-term by modulating gene transcription (genomic) but there is also an action 
that occurs over the cell surface receptor integrin ανβ3 (non-genomic), which is ex-
pressed by MSCs.  
The rationale of this thesis was to find ways to maximize the therapeutic efficiency of 
engineered MSC-based cancer therapy when using the NIS gene. This included the 
characterization of the biologic mechanisms of thyroid hormones on MSC biology and 
further assessing a new tumor specific promoter targeting approach.  
The observation of especially aggressive, often therapy resistant and fast growing 
tumors like hepatocellular carcinoma (HCC), which still impose therapeutic challen-
ges, showing hypoxic areas led to the idea of hypoxia targeting. So far, these areas, 
where tumor growth outpaces neoangiogenesis had not been targeted by MSC 
based suicide gene therapy. To this end, an in house designed synthetic hypoxia 
responsive promoter was used to evaluate therapeutic efficiency in vitro in compar-
ison to RANTES/CCL5 promoter.  
Non-genomic thyroid hormone effects on MSC biology and therapeutic efficiency of 
the new targeting strategy were evaluated in vitro as well. Examination included 
effects on proliferation, differentiation, gene activation, migration and hypoxia res-
ponse system of MSCs. It was possible to distinguish effects on the tumor stroma 
versus direct effects on the tumor as used tumor cell line HUH7 (HCC derived) does 
not express integrin αβ3. 
Results of this thesis show significantly stronger activation of the new promoter under 
hypoxic conditions in vitro compared to the RANTES/CCL5 promoter, which does not 
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activate in hypoxia in vitro at all. Additionally MSCs carrying the hypoxia responsive 
promoter invade hypoxic areas of an in vitro tumor spheroid model and show hypoxia 
regulated gene activation therein. This provides sustainable proof that hypoxia 
targeting is a promising targeting strategy for MSC based suicide gene therapy. 
However, the synthetic hypoxia responsive promoter still shows limitations for in vivo 
use. It has the advantage of targeting hypoxic areas very specifically and efficiently 
while it does not activate in other areas of the tumor than hypoxic areas. The required 
tandem repeat build up to ensure specific targeting leads to instability in vivo. 
Therefore, the HIF1α-responsive promoter does not yet reach the level of therapeutic 
efficiency RANTES/CCL5 promoter shows in vivo even though it surpasses the level 
in vitro under hypoxic conditions. Moreover, the targeting of metastases remains to 
be evaluated. Nevertheless further research in the direction of hypoxia targeting 
seems to be promising as further results of this thesis show that non-genomic thyroid 
hormone effects upregulate hypoxia response and hypoxia regulated gene 
expression (e.g. VEGFa, IL6) in MSCs. In addition, this thesis provides proof that 
thyroid hormones enhance MSC chemotaxis and tumor homing in vitro over the 
integrin αβ3 pathway. These insights into the detailed mechanisms of thyroid hor-
mone effects on MSC biology imply that potential side effects by means of the thyroid 
hormone pretreatment are controllable and do not limit positive effects on therapeutic 
efficiency like upregulation of hypoxia response and enhancement of tumor homing. 
The findings also suggest that before any therapeutic use of MSCs in other thera-
peutic contexts it seems to be attractive to assess the patient´s thyroidal status and 
possible influence on the therapeutic efficiency.  
Further research is necessary to refine hypoxia targeting and increase therapeutic 
efficiency in vivo. The next step is to find a native and therefore in vivo stable, 
promoter responsive to hypoxia and other tumor signals, which is equally positively 
influenced by thyroid hormone treatment. This thesis reveals VEGFa and IL6 as 
possible candidates and further experiments beyond the scope of this thesis are 
already being conducted in this direction. 
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Zusammenfassung 
Krebserkrankungen sind trotz allen medizinischen Fortschrittes immer noch eine der 
Hauptursachen von Mortalität und Morbidität, sodass neue therapeutische Konzepte 
gebraucht werden. Solide Tumore bestehen aus malignen Zellen in einem Tumor-
stroma. Dieses Tumormikromilieu ist in den Fokus der laufenden Krebstherapie-
forschung gerückt. Derzeit werden gentechnisch veränderte mesenchymale Stamm-
zellen (MSC) entwickelt, die einen neuen Therapieansatz für solide Tumore dar-
stellen.  
MSCs sind multipotente Vorläuferzellen, die in vielen Geweben vorkommen unter 
anderem im Knochenmark und eine wichtige Rolle bei der Regulation der Gewebs-
homöostase und Wundheilung spielen. Die Signale, die ein solider Tumor produziert, 
ähneln denen chronischer, nicht verheilender Wunden. Daher zeigen MSCs eine 
natürliche zielgerichtete Migration in solide Tumore und dienen dort als Vorläufer für 
viele Zellarten des Tumorstromas. Diese Eigenschaften können genutzt werden, um 
extern verabreichte MSCs wie trojanische Pferde beladen mit Krebsmedikamenten 
(z.B. Suizidgenen) in den Tumor migrieren zu lassen. Nach Einwanderung in den 
Tumor werden MSCs von Tumorsignalen aktiviert. Diese Signale können auch 
genutzt werden um selektiv so genannte tumorspezifische Genpromotoren zu 
aktivieren und damit die Transkription von Suizidgenen auf den Tumor zu begrenzen. 
Somit bleiben andere Gewebe nahezu unbeeinträchtigt. Bisher ist der 
RANTES/CCL5 Promoter der effektivste tumorspezifische Promoter. Dieser Ansatz, 
der die Herpes Simplex Virus Thymidin Kinase (HSV-TK) in Kombination mit Gan-
ciclovir als Suizidgensystem nutzt, wird bereits in klinischen Studien bei fortge-
schrittenen gastrointestinalen Tumoren untersucht.  
In unserem Labor wurde vor kurzem ein neuer MSC-basierter Ansatz entwickelt, der 
den thyreoidalen Natrium-Iodid-Symporter (NIS) nutzt, welcher verbesserte thera-
peutische Effizienz zeigt durch die aktive Aufnahme von Radionukliden und auch für 
diagnostische Zwecke verwendet werden kann. Der Einsatz dieses Gens für nicht-
thyreoidalen Krebs erfordert jedoch den Schutz der Schilddrüse vor Aufnahme von 
Radionukliden. Dies wird durch Vorbehandlung mit Schilddrüsenhormonen erreicht, 
welche die Oberflächenexpression von NIS auf thyreoidalen Zellen verringert. Erste 
in vivo Experimente zeigten keine nachteiligen Effekte der Behandlung, jedoch 
wurden bisher die Effekte auf MSC Zellen nicht im Detail untersucht. Schilddrüsen-
hormone beeinflussen Zellen langfristig durch Modulation der Gentranskription (ge-
nomisch), aber es gibt auch Effekte vermittelt durch den Zelloberflächenrezeptor 
Integrin ανβ3 (nicht-genomisch), der von MSCs exprimiert wird.  
Der Grundgedanke dieser Arbeit war es, die therapeutische Effizienz der MSC-
basierten Krebstherapie, insbesondere bei Nutzung von NIS, zu maximieren. Dies 
beinhaltete einerseits die Charakterisierung der biologischen Effekte von Schild-
drüsenhormonen auf die Biologie der MSCs sowie die Evaluation eines neuen tumor-
spezifischen Promoters für das Targeting. 
Die Beobachtung, dass vor allem aggressive, oft therapieresistente und schnell 
wachsende Tumore wie das Hepatozelluläre Karzinom (HCC), die immer noch eine 
therapeutische Herausforderung darstellen, große hypoxische Areale aufweisen, 
führte zur Idee des Hypoxie-gerichteten Targetings. Bisher wurden diese Bereiche, in 
denen das Tumorwachstum schneller erfolgt als die Neoangiogenese, nicht gezielt 
angesteuert durch MSC-basierte Suizidgentherapie. Um das zu ändern wurde ein 
hausinterner, synthetischer Hypoxie-reagibler Promoter benutzt um die therapeu-
tische Effizienz in vitro im Vergleich zum RANTES/CCL5 Promoter zu evaluieren.  
Nicht-genomische Schilddrüsenhormoneffekte auf MSCs und auf die therapeutische 
Effizienz der neuen Targetingstrategie wurden ebenfalls in vitro untersucht. Die Un-
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tersuchung beinhaltete Effekte auf die Proliferation, Differenzierung, Genaktivierung, 
Migration und Hypoxieantwort in MSCs. Direkte Effekte auf Tumorzellen konnten von 
Effekten auf das Tumorstroma unterschieden werden durch Auswahl einer Integrin 
ανβ3-negativen HCC Tumorzellline (HUH7) als Tumormodell. 
Die Ergebnisse dieser Arbeit zeigen signifikant stärkere Aktivierung des neuen 
Promoters unter hypoxischen Bedingungen in vitro, während der RANTES/CCL5 
Promoter in vitro keine Aktivierung in Hypoxie zeigt. Zusätzlich wandern MSCs, die 
den Hypoxie-reagiblen Promoter tragen, in hypoxische Areale eines in vitro 
Tumorspheroidmodells ein und zeigen dort Hypoxie-regulierte Genaktivierung. Dies 
liefert den tragfähigen Beweis, dass Hypoxietargeting einen vielversprechenden 
Ansatz für die MSC-basierte Suizidgentherapie darstellt. Der synthetische Hypoxie-
reagible Promoter zeigt jedoch noch Limitierungen im in vivo-Gebrauch. Sein Vorteil 
besteht darin, dass er hypoxische Areale sehr spezifisch und effizient ansteuert, 
während er in anderen Tumorbereichen keine Aktivierung zeigt. Dies erfordert einen 
Aufbau im Sinne eines Tandem Repeats, welcher in vivo zu Promoterinstabilität führt. 
Eine Konsequenz davon ist, dass die Effizienz des HIF1α-reagiblen Promoters noch 
nicht das Effizienzlevel des RANTES/CCL5 Promoters in vivo erreicht, obwohl er ihn 
in vitro unter hypoxischen Bedingungen übertrifft. Weiterhin bleibt zu evaluieren, ob 
der neue Promoter auch Metastasen erreicht. Trotzdem scheinen weitere Nachfor-
schungen im Bereich des Hypoxietargeting vielversprechend zu sein, da weitere 
Ergebnisse dieser Arbeit zeigen, dass nicht-genomische Schilddrüsenhormonefffekte 
die Hypoxieantwort und Hypoxie-regulierte Genexpression (z.B. VEGFa, IL6) in 
MSCs hochregulieren. Zusätzlich liefert diese Arbeit Beweise, dass Schilddrüsen-
hormone über das Integrin αβ3 die MSC Chemotaxis und Einwanderung in Tumore 
in vitro verbessern. Diese Einblicke in die genauen Mechanismen der Schilddrüsen-
hormoneffekte auf die MSC Biologie implizieren, dass potentielle Nebenwirkungen 
durch eine Schilddrüsenhormonvorbehandlung kontrollierbar sind und die positiven 
Effekte auf die therapeutische Effizienz, wie die Hochregulierung der Hypoxieantwort 
und verbessertes Tumorhoming, nicht limitieren. Weiterhin deuten die Erkenntnisse 
darauf hin, dass vor jeglichem therapeutischen Einsatz von MSCs in anderen thera-
peutischen Feldern eine Untersuchung des Schilddrüsenstatus des Patienten und 
potenzieller Einflüsse auf die therapeutische Effizienz von Nutzen zu sein scheint.  
Weitere Forschung ist notwendig um das Hypoxietargeting zu verfeinern und die 
therapeutische Effizienz in vivo zu erhöhen. Der nächste Schritt ist, einen nativen, 
und daher in vivo stabilen, Promoter zu finden, der auf Hypoxie und weitere Tumor-
signale reagiert und gleichermaßen positiv beeinflussbar ist durch Schilddrüsen-
hormonvorbehandlung. Diese Arbeit zeigt VEGFa and IL6 als mögliche Kandidaten 
auf und weitere Experimente in diese Richtung über den Rahmen dieser Arbeit hin-
ausgehend werden bereits durchgeführt.      
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1. Introduction  
1.1. New approaches for cancer treatment 
Despite our medical advances, cancer still represents one of the leading causes of 
morbidity and mortality worldwide imposing an economic burden on healthcare 
systems (Rajab et al. 2013, Stewart 2014). Much effort has gone into the search for 
novel cancer treatments to replace or augment the established options of chemo-
therapy, surgery and radiotherapy. 
Particularly aggressive, often therapy resistant and fast growing solid tumors such as 
hepatocellular carcinoma (HCC) create therapeutic challenges. These neoplasias are 
composed of malignant cells within a tumor stroma. The tumor stroma has become 
the focus of ongoing cancer therapy research. Cell-based therapy represents one of 
the most promising new cancer treatment approaches. Engineered mesenchymal 
stem cells (MSCs) are currently under development as vehicles for the delivery of 
antitumor agents or suicide transgenes to reduce tumor load (Hagenhoff et al. 2016).  
HCC is a good model cancer for investigations in this direction. HCC is a solid, 
primary liver tumor, which generally occurs in the context of an underlying liver 
disease. It is one of the most common tumors and can be very difficult to treat. The 
main risk factor for HCC is liver cirrhosis, which also enhances the formation and 
growth of tumors elsewhere in the body (Yang et al. 2011, Heindryckx et al. 2015). 
When detected in early stages the five–year survival is above 50 percent (Lee et al. 
2006). Most of the time however, the cancer has already progressed and is largely 
therapy resistant. Therefore, new therapeutic approaches consider targeting the 
interactions between malignant cells and the tumor stroma.  
1.2. Role of MSCs within tumor microenvironments 
1.2.1. The importance of tumor stroma for tumor growth and progression 
MSC-based therapy targets the tumor stroma, which consists of supporting cells that 
include fibroblasts, endothelial cells, pericytes and lymphocytes. For each solid 
tumor, this microenvironment is vital for the survival and growth of neoplastic cells 
and it can influence malignancy and invasiveness (De Wever et al. 2003, Zischek et 
al. 2009). Tumor or cancer associated fibroblasts (TAF/CAF) play an important role in 
tumor biology. Spaeth et al. reported that MSCs originating from the bone marrow or 
from locally resident MSC populations can differentiate into TAF as a response to 
tumor-derived signals. (Spaeth et al. 2009)  
Exogenously administered MSCs are able to engraft into tumors and can contribute 
to tumor stroma (Hung et al. 2005). 
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Figure 1: MSC sources for tumor stroma: Local (a), distal or exogenous (b) MSCs are recruited to 
tumor stroma via tumor-derived cytokines, chemokines and growth factors. Subsequently, they 
differentiate e.g. into tumor-associated fibroblasts (TAF). Red arrows show regulatory interactions of 
tumor cells on MSC biology; dark blue arrows show cell movements and action of MSCs on tumor 
cells. [adapted from (Barcellos-de-Souza et al. 2013, Droujinine et al. 2013)] 
TAF produce diverse growth factors including HGF, IL6, VEGFa and TGFβ that 
strongly contribute to the formation of tumor stroma (Figure 1). They promote 
disordered, rapid tumor growth that is associated with an increased tumor 
aggressiveness and poor prognostic outcome (Yang et al. 2011). Furthermore, MSCs 
can promote metastases e.g. in breast cancer through the enhancement of metas-
tatic niches and the induction of mesenchymal to epithelial or epithelial to mesen-
chymal transition (Barcellos-de-Souza et al. 2013). For these reasons, the tumor 
stroma has become an important new target in the therapy of solid tumors (De Wever 
et al. 2003, Ahmed et al. 2008). 
In HCC, the stroma regulates malignant transformation, survival, progression and 
invasiveness (Yang et al. 2011, Heindryckx et al. 2015). It has been targeted by 
antibodies such as the antiangiogenic Bevacizumab (Heindryckx et al. 2015) or the 
hypoxia activated prodrug (Q6) (Liu et al. 2014). 
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Figure 2: MSC tumor promoting functions: (a) MSCs promote tumor cell proliferation and inhibit cell 
death. (b) MSCs promote angiogenesis within tumors. (c) MSCs inhibit some immune functions, while 
promoting others. (d) MSCs promote tumor metastasis. (e) MSCs may regulate cancer stem cell self-
renewal and differentiation. [adapted from (Droujinine et al. 2013)] 
1.2.2. Biology of human MSCs 
MSCs are referred to as mesenchymal stromal cells or marrow stromal cells (Horwitz 
et al. 2005, Salem et al. 2010). They are multipotent, non-hematopoietic progenitor 
cells that have the capacity of self-renewal and differentiation, thus supporting 
maintenance and remodeling in diverse tissues including the tumor stroma (Zischek 
et al. 2009, Niess et al. 2011, Maxson et al. 2012). As there are no single markers 
available to characterize MSCs, the International Society for Cellular Therapy has 
determined minimum criteria to characterize this heterogeneous cell population 
(Dominici et al. 2006): Human MSCs are plastic-adherent under standard culture 
conditions, they show expression of CD105, CD73 and CD90 and lack the 
hematopoietic markers CD34, CD45, CD14, CD19 and HLA-DR. Following the 
administration of specific stimuli, the cells are able to differentiate into osteocytes, 
adipocytes and chondrocytes in vitro. (Dominici et al. 2006, Salem et al. 2010)  
Within the scope of this thesis, human MSCs, isolated from the bone marrow of 
healthy donors, met the minimum criteria for human MSCs. Chondrogenic differen-
tiation was not explored individually for every isolate due to very complex experi-
mental set up and subordinate relevance to the topic. However, it can be assumed 
that untested samples are able to differentiate in this pathway as all other charac-
teristics match.   
While found in adult bone marrow, where MSCs reside in low frequency within 
hypoxic niches, they can also be isolated from adipose tissue, umbilical cord blood 
and other tissues such as brain, kidney and liver (Fritz et al. 2008).  
MSCs migrate into various healthy tissues such as secondary lymphatic tissue, 
spleen, gut, salivary gland, skin and lung as part of normal tissue homeostasis. While 
specific homing may occur, fine structure and microvessels are also thought to 
transiently entrap MSCs in lung, liver and spleen. (Hagenhoff et al. 2016) 
Chemokine and cytokine signaling recruit MSCs to sites of increased cell turnover, in 
general, and injuries in particular (Karp et al. 2009). The signals include CXCL12, 
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CX3CL1, CXCL16, CCL3, CCL19 and CCL21 (Salem et al. 2010). MSCs exoge-
nously applied show equally strong recruitment to sites of injury (Bao et al. 2012).  
The signals produced by a solid tumor resemble those of a chronic wound. It has 
been suggested that the body sees cancer as something like a “chronic injury that 
does not heal” (Dvorak 2015).  For this reason, MSCs show a strong, natural tropism 
for solid neoplasia and microscopic tumor lesions (Hung et al. 2005, Spaeth et al. 
2008, Dvorak 2015), which can be enhanced for example through stimulation with 
TNFα (Hagenhoff et al. 2016). 
MSCs’ immunoprivileged nature uniquely suites them as vehicles for cell-based 
cancer treatment. MSCs are reported to inhibit T-cell function and to be resistant to 
natural killer cell cytolysis (Bao et al. 2012). This is partly due to their lack of major 
histocompatibility complex II (MHC II) and helps make rejection issues rare (Rajab et 
al. 2013, Hagenhoff et al. 2016). 
The biosafety of MSCs has been examined and yielded controversial results regar-
ding the tumorigenic potential of MSCs (Lazennec et al. 2008, Hagenhoff et al. 
2016). This question needs to be further elucidated for the future clinical application 
of these cells. To date, only minor adverse effects have been seen in clinical trials 
(D’souza et al. 2015).  
1.2.3. Potential clinical application of MSCs in cancer therapy and other fields 
The clinical potential of MSCs has become evident over the last two decades and a 
wide field of applications (Reiser et al. 2005). MSCs are suitable vectors for the 
delivery of therapeutic agents in many different settings. Potential applications for 
MSCs include treatment of graft-versus-host disease, tissue repair including cerebral 
injury, bone fraction and myocardial infarction as well as muscular dystrophy (Spaeth 
et al. 2008). MSCs are also being evaluated in the treatment of renal disease, 
Crohn´s disease, osteogenesis imperfecta, amyotrophic lateral sclerosis (Salem et al. 
2010), acute lung injury, asthma, sepsis and multiple sclerosis (Dimarino et al. 2013, 
D’souza et al. 2015). MSCs have been tested for lymphatic regeneration (Conrad et 
al. 2009). The use of MSCs as vehicles for cell-based cancer therapy ranges among 
the most promising applications. MSCs show great potential to enhance tumor-
specificity and reduce side effects of therapies in comparison to conventional cancer 
treatments. 
1.2.4. Use of engineered MSCs as vehicles for cancer therapy  
The tumors shown to recruit exogenously administered MSCs include gastrointestinal 
and gynecological neoplasia as well as gliomas, melanomas and sarcomas 
(Hagenhoff et al. 2016). Various approaches have been developed to target tumor 
stroma therapeutically via MSC-based delivery of anticancer agents. Among these 
agents are immune-modulating agents like Interferon β (Studeny et al. 2004), 
cytotoxic agents or growth factor antagonists like TRAIL (Grisendi et al. 2015). 
Combiningthis approach with radiation therapy increases the therapeutic efficiency of 
MSC-based therapeutic concepts (Hagenhoff et al. 2016).  
When MSCs are recruited to the tumor microenvironment containing cytokines, 
chemokines and growth factors, the milieu initiates a specific response in the MSCs 
to these signals. MSCs can differentiate into fibroblasts or enhance angiogenesis 
depending on the needs of the tumor and in this way can promote tumor growth 
(Spaeth et al. 2009). While on the surface this appears to limit their potential utility as 
therapeutic vehicles, their natural ability to penetrate deeply into tumor 
microenvironments can be exploited in a “Trojan horse”-like (Bao et al. 2012) therapy 
approach. The differentiation can be used to activate specific gene promoters and 
thus, the expression of transgenes can be largely limited to the tumor stroma (Conrad 
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et al. 2007). This can act to limit potential side effects of the therapy as intravenously 
administered MSCs can also home into healthy tissues (Bao et al. 2012). 
The combination of tumor tropism and the capacity to differentiate make MSCs  a 
potentially efficient system for the delivery of suicide gene systems into tumors 
(Rajab et al. 2013). 
The suicide gene systems evaluated to date include: cytosine deaminase combined 
with 5-FU (5-Fluorouracil), carboxyl esterase with irinotecan (CE/CPT-11), varicella 
zoster virus thymidine kinase with 6-methoxypurine arabinonucleoside (Vzvtk/Aram), 
nitro-reductase (Nfsb) with 5-Aziridinyl-2,4-dinitrobenzamide (NTR/CB1954) and 
carboxy-peptidase G2 with CMDA (CPG2/CMDA) (Rajab et al. 2013). These systems 
have been evaluated in experimental glioblastoma multiforme (Sasportas et al. 
2009), mesothelioma, gastrointestinal cancer, prostate cancer and gynecologic 
cancers (Rajab et al. 2013). 
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Figure 3: A) Tissue specific MSC differentiation: MSCs are able to differentiate in response to 
tissue-specific cytokine-, chemokine- and growth factor-signals in tissues. For example, tumor-derived 
signals initiate the differentiation into pericytes or fibroblasts. B) Tumor-specific expression of 
engineered genes in MSCs: The concept of MSC-based cancer therapy (“Trojan horse” concept) 
makes use of MSCs´ natural tumor tropism and ability to differentiate. Consecutively, tumor specific 
promoters drive the activation of target genes and limit effects to cancerous sites. [B) adapted from 
(Bao et al. 2012)] 
The research in our group that preceding this thesis made use of another enzyme, 
the Herpes Simplex Virus Thymidine Kinase (HSV-TK) in combination with gancic-
lovir. Various gene promotors were evaluated in vitro and in vivo (mouse model) in 
different tumor settings with this suicide gene system. An approach by Conrad et al. 
targeted tumor angiogenesis selectively by making use of MSC differentiation in 
response to angiogenic signals. Applying MSCs engineered with the Tie2 enhancer 
controlling HSV-TK in a syngeneic, orthotopic pancreatic cancer mouse model led to 
gene activation almost exclusively at sites of neoangiogenesis within the tumor. MSC 
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therapy combined with ganciclovir treatment significantly decreased primary tumor 
growth and prolonged life span.(Conrad et al. 2011)  
The cytokine CCL5 is induced during the differentiation of MSC into TAF inside the 
tumor stroma (Rajab et al. 2013). This biology was used in a second approach by 
Zischek et al. MSCs were engineered with the HSV-TK under control of a 
RANTES/CCL5 promoter. In an orthotopic pancreatic cancer mouse model, and a 
spontaneous breast cancer mouse model, effects on tumor growth and tumor 
metastases were evaluated. Results showed a significant reduction of tumor growth 
and incidence of metastases as well as prolongation of life span in both models. 
(Zischek 2011) 
The direct comparison of the effectiveness of the Tie2 promoter with the 
RANTES/CCL5 promoter in an orthotopic HCC mouse model, suggested that the 
CCL5 targeting was more effective, while effects on tumor growth were equal (Niess 
et al. 2011). The RANTES/CCL5 protocol has now advanced into phase II of clinical 
trial (Niess et al. 2015). 
In the next generation of experiments, we have sought to enhance the effectiveness 
of the concept by making use of a combined therapeutic and diagnostic (theranostic) 
gene, the sodium iodine symporter (NIS). An initial study by Knoop et al. in a HCC 
xenograft mouse model showed that MSCs engineered with the NIS gene 
constitutively expressed (CMV promoter) effectively homed to the tumor. Treatment 
with 131I application significantly delayed tumor growth. (Knoop et al. 2011)  
To increase tumor-specificity of the concept Knoop et al. engineered MSCs with NIS 
gene under control of RANTES/CCL5 promoter. In the same HCC mouse model, 
tumor growth was significantly reduced and overall survival improved by MSC 
treatment in combination with 131I or 188Re application. (Knoop et al. 2013) In a 
metastatic colon cancer mouse model CCL5-NIS engineered MSCs were shown to 
home to liver metastases and with treatment reduced the level of metastases and 
tumor load (Knoop et al. 2015).  
When using NIS therapy for extra-thyroidal tumors, it becomes necessary to protect 
the thyroid gland from damage by uptake of radioactive iodine (Knoop et al. 2011). 
Pretreatment of experimental animals (or human patients) with thyroid hormones 
reduces the endogenous expression of NIS in the thyroid gland (Knoop et al. 2011) 
and ensures protection of the vital thyroidal tissue. 
1.3. Role of thyroid hormones in tumor microenvironments and 
MSC biology 
Thyroid hormones 3,3´,5-triiodo-L-thyronine (T3) and L-thyroxine (T4) help control the 
growth, differentiation and metabolism of many types of tissues and also play an 
important role in tumor stroma formation (Yen et al. 2006, Davis et al. 2011). 
 
Figure 4: Molecular structure of T3 and T4 (Davis et al. 2011) 
Originally, it was thought that T3 and T4 mediate their effects only through nuclear 
receptors. By binding to a heterodimeric nuclear thyroid hormone receptor (TR), T3 
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initiates genomic events (Bergh et al. 2005). The receptor trafficks into the nucleus 
and drives transcription of thyroid hormone responsive genes (Bergh et al. 2005). 
Circulating T4 has to be deiodinased first in order to become active (Bergh et al. 
2005).  
Within the last two decades, Davis et al. showed that thyroid hormones can also 
influence cell proliferation through an immediate mechanism. This “non-genomic” 
pathway can also alter gene expression (Davis et al. 2014a) and influence 
proliferative pathways including the growth of tumor stroma via upregulation of 
angiogenesis and tumor cell proliferation (Davis et al. 2014b, Cayrol et al. 2015). 
Moreover, it can downregulate apoptosis (Sharma et al. 2014, Straub 2014, Lin et al. 
2015). 
The effects of this second pathway are mediated by a cell surface receptor identified 
as integrin αβ3 (Davis et al. 2011). Integrin membrane receptors are a family of 
transmembrane glycoproteins that form noncovalent heterodimers transmitting 
signals from the extra cellular matrix to the cytosol (Bergh et al. 2005, Cody et al. 
2007). The cells expressing integrin αβ3  include endothelial cells, vascular smooth 
muscle cells, osteoclasts and most cancer cells (Davis et al. 2009). The receptor 
contains two different binding sites. The first controls mainly cell proliferation, and 
binds T3 and T4 (Davis et al. 2014b). It activates the mitogen-activated protein 
kinase (MAPK respectively ERK1/2) pathway downstream, which plays an important 
role in the induction of angiogenesis (Davis et al. 2014b).  
The second site binds T3, and activates phosphatidylinositol 3-kinase (PI3K), which 
influences angiogenesis, tumor cell division, and drives the transcription of HIF1α, 
the main regulator of hypoxia response system (Hiroi et al. 2006, Patiar et al. 2006, 
Davis et al. 2009, Davis et al. 2014b). In addition, PI3K activation mediates a 
normoxic upregulation of HIF1α (Moeller et al. 2005) and promotes cancer cell 
proliferation, apoptosis, migration and invasion (Kim et al. 2013b). PI3K signaling has 
also been linked to pluripotency in somatic cells making it possible to cultivate 
induced pluripotent stem cells (Chen et al. 2012). 
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Figure 5: Overlap of non-genomic and genomic thyroid hormone effects. Integrin αβ3 receptor 
domains and downstream effects including upregulation of HIF1α: Genomic pathway (blue) 
initiated by T3 (or deiodinased T4) leading to transduction of constitutively expressed TRβ1 into 
nucleus driving gene expression and protein synthesis e.g. in cell proliferation and angiogenesis. Non-
genomic pathway (purple) initiated at α or β3 integrin receptor domain activating either PI3K or 
MAPK (ERK1/2). Downstream effects include transduction of TRα into nucleus, upregulation of 
hypoxia responsive genes including VEGFa and EGF-R, as well as transduction of TRβ1 into nucleus, 
which lead to activation of angiogenesis and tumor cell proliferation. [adapted from (Fujita et al. 2007, 
Davis et al. 2011, Hammes et al. 2015)] 
Based on these diverse effects integrin αβ3 has become strategically important as a 
target for anticancer therapies. Tetraiodothyroacetic acid (Tetrac), a deaminated T4 
derivative, is an inhibitor of the integrin αβ3 (Davis et al. 2014b). This inhibition 
alters gene transcription within the cell including VEGFa, EGFR, MMP9 and HIF1α 
genes (Davis et al. 2014b). Furthermore, it induces radiosensitization and 
chemosensitization of cancer cells (Davis et al. 2014b). 
 
Figure 6: Molecular structure of Tetrac (Davis et al. 2011) 
In addition to proliferation and angiogenesis, thyroid hormones also influence the 
invasiveness and migratory capacities of tumor cells by signaling via integrin αβ3 
(Cohen et al. 2014). In general, integrin receptors play an important role in the 
adhesion and migration of many cells e.g. leucocytes (Fox et al. 2007). MSCs and 
fibroblasts use these cell surface molecules likewise (De Wever et al. 2003, Fox et al. 
2007, Salem et al. 2010). 
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Figure 7: Role of integrin receptors in MSC recruitment and tumor homing: Although the mecha-
nisms of MSC homing are poorly understood, they likely involve partially overlapping steps of 
deceleration in the blood flow, rolling, adhesion, transmigration through the endothelium, and migra-
tion into surrounding tissues. The possible molecular determinants are indicated. Integrin receptors 
play an important role in MSC adhesion. [adaped from (Droujinine et al. 2013)] 
1.4. MSCs as vehicles for cancer therapy: Hypoxia as possible new 
mechanism for selective transgene induction  
Aggressive and rapidly growing solid tumors like HCC contain a hypoxic 
microenvironment due to their fast growth outpacing simultaneous growth of 
vascularization. Hypoxia fuels treatment resistance to conventional cancer therapy as 
well as upregulation of epithelial mesenchymal transition (EMT) markers, which is 
associated with a poor prognosis (Gammon et al. 2013, Casazza et al. 2014, Liu et 
al. 2014). In addition, tumor hypoxia strongly induces expression of the hypoxia 
induced transcription factors (HIFs), which leads to downregulation of adhesion 
molecules potentially promoting metastases (Chaturvedi et al. 2013). Hypoxia also 
leads to increased angiogenesis and contributes to a metabolic shift from aerobic to 
anaerobic metabolism by glycolysis (Vaupel 2004). Summing up, hypoxia promotes 
transcription of genes that are crucial to cancer development (Figure 4). Affected are 
angio-genesis, cell survival, glucose metabolism and invasion (Semenza 2003). 
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Figure 8: Circle of tumor hypoxia: Promotion of tumor growth, invasion and metastases 
[adapted from (Vaupel 2004)] 
These observations led to the idea of selectively directing MSC-based gene therapy 
into hypoxic areas within the tumor. 
A key player in adaptation to changing oxygen levels is expression of the 
transcription factor HIF1 (Liu et al. 2012), a heterodimeric protein composed of the 
constitutively expressed β subunit, also named aryl-hydrocarbon receptor nuclear 
transporter (ARNT), and the α subunit, whose expression is regulated by intracellular 
oxygen levels (Figure 5). Both are basic helix-loop-helix transcription factors that bind 
to hypoxia responsive elements (HRE) within the promoters of hypoxia-regulated 
genes (Liu et al. 2012). The α subunit contains an oxygen-dependent degradation 
domain as well as two transactivation domains, which allow the hypoxia-dependent 
stabilization or oxygen-dependent degradation by hydroxyllation and ubiquitination 
via the proteasome pathway under normoxic conditions (Liu et al. 2012). In addition 
to effects that occur after several hours, more rapid responses occur on the 
posttranslational level, or through membrane depolarization (Bruick 2003).  
Approximately 90% of all known cancers are solid tumors (Vaupel 2004). The 
hypoxic microenvironment represents an important therapeutic target. For example, 
HIF1α inhibitors (Patiar et al. 2006), HIF1α stability suppressors (Kim et al. 2013a) or 
hypoxia activated prodrugs such as Q6 are currently being used. Q6 significantly 
reduces proliferation under hypoxic conditions, and induces caspase-dependent 
apoptosis in HCC cell lines (Liu et al. 2014).  
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Figure 9: Hypoxia response system: HIF1α is the central regulator of the hypoxia response. It forms 
heterodimers with constitutively expressed HIF1β subunit and subsequently activates hypoxia 
responsive elements (HREs) of HIF1-responsive genes. HIF1α expression is regulated by intracellular 
oxygen level. Dependent on oxygen supply HIF1α underlies hydroxylation by prolyl hydroxylases 
(PHDs). This allows binding of von Hippel-Lindau tumor suppressor protein (VHL) and subsequent 
targeting for ubiquitination and proteasomal degradation. [adapted from (Kizaka-Kondoh et al. 2009)] 
Oxygen levels play an important role in the life cycle of MSCs. These cells reside in 
hypoxic perivascular niches, mainly located in the bone marrow, and are reported to 
show a normoxic stabilization of HIF1α, which allows them to have an alternate 
energy metabolism (Palomaki et al. 2013). Additionally, it has been reported that 
hypoxia contributes to MSC tumor tropism as it promotes the inflammatory signals 
emitted by the tumor (Spaeth et al. 2008) as well as MSC adhesion and 
transmigration (Hagenhoff et al. 2016). Consequently, the circulating pool of MSCs 
increases under hypoxic conditions (Salem et al. 2010). Hypoxia also leads to the 
upregulation of CXCL12 within the tumor (Hagenhoff et al. 2016). Activated MSCs 
can express the receptor for this chemokine (CXCR4). This ligand-receptor 
interaction is thought to be one of the most important factors influencing MSC 
migration (Hagenhoff et al. 2016). 
Thyroid hormones have been proposed to enhance the hypoxia response of MSCs 
by the upregulation of HIF1α (Figure 5), leading to an enhancement of the 
effectiveness of hypoxia targeted MSC-based NIS-therapy.  
1.5. Rationale of this study 
This study focused on ways to maximize the therapeutic efficiency of MSC cancer 
therapy based on use of the theranostic NIS gene product.  
The use of NIS-based therapy for non-thyroidal tumors requires the establishment of 
a hyperthyroid status to protect the thyroid gland from damage. Non-genomic thyroid 
hormone effects caused by this metabolic state including upregulation of hypoxia 
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response can alter effectiveness of MSC-based cancer therapy, as the thyroid 
hormone receptor integrin ανβ3 is expressed by MSCs.  
As described above, the choice of gene promoter used to drive the therapy 
transgene can make MSC-based gene therapy more tumor-specific. With the goal of 
identifying new tumor-specific promoters, we focused on making use of the biology 
driving hypoxic areas within aggressive, therapy resistant and rapidly growing solid 
tumors like HCC. To this end, we sought to evaluate a synthetic hypoxia responsive 
promoter with regards to effectiveness of gene activation inside the tumor milieu, as 
well as the applicability to target hypoxic areas in tumors. Secondly, the potential 
non-genomic influence of thyroid hormones on MSC biology in the context of tumor 
stroma, and the effectiveness of the new targeting approach, was assessed in vitro. 
The effects of these factors on MSC proliferation, differentiation, gene activation, 
chemotaxis and hypoxia response system were examined.  
1.6. Specific aims and scope 
To study in detail a hypoxia-based protocol for MSC gene therapy and to compare its 
general efficiency with the current RANTES/CCL5 protocol, the potential tumor-
specificity of gene activation was evaluated, and potential influences of thyroid 
hormone treatment on MSC biology that might alter the efficiency of the therapy were 
assessed. The scope of this study was directed toward the following specific aims:  
 Evaluation of synthetic HIF1α-responsive promoter as tumor-specific  
  promoter: 
 Evaluation of HIF1α protein levels in MSCs under different oxygen 
conditions. 
 Comparison of HIF1α- and RANTES/CCL5-driven reporter gene 
activation in hypoxia and normoxia. Evaluation of potential tumor 
tropism and gene activation within tumor stroma.  
 Evaluation of non-genomic, integrin αβ3-mediated thyroid hormone effects on 
MSC biology: (Tetrac, integrin αβ3-inhibitor, was used to confirm pathway ) 
 Evaluation of non-genomic thyroid hormone effects on MSC hypoxia 
    response. 
- Influence on HIF1α protein levels in MSCs under different oxygen 
conditions.  
- Influence on reporter gene activation of HIF1α- and CCL5-driven 
reporter genes.  
- Influence on mRNA levels of HIF1α regulated genes in MSCs.  
 Examining effects of thyroid hormones on MSC chemotaxis and 
chemokinesis. 
 Examining potential thyroid hormone effects on MSC proliferation.  
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2. Materials and Methods 
2.1. Materials  
2.1.1. Cell culture 
2.1.1.1. Media and supplements, dyes and other reagents 
Media  
Dulbecco´s Modified Eagle Medium 
(DMEM), 10x (#D2429) 
Sigma-Aldrich, St. Louis 
Dulbecco´s Modified Eagle Medium 
(DMEM), 1g glucose, GlutaMAX™ 
supplement, pyruvate (# 21885-025) 
GIBCO ™, Thermo Fisher Scientific Inc., 
Waltham 
F12 Nut Mix Ham, L-Glutamine (# 21765-
029) 
GIBCO ™, Thermo Fisher Scientific Inc., 
Waltham 
MEM α-medium, GlutaMAX™ supplement, 
no nucleosides (#32561-029) 
GIBCO ™, Thermo Fisher Scientific Inc., 
Waltham 
RPMI 1640, GlutaMAX™ supplement 
(#61870-150) 
GIBCO ™, Thermo Fisher Scientific Inc., 
Waltham 
RPMI, 10x (#R1145) Sigma-Aldrich, St. Louis 
RPMI 1640 without phenol red (#11835-
063) 
GIBCO ™, Thermo Fisher Scientific Inc., 
Waltham 
 
Supplements 
2-Mercaptoethanol (2-ME) 99% p.a. Carl Roth GmbH, Karlsruhe 
3,3´,5-triiodo-L-thyronine (T3) sodium salt Sigma-Aldrich, St. Louis 
Blasticidin (#ant-bl-1), 10mg/ml Invitrogen, Toulouse 
Bovine serum albumin  (BSA) Fraction V GIBCO ™, Thermo Fisher Scientific Inc., 
Waltham 
β-GP-glycerophosphate disodium salt 
hydrate (in house solution 5g/l in aqua dest.) 
(#G9891) 
Sigma-Aldrich, St. Louis 
BSA fraction V GIBCO ™, Thermo Fisher Scientific Inc., 
Waltham 
Cobalt(II)chloridehexahydrate (CoCl2)  Sigma-Aldrich, St. Louis 
Dexamethasone powder (#D4902) Sigma-Aldrich, St. Louis 
Fetal calf serum (FCS) Biochrom AG, Berlin 
Heparin Ratiopharm, Ulm 
HEPES 1M (4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid ) 
GIBCO ™, Thermo Fisher Scientific Inc., 
Waltham 
G418-BC 50mg/ml Biochrom AG, Berlin 
Indomethacin (#I7378) Sigma-Aldrich, St. Louis 
Insulin solution, human (#I9278) Sigma-Aldrich, St. Louis 
3-isobutyl-1-methylxanthine (IBMX) (#I7018) Sigma-Aldrich, St. Louis 
L-Ascorbic acid -2-phosphate Sigma-Aldrich, St. Louis 
L-Glutamine Biochrom AG, Berlin 
L-Thyroxine sodium salt pentahydrate (T4) Sigma-Aldrich, St. Louis 
NaOH 1M Merck, Grafing 
Penicillin/Streptomycin (P/S), 100x PAA-Laboratories, Pasching 
Sodiumhydrogencarbonat (NaHCO3)  GIBCO ™, Thermo Fisher Scientific Inc., 
Waltham 
Stripped fetal calf serum (sFCS) produced in house 
Tetrac 100µM  Provided by Prof. Spitzweg, Med. Klinik und 
Poliklinik II, Klinikum Großhadern, München 
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Platelet concentrate Blood bank of Städtisches Krankenhaus 
Schwabing, München 
Trypsin 0.05%/EDTA 0.02% in PBS Pan Biotech, Aidenbach  
2-Mercaptoethanol (2-ME) 99% p.a. Carl Roth GmbH, Karlsruhe 
 
Dyes 
Alizarin-Red Sigma-Aldrich, St. Louis 
Nuclear fast red Carl Roth GmbH, Karlsruhe 
Oil-Red-O Sigma-Aldrich, St. Louis 
Trypan blue Sigma-Aldrich, St. Louis 
Bromphenol blue Carl Roth GmbH, Karlsruhe 
Rox Reference dye (RNA) (12223-012) Thermo Fisher Scientific, Waltham 
 
Other chemicals 
Collagen I 5mg/ml Bovine Protein GIBCO ™, Thermo Fisher Scientific Inc., 
Waltham 
Dimethylsulfoxide (DMSO) Merck, Darmstadt 
Dulbecco´s Phosphate buffered salt solution 
(PBS) without Ca2+ or Mg2+, 1x/10x 
Pan Biotech, Aidenbach 
Lipofectamine 2000 DNA transfection 
reagent 
Invitrogen, Carlsbad 
MTT powder (Thiazolyl Blue Tetrazolium 
Bromide) 
Sigma-Aldrich, St. Louis 
Poly HEMA Sigma-Aldrich, St. Louis 
2.1.1.2. Cell lines and primary cells 
Cell line Description Source Medium Supplements 
L87, adherent Clonal, human 
bone marrow 
derived MSC 
cell line 
In house RPMI 1640 
with 
GlutaMAX™ 
10%sFCS, 1%P/S 
MSC09, adherent 
 
Polyclonal, 
human bone 
marrow 
derived, 
immortalized 
with pIRES 
EGFP-SV40  
Extracted from bone 
marrow donations of 
healthy donors provided 
by AKB Gauting 
DMEM with 
GlutaMAX™ 
10%sFCS, 1%P/S 
hBMSC120809/1
20503/140826/ 
120814, 
adherent 
 
Primary, 
polyclonal, 
human bone 
marrow 
derived MSC 
Extracted from bone 
marrow donations of 
healthy donors provided 
by AKB Gauting 
DMEM with 
GlutaMAX™ 
10%sFCS, 1%P/S 
5% platelet 
concentrate 
(~5x107 
thrombocytes/ml),  
1000IEHeparin 
Ap00172_1, 
adherent 
Primary, 
polyclonal, 
human bone 
marrow 
derived MSC 
Extracted by Apceth 
GmbH, München from 
bone marrow donations 
of healthy donors 
provided by AKB 
Gauting 
DMEM with 
GlutaMAX™ 
10%sFCS, 1%P/S 
5% platelet 
concentrate 
(~5x107 
thrombocytes/ml), 
1000IEHeparin 
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HUH7, adherent Human 
hepatocellular 
carcinoma cell 
line 
Provided by Prof. 
Spitzweg, 
Medizinische 
Klinik und 
Poliklinik II, 
Klinikum 
Großhadern, 
München (from 
JRCB Cell bank, 
Osaka, Japan)  
DMEM with 
GlutaMAX™ and 
HAM F12, ratio 
1+1 
10% FCS/sFCS,  
1% P/S 
HT29, adherent Human colorectal 
adenocarcinoma 
cell line 
Present by Prof. 
Griffeon, 
Maastricht, 
Netherlands 
DMEM with 
GlutaMAX™ 
10% FCS,  1% 
P/S 
All primary bone marrow derived MSCs  used within the scope of this thesis were iso-
lated from human bone marrow donations by healthy male volunteers obtained at the 
Stiftung Aktion Knochenmarksspende Bayern Gauting (Robert-Koch-Allee 7, 82131 
Gauting). The contact and consent by the ethics committee was obtained by PD Dr. 
Dr. med. Irene Teichert von Lüttichau (Kinderklinik München Schwabing).  
All specimens were obtained by informed consent and according to protocols ap-
proved by institutional ethics committees.  
Information about donors: 
Name of cell line Isolation date Donor Health status 
Ap00172_1 28.08.2014 Male, 37 yrs Healthy 
hBMSC140826 26.08.2014 Male, 24 yrs Healthy 
hBMSC120809 09.08.2012 Male, 42 yrs Healthy  
hBMSC120503 03.05.2012 No information Healthy  
hBMSC120814 14.08.2012 Male, 25 yrs  Healthy  
After isolation in house, or by Apceth GmbH (Munich, Germany) modified after the 
Tübinger method (2.2.1.4.), primary human bone marrow derived CD34 negative 
MSCs were characterized with standard laboratory procedures according to the 
minimal cri-teria for MSCs released by the international society for cellular therapy in 
passage three to five (Dominici et al. 2006). (for methods used, see 2.2.1.5.) 
All isolated primary human mesenchymal stem cells used within the scope of this 
thesis met the following minimum criteria: 
 Plastic adherence (Figure 10A)  
 FACS-profile: (data not shown) 
negative for: CD14, CD19, CD34, CD45, HLA-DR  
positive for: CD73, CD90, CD105  
 Adipogenic and osteogenic differentiation 
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A)                                       B)                                       C) 
         
Figure 10: MSCs showing adipogenic (after 20 days) and osteogenic (after 12 days) differen-
tiation: A) Undifferentiated MSCs showing plastic adherent growth pattern. B) Osteogenic differen-
tiated MSCs stained with Alizarin Red. C) Adipogenic differentiated MSCs stained with Red Oil. 
After isolation, cells were sometimes immortalized by transfection with plasmid 
pIRES-EGFP-SV40 in passage three or four (2.2.1.10.). Immortalized MSCs 
appeared to retain characteristics of primary MSCs (FACS profile, differentiation, 
plastic adherence; data not shown). For all experiments immortalized MSCs 
passaged five to ten times, and primary MSCs passaged two to seven times were 
used. 
The MSC cell line L87 is a SV40 immortalized human bone marrow derived MSC cell 
lines that retains important characteristics of MSCs (Thalmeier et al. 1994, Conrad et 
al. 2008). This cell line was used to establish experimental conditions before 
performing experiments with primary MSCs. Immortalized MSCs were used only for 
Luciferase reporter gene assays as the experimental setup was too challenging for 
primary MSCs. Chemotaxis, invasion, western blot, qPCR, MTT-Assay experiments 
were performed using primary MSCs from different bone marrow donations.  
Integrin αβ3 characterization (Schmohl et al. 2015) 
The MSCs used in this thesis were shown to express integrin αβ3. This expression 
was not altered by thyroid hormone or Tetrac treatment. The HCC cell line HUH7 did 
not express integrin αβ3.  
2.1.2. Bacteria/Microbiology 
E.coli DH5α; Genotype:  supE44, ΔlacU169 (Φ80 lacZΔM15) hsdR17 recA1 endA1  
gyrA96 thi-1 relA1 
E.coli XL1-blue supercompetent cells for site-directed mutagenesis kit: Fermentas, 
St. Leon-Rot 
2.1.3. Buffers and solutions  
If not stated otherwise, all buffers were prepared in ultra-pure H2O.  
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2.1.3.1. SDS-PAGE and western blot 
Buffers and solutions produced in house: 
Ammoniumpersulfate (APS) 10% APS (w/v) 
Blocking solution 5% skimmed milk powder (w/v) in TBST 
Dual Extraction buffer A (Kumar 2009) 20mM HEPES (pH 7.9) 
20% glycerol 
10mM NaCl 
1.5mM MgCl2 
0.2mM EDTA (pH 8.0) 
1mM DTT 
0.1 % Triton X100 
1mM CoCl2 
Protease inhibitor (1 tablet/50ml) 
Dual Extraction buffer B (Kumar 2009) Like A 
500mM NaCl instead of 10mM NaCl 
Electrophoresis buffer 1.9M Glycine 
0.25M Tris 
1% SDS (w/v) 
HIF1α extraction buffer (Srinivasan et al. 
2011) 
  
20mM HEPES 
1.5mM MgCl2  
0.2mM EDTA 
450nM NaCl 
1mM CoCl2 
Laemmli buffer 3x 150mM Tris/HCl, pH 6.8 (rt) 
30% Glycine (v/v) 
6% SDS (w/v) 
0.3% Bromphenol blue (w/v) 
7.5% β-mercaptoethanol (v/v) 
RIPA lysis buffer Tris/HCl 50mM, pH 7.4 
NaCl 150mM 
EDTA 1mM 
Trition X100 1% 
sodium orthovanadate 1% 
SDS 0.1% 
CoCl2  1mM 
Protease inhibitors (Roche complete 
#04693116001) 1 tablet per 50ml 
Sodiumdodecylsulfate (SDS), 10% 10% SDS (w/v) 
Tris, 1M, pH 6.8  Dissolved in ultrapure H2O, pH adjusted with 
HCl at room temperature 
Tris, 1.5M, pH 8.8  Dissolved in ultrapure H2O, pH adjusted with 
HCl at room temperature 
Tris-buffered saline (TBS), 10x 1.5M NaCl 
100mM Tris 
10mM NaN3 
Tris-buffered saline with Tween (TBST) 0.05% Tween 20 (v/v) in 1x TBS 
 
Commercially available buffers and solutions: 
Acrylamide/Bisacrylamide solution, 30% Carl Roth GmbH, Karlsruhe 
ECL plus detection reagents (Cat. Nr. 
RPN2132)  
GE Healthcare, München 
NuPAGE LDS sample buffer, 4x Invitrogen, Carlsbad 
NuPAGE transfer buffer, 20x, #NP0006-1 Invitrogen, Carlsbad 
WesternBreeze® Blocking solution Invitrogen, Carlsbad 
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2.1.3.2. Molecular biology 
Buffers and solutions produced in house: 
Agarose gel 0.6/2% 300ml TBE buffer 
0.6/2% agarose powder (w/v) 
Agarose-gel-electrophoresis buffer 1l 5x TBE buffer 
1 drop ethidium bromide  
Agarose-gel-electrophoresis loading buffer 0.25% bromophenol blue (w/v) 
0.25% xylen-cyanol FF (w/v) 
30% glycerin (w/v)  
Hexanucleotide mix, 10x, solution (#11 277 
081 001) 
Roche, Mannheim 
SYBRgreen master mix (500µl volume) 
 
 
10x Taq buffer 
without detergent  
100µl  
 
dNTPs (25mM) 7.5µl 
Rox 20µl 
PCR optimizer 200µl 
BSA PCR grade 10µl 
SYBRgreen1(stock 
1:100 in 20% DMSO)  
2µl 
MgCl2 25mM 
H2O 
120µl 
40.5µl 
Tris-borate-EDTA (TBE) buffer, 1x 90mM Tris 
2mM boric acid 
0.01M EDTA 
pH 8.0 (rt) 
Commercially available buffers and solutions:  
Buffers for DNA restriction enzymes NEB, Frankfurt 
First strand buffer, 5x Invitrogen, Carlsbad 
Linear Acrylamid, 5mg/ml (#9520) Ambion®, Thermo Fisher Scientific, 
Waltham 
PCR assays Applied Biosystems, Thermo Fisher 
Scientific, Waltham 
Platinum Quantitative PCR SuperMix-UDG 
with ROX, 1x (#11743-100) 
Invitrogen, Carlsbad 
SpeedAmp PCR buffer, 10x Analytik Jena, Jena  
Taq buffer without detergent, liquid, 10x 
(#B55) 
Thermo Fisher Scientific, Waltham 
ThermoPol buffer for Taq polymerase, 10x NEB, Frankfurt 
T4 DNA Ligase buffer, 10x NEB, Frankfurt 
2.1.3.3. Microbiology 
Buffers and solutions produced in house: 
Agar 2x 3% Agar-Agar (w/v), autoclaved 
Ampicillin solution 50mg/ml Ampicillin in 70% ethanol (w/v) 
CaCl2 solution (for preparation of competent 
bacteria 
60mM CaCl2 
15% Glycerol (v/v) 
10mM PIPES, ph7 (rt) 
Sterile filtered (0.2 µm) 
Freezing solution for bacteria 10x 
(autoclaved) 
132.3 mM KH2PO4 
21mM Sodiumcitrate 
3.7mM MgSO4*3H2O 
68.1mM (NH)2SO4 
459.3mM K2HPO4*3H2O 
35.2% Glycerin (w/v) 
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LB-Medium 1x  2% bacto tryptone (w/v) 10g 
342 mM NaCl 10g 
1% yeast extract (w/v) 5g 
Ad 1l 
pH 7.2-7.3 (rt) through 1M NaOH, autoclaved 
LB-Medium 2x (for agar plates) 5g bacto tryptone 
5g NaCl 
2.5g yeast extract 
Ad 250ml 
Commercially available materials: 
Ampicillin sodium salt (#K029) Carl Roth GmbH, Karlsruhe 
Bacto tryptone (#211705) BD Biosciences, Heidelberg 
Yeast extract (#212750) BD Biosciences, Heidelberg  
2.1.3.4. Histological and immunohistological staining 
Alexa Fluor® 594 AffiniPure Donkey Anti-
Mouse IgG (H+L) (a-mIgG) 
Jackson Immunoresearch, West Grove  
Cell Tracker™ green CMFDA (5-
Chloromethylfluorescin Diacetate) 
Molecular probes®, Life technologies, 
Carlsbad 
DAPI (4´,6-Diamidino-2-Phenylindole, 
Dihydrochloride) 
Molecular probes®, Life technologies, 
Carlsbad 
donkey serum Jackson Immunoresearch, West Grove  
Eosin Y solution, alcoholic Sigma-Aldrich, St. Louis 
Hematoxylin solution, Harris modified Sigma-Aldrich, St. Louis 
Hoechst 33342 Invitrogen, Carlsbad 
Hypoxyprobe™-1 Kit Hpi, Burlington 
PI (P4864) Sigma-Aldrich, St. Louis 
TritonX100 Sigma-Aldrich, St. Louis 
Tween 20 Carl Roth GmbH, Karlsruhe 
Xylol Sigma-Aldrich, St. Louis 
Vectamount mounting medium Vector laboratories, Burlingame 
2.1.3.5. Cell culture 
Buffers and solutions produced in house: 
Acidified isopropyl 0.4ml 1N HCl 
9.6ml Isopropyl 
Erythrocyte lysis buffer 8.29g Ammonium chloride NH4Cl 
1g Potassiumhydrogencarbonate KHCO3 
0.037g Triplex III Na2-EDTA 
Dissolved in 1l ultra-pure H2O 
Sterile filtered (0.2 µm) 
PolyHEMA solution 2% polyHEMA 
95% ethanol 
2.1.3.6. Other buffers and solutions   
FACS-buffer 1x PBS (cell culture grade) 
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2.1.4. Antibodies for FACS and WB  
Primary antibodies (target species: human): 
Immuno- 
gen 
Host 
species/ 
isotype 
Appli-
cation 
Label Source Concentration Incubation 
HIF-1α Mouse/ 
IgG1 
WB none BD 
Biosciences 
Heidelberg  
1:1000 overnight at 4°C 
α-tubulin Rabbit/ 
polyclo-
nal 
WB none Cell 
signaling, 
Danvers 
(#2144) 
1:1000 overnight at 4°C 
Integrin αβ3 Mouse/ 
IgG1 
FACS none abcam®, 
Cambridge 
(#ab78289) 
 
2µg/106 cells 45 min on ice 
CD14 Mouse/ 
IgG2 
FACS APC BD 
Biosciences 
Heidelberg 
(#345787) 
1:50; 
0.1µg/106  
cells 
30 min on ice 
CD19 Mouse/ 
IgG1 
FACS FITC BD 
Biosciences 
Heidelberg 
(#555412) 
1:50 30 min on ice 
CD34 Mouse/ 
IgG1 
FACS FITC BD 
Biosciences 
Heidelberg 
(#345801) 
1:50; 
0.05µg/106 
cells 
30 min on ice 
CD45 Mouse/ 
IgG1 
FACS PE-CY5 BD 
Biosciences 
Heidelberg 
(#555484) 
1:50 30 min on ice 
CD73 Mouse/ 
IgG1 
FACS APC BD 
Biosciences 
Heidelberg 
(#560847) 
1:50 30 min on ice 
CD90 Mouse/ 
IgG1 
FACS PE-CY5 BD 
Biosciences 
Heidelberg 
(#555597) 
1:300; 
66ng/106 
cells 
30 min on ice 
CD105 Mouse/ 
IgG1 
FACS PE BD 
Biosciences 
Heidelberg 
(#560839) 
1:50 30 min on ice 
HLA-DR Mouse/ 
IgG2 
FACS PE BD 
Biosciences 
Heidelberg 
(#555812) 
1:50 30 min on ice 
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Secondary antibodies (target species: mouse): 
Immuno-
gen 
Host species/ 
Isotype 
Appli-
cation 
Label Source Concen-
tration 
Incubation 
IgG (H+L) Donkey Polyclonal 
IgG (H+L) 
FACS Cyanine 
Cy™3 
Jackson 
Immuno 
Research 
Europe 
Ltd., Suffolk 
(#715-165-
151) 
2µg/106 
cells 
30 min on ice 
Polyclonal 
Rabbit 
Anti- 
Mouse 
Immuno-
globulins/ 
HRP 
 
Rabbit/Polyclonal WB, 
HIF1α 
none Dako, 
Glostrup 
(#P0260) 
1:5000 1 hr at RT 
Amersham 
ECL 
Rabbit 
IgG, HRP-
linked 
 
Donkey/ IgG WB, α-
tubulin 
none GE 
Healthcare 
Life 
Sciences, 
Freiburg 
(#NA934-
100UL) 
1:5000 1 hr at RT 
2.1.5. Enzymes 
Alkaline phosphatase Roche, Mannheim 
Phusion DNA polymerase NEB, Frankfurt 
Restriction enzymes NEB, Frankfurt  
Super script II reverse transcriptase Invitrogen, Carlsbad 
T4 DNA ligase NEB, Frankfurt 
Taq DNA polymerase NEB, Frankfurt 
2.1.6. Size standards for electrophoresis 
1kb DNA ladder Invitrogen, Carlsbad 
MagicMarkTM XP western protein standard Invitrogen, Carlsbad 
Molecular weight marker (Cat. Nr. 27-2111)  PeQLab, Erlangen 
2.1.7. Primers/Oligonucleotides 
Application Gene Sequence/melting point Source 
qPCR,  hCCL5 fw TACACCAGTGGCAAGTGCTC 58.3°C AG Spitzweg,  
SYBRgreen hCCL5 rv TGTACTCCCGAACCCATTTC  58.3°C Großhadern 
qPCR,  hCTGF fw CCAATGACAACGCCTCCTG    61°C Invitrogen,  
SYBRgreen hCTGF rv TGGTGCAGCCAGAAAGCTC   61°C Carlsbad 
qPCR, hCXCL12 fw AGAGCCAACGTCAAGCATCT 58.5°C Invitrogen,  
SYBRgreen hCXCL12 rv CTTTAGCTTCGGGTCAATGC  58.4°C Carlsbad 
qPCR, hFGF2 fw GGAGAAGAGCGACCCTCAC   61°C Invitrogen,  
SYBRgreen hFGF2 rv AGCCAGGTAACGGTTAGCAC  
                                                    59.4°C 
Carlsbad 
qPCR, hHGF fw CTGGTTCCCCTTCAATAGCA  60.1°C AG Spitzweg 
SYBRgreen hHGF rv CTCCAGGGCTGACATTTGAT  60°C Großhadern 
qPCR, hHIF1α fw GCTTTAACTTTGCTGGCCCC  60°C AG Spitzweg, 
SYBRgreen hHIF1α rv TTCAGCGGTGGGTAATGGAG 60°C Großhadern 
qPCR, 
SYBRgreen 
hID1 fw 
hID1 rv 
GTCTGTCTGAGCAGAGCGTG 51°C 
CGTTCATGTCGTAGAGCAGC  49°C 
Self-designed 
(Invitrogen, 
Carlsbad) 
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qPCR, hIL6 fw TACCCCCAGGAGAAGATTCC 60.3°C AG Spitzweg, 
SYBRgreen hIL6 rv TTTTCTGCCAGTGCCTCTTT   60°C Großhadern 
qPCR, 
taqman 
hMMP2 fw 
hMMP2 rv 
ATGCCGCCTTTAACTGGAG    56.7°C 
GGAAAGCCAGGATCCATTTT  55.3°C 
Entelechon, 
Bad Abbach 
qPCR, 
SYBRgreen 
hMMP9 fw 
hMMP9 rv 
ACGACGTCTTCCAGTACCGA 59.4°C 
TTGGTCCACCTGGTTCAACT  57.3°C 
Entelechon, 
Bad Abbach 
qPCR,  
SYBRgreen 
hTGFβ1 fw 
hTGFβ1 rv 
CAGCACGTGGAGCTGTACC   62°C 
AAGATAACCACTCTGGCGAGTC 
                                                    62°C 
QuantiTect, 
Hilden 
 
qPCR, 
SYBRgreen 
hTIMP1 fw 
hTIMP1 rv 
CTGTTGTTGCTGTGGCTGAT  47°C 
ACTTGGCCCTGATGACGAG   48°C 
Self-designed 
(Invitrogen, 
Carlsbad) 
qPCR, hVEGFa fw CTACCTCCACCATGCCAAGT  60°C AG Spitzweg 
SYBRgreen hVEGFa rv ATGATTCTGCCCTCCTCCTT   60°C Großhadern 
qPCR, 
Control 
taqman 
assay 
Eukaryotic 
18S rRNA 
(VIC/TAMRA 
Probe)  
 Thermo Fisher 
Scientific, 
Waltham 
(#4310893E) 
qPCR, 
SYBRgreen 
18SRNA fw 
18SRNA rv 
GCAATTATTCCCCATGAACG  58.6°C 
AGGGCCTCACTAAACCATCC 58.8°C 
Entelechon, 
Bad Abbach 
2.1.8. Plasmids and vectors 
For plasmid maps, see cloning strategies (2.2.5.) 
Plasmid Description Source Selection Application 
pIR-EGFP-SV40 CMV promoter, SV40 
Large T antigen, 
internal ribosomal 
entry site,  green 
fluorescent protein 
In house 
(Anke 
Fischer) 
Kana-
mycin 
Immortalization 
of MSCs 
(success can 
be evaluated 
by expression 
of GFP) 
pRL-TK/CMV CMV promoter, 
Renilla luciferase, 
constitutive 
expression of 
luciferase 
Promega, 
Madison 
Ampicillin Control plasmid 
for dual 
luciferase 
assays 
pGL3-RFL RANTES promoter, 
firefly luciferase, 
promoter dependent 
expression of 
luciferase 
In house 
(Fessele 
2001) 
Ampicillin RANTES 
dependent 
luciferase 
expression  
pGL3-6xHRE-luc-
blasti_clockwise 
HIF1α-responsive 
promoter, firefly 
luciferase, promoter 
dependent expression 
of luciferase 
In house 
(Anna 
Hagenhoff) 
Blastici-
din, 
Ampicillin  
Reporter gene 
activity under 
different 
oxygen 
conditions 
2.1.9. Kits 
BioLux® Gaussia Luciferase Flex Assay Kit NEB, Frankfurt 
ECL-Kit Perkin Elmer, Waltham 
QIAquick Gel Extraction Kit  Qiagen, Hombrechtikon 
Dual-Luciferase® Reporter Assay Promega, Fitchburg 
Endofree Plasmid Maxi Kit Qiagen, Hilden 
Innuprep Plasmid Mini kit Analytik Jena, Jena 
Pierce™ BCA Protein Assay Kit Thermo Fisher Scientific, Waltham 
PureLink RNA Mini Kit Life technologies, Carlsbad 
Quant-iT RNA assay Life technologies, Carlsbad 
Materials and Methods  24 
Quant-IT dsDNA high sensitivity Assay Kit Invitrogen, Carlsbad 
Quant-IT dsDNA broad range Assay Kit Invitrogen, Carlsbad 
Quickchange Site-directed mutagenesis it Stratagene, Santa Clara 
MykoAlert Mycoplasma Detection Kit Lonza, Basel 
RNase-free DNase set Qiagen, Hilden 
2.1.10. Chemicals  
Active charcoal (#C9157) Sigma-Aldrich, St. Louis 
Agar (# 214010) BD Biosciences, Heidelberg 
agarose powder (# 15510-500) Invitrogen, Carlsbad 
ammonium chloride (NH4Cl) (#101145) Merck, Darmstadt 
Ammoniumperulfate (APS) 10g Carl Roth GmbH, Karlsruhe 
Boric acid Carl Roth GmbH, Karlsruhe 
β-Mercaptoethanol Sigma-Aldrich, St. Louis 
BSA (molecular biology grade), 20mg/ml  Thermo Fisher Scientific, Waltham 
CaCl2 Merck, Darmstadt 
Dextran Carl Roth GmbH, Karlsruhe 
EDTA Merck (Calbiochem), Darmstadt 
Ethanol 70% Pharmacy Klinikum Großhadern, 
München 
Ethanol 95% Pharmacy Klinikum Großhadern, 
München 
Ethanol 96% Pharmacy Klinikum Großhadern, 
München 
Ethanol 99% Sigma-Aldrich, St. Louis 
Ethanol 100% Sigma-Aldrich, St. Louis 
Ethidium bromide, 0,5% solution (#HP46) Carl Roth GmbH, Karlsruhe 
Formalin 4% Sigma-Aldrich, St. Louis 
dNTP Set (100mM aquaeous solution of each of 
dATP, dCTP, dGTP, dTTP) (#R0182) 
Thermo Fisher Scientific, Waltham 
DTT   Serva, Heidelberg 
Glycine Carl Roth GmbH, Karlsruhe 
Glycerol Carl Roth GmbH, Karlsruhe 
HCl Merck, Darmstadt 
Isopropyl Carl Roth GmbH, Karlsruhe 
K2HPO4 Carl Roth GmbH, Karlsruhe 
Methanol Merck, Darmstadt 
MgCl2 Carl Roth GmbH, Karlsruhe 
MgSO4 Sigma-Aldrich, St. Louis 
MTT Sigma-Aldrich, St. Louis 
NaCl 5M Sigma-Aldrich, St. Louis 
(NH)2SO4 Sigma-Aldrich, St. Louis 
PCR optimizer Bio Stab (LC120-0001) Bitop, Witten 
PIPES Sigma-Aldrich, St. Louis 
Potassiumhydrogencarbonate (KHCO3) 
(#104854) 
 
Merck, Darmstadt 
n-propyl gallate Sigma-Aldrich, St. Louis 
Protease Inhibitor cocktail tablets Complete Roche, Mannheim 
RNasin Rnase inhibitor Promega, Madison 
Rnase free water Thermo Fisher Scientific, Waltham 
SDS Carl Roth GmbH, Karlsruhe 
Skimmed milk powder Carl Roth GmbH, Karlsruhe 
Sodium Azide NaN3 Merck, Darmstadt 
Sodium citrate Merck, Darmstadt 
Sodium orthovanadate Sigma-Aldrich, St. Louis 
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SYBR® Green I nucleic acid gel stain, 10000x, in 
DMSO (#86205) 
Fluka, Sigma-Aldrich, St. Louis  
Tissue Tek ® O.C.T.™ Compound Sakura Finetek Europe B.V. 
Titriplex III Na2-EDTA (#108418) Merck, Darmstadt 
Tris-borate-EDTA Carl Roth GmbH, Karlsruhe 
Triton X100 hydrogenated (Triton X100h) Calbiochem./Merck, Darmstadt 
Tween 20 Carl Roth GmbH, Karlsruhe 
Vectashield® Mounting Medium  Vectorlaboratories, Burlingame 
Water injection grade (Aqua ad iniectabilia) Braun Melsungen AG, Melsungen 
Xylen-cyanol FF Carl Roth GmbH, Karlsruhe 
2.1.11. Disposables and other materials 
µ-slide Chemotaxis 3D, ibiTreat, tissue culture 
treated, sterile 
Ibidi, Martinsried 
0.22µm filter (for seringue) BD Biosciences, Heidelberg 
4mm cuvettes  PeqLab Biotechnologie GmbH, 
Erlangen 
96 well tissue culture plates round/flat bottom TPP Techno plastic products, 
Trasadingen 
48/24/6 well plate TPP Techno plastic products, 
Trasadingen 
6/10/15cm2 cell culture vessels TPP Techno plastic products, 
Trasadingen 
Amersham Hyperfilm ECL autoradiography film GE Healthcare, Uppsala 
Al2O3 notched plate (for WB) GE Healthcare, Uppsala 
Beveled pipette tips (20µl pipette) Greiner Bio-One GmbH, 
Frickenhausen 
Centrifuge tubes 15/50ml TPP Techno Plastic Products, 
Trasadingen 
Combitipps migration Greiner Bio-One GmbH, 
Frickenhausen 
Counting chamber Hecht-Assistant, Sondheim 
Cryomold embedding cassettes Sakura Finetek Inc., St. Torrence 
Cryovials 2ml Alpha laboratories, Hampshire 
FACS tubes BD Biosciences, Heidelberg 
Humid chamber for chemotaxis assay: 15cm2 cell 
culture dish, facial tissues, deionized water 
TPP Techno Plastic Products, 
Trasadingen; Wepa Mainz 
Luminometer tubes Sarstedt, Kleinstadt 
Microlance 3 BD Biosciences, Heidelberg 
Microtubes 1.5/2ml Böttger, Bodenmais 
Microtubes 5ml Eppendorf Research, Hamburg 
Millipore Immobilon-P PDVF membrane  Merck Millipore, Darmstadt 
Pasteur pipettes Peske 
Pipette tips 1250/200/20/10 µl Greiner bio-one, Frickenhausen 
Scraper TPP Techno Plastic Products, 
Trasadingen 
Seringue 2ml Discardit II BD Biosciences, Heidelberg 
Serological pipettes 50ml with reservoir TPP Techno Plastic Products, 
Trasadingen 
Serological pipettes cellstar 5/10/25ml Greiner bio-one, Frickenhausen 
Serological pipettes 1/2ml TPP Techno Plastic Products, 
Trasadingen 
Superfrost™ plus microscope slides  Thermo Fisher Scientific, Waltham 
Transofix Braun Melsungen AG, Melsungen 
Tissue culture dishes  6/10/15 cm TPP Techno Plastic Products, 
Trasadingen 
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Tweezer Merck Millipore, Darmstadt 
Vacuum filter system TPP Techno Plastic Products, 
Trasadingen 
2.1.12. Other laboratory equipment (devices) 
Assistent Rollenmischer RM5, Nr. 348 Karl Hecht KG, Sondheim/Rhön 
Autoclave WEBECO GmbH, Selmsdorf 
Binocular stereomicroscope SZX90 Olympus, Shinjuku 
Biofuge pico  Heraeus Instruments GmbH, Hanau 
BioRad 3000 Xi Bio-Rad, München 
BioRad power Pac300 Bio-Rad, München 
Capacitance Extender Bio-Rad, München 
Centrifuge 5402 Eppendorf Research, Hamburg 
Centrifuge Rotanta 460R Hettich Zentrifguen, Ebersberg 
Cold light source KL1500 Schott AG, Mainz  
Cryostat Jung CM 3000 Leica, Wetzlar 
Curix60 (Developer for autoradiography films) Agfa, Mortsel 
Dispenser pipette Eppendorf Research, Hamburg 
Eppendorf Easypet®  3 Eppendorf Research, Hamburg 
Fluorescence activated cell scanner FACSCalibur Becton, Dickinson  
Fluorometer Qubit Invitrogen, Carlsbad 
Gene Pulser (Electroporation cell culture) Bio-Rad, Hercules  
Incubator Galaxy 48 R  Eppendorf Research, Hamburg 
Incubator  Thermo Fisher Scientific, Waltham 
Incubator Memmert, Schwabach 
Inverted fluorescence microscope DMIL Leica, Wetzlar 
      CCD Camera ProgRes® CF Jenoptiik, Jena 
      Heated, incubation chamber Ibidi, Martinsried 
      Motorstage Prior Scientific Instr. Ltd., Fulbourn 
Light Cycler® 480 II Roche, Mannheim 
Lumat LB9507 EG&G Berthold 
Megafuge 1.0R Thermo Fisher Scientific, Waltham 
Microtome  HM-340-E Microm, Walldorf 
Multiwell plate reader GFNios Plus Tecan, Crailsheim 
PCR machine Mastercycler®pro Eppendorf Research, Hamburg 
Pipetman Pipettes 1000/200/20/2µl Gilson, Middleton 
Power Pac 300 Bio-Rad, Hercules 
RCT basic IKA® Labortechnik, Staufen 
Rotilabo®-mini-centrifuge Carl Roth GmbH, Karlsruhe 
Scale BP1109 Sartorius, Bradford 
Scale Excellence E2000 D Sartorius, Bradford 
Scale P1200N Mettler-Toledo LLC, Columbus 
Scale PJ3000 Mettler-Toledo LLC, Columbus 
Sorvall RC 5B plus centrifuge Thermo Fisher Scientific, Waltham 
Sterile Hood Class II Type A/B3 The Baker Company inc., Sanford, 
Maine 
Thermomixer comfort Eppendorf Research, Hamburg- 
UV Transilluminator  UVP, LLC, Upland 
Vortex-Genie 2 Scientific industries Inc., Boehmia 
Water bath GFL, Burgwedel 
Water jet vacuum pump In house 
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2.1.13. Software 
Name Application Source 
CellQuest Acquisition of FACS data BD Biosciences, Bedford 
Clone manager Planning of cloning 
strategies, generation of 
plasmid maps 
Sci-Ed Software, Morrisville 
Endnote X 7.3.1. Organization of literature 
resources 
License from Ludwig 
Maximilians University 
Munich 
Fiji 1.48q Analysis of MSC distribution 
in invasion experiments 
National Institute of Health, 
Bethesda 
FlowJo Evaluation of FACS data TreeStar Inc., Ashland 
Graph Pad Prism 6 Statistical analysis, 
generation of diagrams 
GraphPad Software, La Jolla  
Image J and plugins 
manual tracking, 
chemotaxis tool 
Image editing, Evaluation of 
migration data 
National Institutes of Health, 
USA 
Light Cylcer® 480 Software 
release 1.5.0. SP4 
Analysis of q-PCR data Roche, Mannheim 
Micro-Manager Picture acquisition video 
microscopy (open source 
microscopy software) 
Open Imaging Inc., San 
Francisco 
Mircosoft office Generation of diagrams, 
analysis of q-PCR data 
License from Ludwig 
Maximilians University 
Munich 
ProgRes Capture Leica fluorescence 
microscope image 
acquisition 
Jenoptik, Jena 
SnapGene Plasmid maps GSL Biotech LLC, Chicago 
XFluor Control of ELISA plate 
reader 
Tecan, Crailsheim 
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2.2. Methods  
2.2.1. Cell culture 
2.2.1.1. General cell culture 
The culture of living cells was performed in a laminar flow hood. Penicillin and 
Streptomycin were added to the culture media. All reagents and supplements were 
preheated to 37°C using a water bath except for those used for the chemotaxis 
assay. These solutions were incubated in a cell culture incubator set to 37°C and 5% 
CO2 to allow pH adjustment as well as preheating. Incubation of cells was performed 
in humidified atmosphere at 37°C, 21% O2 and 5% CO2 unless stated otherwise for 
experiments using hypoxic conditions (see 2.2.1.8.). When splitting cells, they were 
first rinsed with PBS and then detached using Trypsin-EDTA at room temperature. 
The reaction was stopped by adding an equal volume of medium containing 10% 
sFCS (or twice the volume if the medium contained less sFCS), and the cells were 
pelleted by centrifugation for 3 min at 200rcf (at room temperature). After carefully 
suspending the cell pellet in fresh culture medium cells were seeded into an appro-
priate cell culture vessel. 
2.2.1.2. Freezing and thawing of cells 
For long-term storage, cells were detached after rinsing with PBS and after the 
centrifugation step, suspended in respective culture medium. In order to prevent 
water crystallization, the cell suspension was subsequently mixed with freezing 
medium in a 1+1 ratio. Freezing medium consisted of 60% sFCS, 20% respective 
culture medium and 20% DMSO. Due to the toxicity of the DMSO, the procedure was 
performed as rapid as possible and the cryotubes were placed into isopropanol 
containers at -80°C for 24 hrs allowing slow decrease of the temperature to -80°C. 
The cells were stored in a liquid nitrogen container at -196°C.  
For thawing cells, cell culture vessels containing preheated culture medium were 
prepared and the frozen cell suspension was thawed quickly in a 37°C water bath. 
When almost completely thawed the cell suspension was transferred into the culture 
vessel rapidly to ensure quick dilution of the DMSO. After cells were adherent (4-6 
hrs) the culture medium was exchanged andtransgene selection medium was added.  
2.2.1.3. Cell quantification 
To quantify the cell numbers, a defined volume of cell suspension was diluted with 
trypan blue solution (0.4%) and subsequently pipetted into a Neubauer counting 
chamber. Cells in four of the big squares were counted and cell concentration 
calculated after the following formula: 
 
Figure 11: Formula for cell counting with Neubauer Chamber 
2.2.1.4. Isolation of primary MSCs 
Primary MSCs were isolated from bone marrow donations preserved in EDTA after 
the Tübinger method (Muller et al. 2006) with slight modifications of the culture 
medium used for isolated MSCs (see 2.1.1.1.) The whole procedure was performed 
at room temperature. Samples were incubated with approximately the same volume 
of erythrocyte lysis buffer (see 2.1.3.5.). From time to time mixture was stirred and 
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after 10 min centrifuged at 500 rcf for 5 min and the sediment transferred into PBS, 
lysated and centrifuged again until lysis was completed. Lysate was rinsed with PBS 
and plated with 2ml respective culture medium (see 2.1.1.1) per 1ml bone marrow 
sample into a 75cm2 culture flask (max. 10ml) and then cultured in 21% O2. Every 
two days medium was changed and cells were subcultured according to their density.  
2.2.1.5. Characterization of MSCs and HUH7 (FACS, differentiation, immortali-
zation) 
As detailed in 2.1.1.2., MSCs had to meet certain minimum criteria. To ensure this, 
differentiation ability and surface markers were examined in house. Moreover, all 
cells used for this thesiswere examined for integrin αβ3 expression in house and at 
the cooperating laboratory of Prof. Spitzweg at Großhadern. 
 
2.2.1.5.1. FACS analysis of characteristic surface markers  
Surface marker analysis cells was performed using fluorescence activated cell 
sorting (FACS). This method uses fluorescence labeled antibodies for the detection 
of surface molecules. Size, granularity and fluorescence signal were detected and 
subsequently expression of targeted molecules was evaluated.  
Cells were detached using trypsin-EDTA and suspended in PBS. Cell number, 
antibody concentration and incubation period can be found in 2.1.4. Antibodies 
without fluorescence tag were incubated with a secondary fluorescence marked 
antibody for 30 min on ice. After washing twice with PBS, cells were analyzed on a 
FACS Calibur with Cell Quest Software. Cell debris was excluded by appropriate 
gating. MSCs were analyzed between passages three and five. HUH7 cells in 
passages ten to fifteen. 
MSCs met the minimum criteria of surface markers. Moreover, MSCs used for this 
thesis expressed integrin αβ3 while tumor cell line HUH7 was negative for integrin 
αβ3. The integrin αβ3 expression on MSCs was not influenced by thyroid hormone 
or Tetrac treatment (Schmohl et al. 2015). 
                  
Figure 12: Integrin αvβ3 expression on MSCs is not influenced by T3/T4/Tetrac treatment: 
MSCs were treated with HUH7 conditioned medium and 1nM T3 or 1µM T4 with or without 100nM 
Tetrac for 24 hrs, harvested and analyzed for integrin αvβ3 expression by flow cytometry with an 
integrin αvβ3-specific antibody and Cy3-conjugated secondary antibody. Cells incubated with second-
dary antibody alone served as negative control. (Schmohl et al. 2015) 
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2.2.1.5.2. Differentiation and histochemical staining 
To demonstrate sustained adipogenic and osteogenic differentiation capability, MSCs 
were plated into three wells on two six well plates. After reaching 80% confluency, 
differentiation was initiated by changing the respective culture medium into differen-
tiation medium.  
Osteogenic differentiation was conducted for twelve days, adipogenic differentiation 
for nineteen days with medium changes every two to three days. After this period, 
cells were fixed in 4% Formalin for 20 min at room temperature.  
Osteogenic differentiated cells were rinsed with NaCl after fixation and incubated with 
alizarin red for 10 min, staining Ca2+ deposits. After another three rinses in NaCl, to 
remove excess stain, cells were characterized under the microscope.  
Adipogenic differentiated cells were rinsed with PBS and then incubated with freshly 
prepared 0.03% Oil Red O solution for 20 min at room temperature, staining accumu-
lated lipid droplets. After rinsing three times to remove excess stain cells were 
characterized under the microscope.  
Two controls were included per differentiation: One incubated with normal culture 
medium and one incubated with the differentiation medium for osteocytes/adipocytes. 
Both were stained as described above with the non-corresponding dye (Figure 13). 
These controls ensured proper experimental quality and excluded spontaneous dif-
ferentiation. All controls were negative in the experiments performed. 
 
Differentiation Medium Specific supplements 
Osteogenic  
 
 
DMEM+10%FCS+1% P/S 
 
10nM dexamethasone   10mM 
β-GP-glycerophosphate  
50µg/ml Ascorbic acid 
Adipogenic 10µM dexamethasone  
0.5mM isobutyl methyl xanthine 
(IBMX) 
50µM indomethacin   
1µg/ml insulin  
Table 1: Media for osteogenic and adipogenic differentiation of MSCs [modified after (Pittenger et 
al. 1999, Liu et al. 2009)] 
 
Figure 13: Plating plan for osteogenic (left) and adipogenic (right) differentiation: MSCs were 
seeded onto a 6-well-plate and differentiation performed as described above. For each differentiation, 
two controls were included, to exclude spontaneous differentiation. Alizarin red stain (for osteocytes) 
was performed after 12 days on the left plate, Oil-Red-O stain (for adipocytes) after 19 days on the 
right plate.  
All primary MSCs isolated and immortalized within the scope of this thesis met the 
minimum differentiation criteria as stated in 2.1.1.2. The established MSC cell line 
L87 retainedlimited features of primary isolated MSCs (Thalmeier et al. 1994, Conrad 
et al. 2008). L87 cells showed osteogenic differentiation after 28 days but no 
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adipogenic differentiation. In addition, migratory capacities were reduced. However, 
in vitro handling was easier due to less vulnerability of cells.  Therefore, the cell lines 
promoted a stable in vitro model of MSC biology for preliminary experiments to 
establish experimental routines. 
2.2.1.5.3. Immortalization 
In order to establish a uniform pool of MSCs out of the heterogenic isolated 
population, cells were stably transfected with an in house established pIR-EGFP-
SV40-plasmid, a plasmid expressing EGFP for transfection efficiency control and 
Simian virus 40 (SV40) large T antigen. SV40 inactivates certain tumor suppressor 
genes and enhances telomerase activity, when incorporated into the genome. This 
transgene engineering leaves migration and invasion capacities as well as 
differentiation capacities unaffected but allows the establishment of clonal uniformity 
not given in isolated primary MSC populations. These experiments were performed in 
collaboration with Anke Fischer (MTA, AG Klinische Biochemie, Prof. Peter Nelson). 
Primary MSCs were transfected in passage three. Transfection did not yield the 
expected effect of persisting immortalization but an expansion of the life span from 
five to ten passages and made cells more robust. Starting in passage ten cells grew 
slower and started to die or differentiate spontaneously. Consequently, only 
immortalized cells up to passage ten were used for experiments. For method of 
stable transfection, see 2.2.1.10. 
 
 
Figure 14: Plasmid map of pIRES-EGFP-SV40 used to immortalize primary MSCs: The plasmid 
contains a CMV promoter driving SV40 Large T Antigen, IRES2 sequence (allowing initiation of trans-
lation in the middle of mRNA) and green fluorescent protein (EGFP). 
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2.2.1.6. Stripping of fetal calf serum  
As fetal calf serum (FCS) normally contains varying concentrations of thyroid 
hormones thus, possibly confounding experiments of this thesis, it had to be depleted 
of thyroid hormones. This was performed by stripping the FCS with dextran coated 
active charcoal after a protocol adapted from the procedure developed by Prof. 
Spitzweg´s research group at Großhadern: 25g active charcoal was coated with 2.5g 
Dextran by adding both ingredients to 1l PBS in a 1l measuring cylinder under a fume 
cupboard. Mixture was stirred at 4°C. Simultaneously, two bottles of FCS were 
thawed at 4°C. After 12hrs, the mixture was filtrated with a sterile 500ml-TPP vacuum 
filtration-system into a sterile 1l glass bottle. The coated charcoal was transferred into 
a second sterile glass bottle and autoclaved. Then 800ml sterile FCS were added to 
the autoclaved charcoal under a laminar flow hood and the mixture was stirred 24 hrs 
at 4°C. Afterwards mixture was centrifuged twice for 15 min at 10000 rcf and 4°C. 
Sub-sequently the mixture was filtrated with a sterile 500ml-TPP vacuum filtration-
system. Then the whole procedure was repeated using the stripped FCS (sFCS) from 
round one instead of fresh FCS. Afterwards sterile sFCS was aliquoted and stored at 
-20°C. Depletion success was confirmed at the clinical chemistry laboratory at 
university hospital Großhadern. The hormone content for different batches was for T3 
between non-detectable and a maximum of 0.13pg/ml (=0.19pM) and for T4 between 
0.81ng/dl (=1nM) and 1.01ng/dl (=1.3nM). These concentrations were at least tenfold 
below the lowest concentrations of thyroid hormone (1nM T3, 10nM T4) used to 
stimulate the cells.  
2.2.1.7. Production of HUH7 conditioned medium (CM)  
HUH7 conditioned medium, used to stimulate MSCs, was produced by plating 2.5 
Mio HUH7 cells [in DMEM+hamF12 (ratio 1:1) medium with 10%sFCS and 1%P/S] 
into 15cm2 culture vessels. After reaching 80% density medium was changed and 
cells were incubated for 48 hrs. Afterwards supernatant was removed, centrifuged at 
330 rcf for 5 min to remove cell debris and then stored at -20°C.  
The supernatant used to stimulate cells in the chemotaxis assay was produced 
slightly different. 2.5 Mio HUH7 cells were cultured in respective culture medium like 
above. When cells reached 100% confluence medium was changed to chemotaxis 
assay medium (RPMI or DMEM + 1%BSA+15mM HEPES) and cells were incubated 
for 48 hrs. Then supernatant was removed and processed as described above. 
2.2.1.8. Stimulation of MSCs with hypoxia, thyroid hormones and HUH7 condi-
tioned medium (CM) 
Hypoxic stimulation of MSCs was either performed in a hypoxic incubator using a 
culture atmosphere of 5% CO2, 1%O2 and 94% N2 (for L87 and HUH7 cell lines a 
culture atmosphere of 5% CO2, 2.5%O2 and 92.5% N2), or mimicked by using 50-
100µM of CoCl2. CoCl2 mimics hypoxia by stabilizing HIF1α, the main mediator of 
hypoxia (Shweta et al. 2015). 
To stimulate cells with thyroid hormones and/or Tetrac for migration, invasion, 
western blot and qPCR experiments cells were subcultured 1:2 into 6cm2 plates with 
respective culture medium. After 24 hrs the medium was renewed and the hormone 
and/or Tetrac was added in various concentrations (T3: 1nM, 10nM, 100nM; T4: 
10nM, 100nM, 1000nM; Tetrac: 100nM). Primary MSCs were also subcultured 1:2 
into 6cm2 plates with respective culture medium. After 24 hrs culture medium was 
changed to medium without thrombocytes and after another 24 hrs stimulation was 
performed as described above.  
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Stimulation with CM produced in house was performed by replacing 20% of the 
respective culture medium with CM. Thyroid hormones, Tetrac and various oxygen 
conditions were applied in addition as described above. 
For western blot experiments, protein was extracted after 14 hrs of culture with sti-
mulants.  
For qPCR experiments the cells were incubated 36 hrs with stimulants and then 
lysated following the PureLink RNA Mini Kit instructions.  
For migration or invasion experiments, cells were incubated with stimulants for 24 hrs 
and then transferred into the migration slides or coincubated with tumor spheroids.  
Transiently transfected cells were stimulated 24 hrs after the transfection in a 24-well 
or 96-well plate without medium change. First various oxygen conditions were added 
for 24 hrs. The following 24 hrs other stimulants were added in addition as described 
above.   
2.2.1.9. Transient transfection and luciferase reporter assay 
To examine function of promoter elements in HUH7 cells and MSCs, the cells were 
transfected with pGL3-luciferase-reporter constructs carrying a hypoxia responsive 
promoter or the RANTES/CCL5 promoter (2.1.8.). Renilla reniformis luciferase 
encoding plasmid (pRL-TK/CMV, Promega) was cotransfected to normalize reporter 
gene activity with the number of viable cells. Consequently, activity of photinus 
pyralis luciferase could be related with the activity of renilla luciferase. Both enzyme 
activities could be determined in the same sample as the enzymes used different 
substrates. Given account to the fact that transfection experiments can yield differing 
results all samples were performed in triplets and all experiments were at least 
repeated three times. 
 
2.2.1.9.1. Transient transfection using electroporation and lipofectamine® rea-
gent 
For transient transfection by electroporation, L87 and HUH7 cells in the exponential 
growth phase (70-80% confluency) were detached using Trypsin-EDTA. Subse-
quently 1.8 Mio cells were suspended in 200µl respective culture medium without any 
supplements. DNA (4µg reporter, 0.04µg control; ratio 1:100) was added and the 
mixture was incubated on ice for 10min in a precooled 4mm cuvette. The ratio of 
reporter plasmid to control plasmid was determined previously in house. Depending 
how many stimuli were tested more cuvettes were needed. All cuvettes were 
prepared in one sample. Cells were electroporated at respective voltage 
(experimentally tested: L87 230V, HUH7 200V) and seeded into cell culture vessels 
at a density of 32,000 cells/cm2. After 4 hrs in normoxic culture, the cells were 
exposed to desired oxygen conditions or CoCl2 for 20 hrs. Subsequently, hormone 
stimulation and/or stimulation with HUH7 conditioned medium was applied for 24 hrs. 
Experiment was terminated by lysating the cells and performing a luciferase assay.  
Lipofectamine® transfection was used for in house isolated and immortalized primary 
MSCs. Cells were seeded into 96-well plates so that on the day of transfection 70-
80% confluency (exponential growth phase) was reached. Transfection was 
performed after manufacturer´s protocol on 96 well plates. Final DNA amount per 
well was 500ng (ratio of reporter to control plasmid 500:1). Final amount of 
lipofectamine® reagent per well was 0.5µl. Transfection was incubated in the 
normoxic incubator for 4-6 hrs. It was terminated by a medium change to normal 
respective culture medium. Now cells were incubated either in the hypoxic or norm-
oxic incubator for 14 hrs and then stimulated with thyroid hormones and tumor super-
natant as described above in 2.2.1.8. and incubated for another 24 hrs. Then cells 
were lysated and a luciferase assay was performed.  
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2.2.1.9.2. Dual Luciferase assay 
For analysis of reporter gene activity, the Dual-Luciferase® Reporter Assay was used 
according to the manufacturer’s protocol. After removing the medium and rinsing the 
cells with 1xPBS, they were lysated with passive lysis buffer (PLB) for 15 min at 
350rpm and room temperature on a thermoshaker. While shaking, assay reagents 
were prepared according to the instructions. Afterwards 20µl of the lysate were ana-
lyzed in the luminometer. 20µl PLB were used as empty control.  
2.2.1.10. Stable transfection of MSCs  
The plasmid of interest was first linearized with appropriate restriction enzymes and 
then purified with the QIAquick Gel Extraction Kit from QIAGEN after the QIAquick 
PCR purification protocol.  
Cells were subcultured to reach 90% confluency on the day of transfection (ca. 10 
Mio cells in a 10cm2 plate). For transfection, they were detached as usual and rinsed 
with PBS twice. Then cells were suspended in 300µl PBS and 30µg linearized 
plasmid/10 Mio cells were added and the mixture incubated on ice for 10 min. 
Afterwards cells were transferred into a precooled 4mm cuvette and then electro-
porated at 960µF and 230V. After another 10 min on ice, cells were transferred into a 
6cm2 plate with respective culture medium. After 24-48 hrs medium was changed 
and dead cells were removed. Selection medium was added after cells had recov-
ered from transfection (for pIR-EGFP-SV40: kanamycin 100µg/ml). After one to two 
weeks, transfection success was evaluated. The SV40 transfected cells were tested 
under the fluorescence microscope and by FACS analysis for EGFP expression.  
2.2.1.11. Mycoplasma test 
Mycoplasma are small prokaryotes that need hosts because of their limited 
biosynthesis capabilities. Frequently they are the reason for cell culture contami-
nations that can lead to reduced cell proliferation and abnormal gene expression. In 
order to exclude the possibility of this contamination before experiments cells were 
tested for mycoplasma on a regular basis with the MykoAlert Mycoplasma Detection 
Kit. In this assay mycoplasma from cell supernatant incubated for at least 24 hrs 
were lysated. Released enzymes initiated a bioluminescence reaction including the 
conversion of ADP to ATP, which could be detected using a luminometer. The ATP 
ratio allowed conclusions regarding the mycoplasma amount.  
2.2.2. Microscopy of cells  
Regular cell microscopy was performed with a binocular stereomicroscope SZX90. 
Fluorescence imaging was performed with an inverted fluorescence microscope at 
10-40x magnification.  
2.2.3. Microbiology   
2.2.3.1. Preparation of agar plates  
Agar plates were prepared by heating 3% Agar and mixing it with an equal volume of 
2xLB medium. If necessary appropriate antibiotics were added (Ampicillin: 100 μg/ml 
final concentration; Kanamycin: 50 μg/ml final concentration) and the mixture was 
dispensed into petri dishes. Finished plates were wrapped in plastic bags and stored 
at 4°C. 
2.2.3.2. Freezing and thawing of bacteria 
Bacteria were long-term preserved in glycerol cultures. 900µl of 12 hrs incubated 
liquid bacteria culture were mixed with 100µl of freezing solution (10x), filled into 
cryotubes and stored at -80°C. To thaw bacteria a part of the glycerol stock was 
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scraped off, spread on agar plates and incubated for 24 hrs. Subsequently one 
colony was picked from the plate and bacteria expanded using liquid culture in LB 
medium. Plasmid DNA was extracted using the Qiagen MiniPrep as described in 
2.2.3.4. 
2.2.3.3. Preparation of competent E.coli DH5α 
To prepare chemically competent E. coli one colony was first picked from an agar 
plate (see 2.2.3.2.) and incubated in 50ml LB medium over night at 37°C and 250 
rpm on a shaker. 4ml of the overnight culture was diluted 1:100 into fresh LB medium 
and incubated at 37°C and 250 rpm until an OD600nm of 0.375 was reached. After 
aliquoting the culture into 50ml aliquots that were kept on ice for 5 min, they were 
centrifuged for 7 min at 1600 rcf (4°C). Bacteria pellet was suspended in 10ml ice 
cold PBS and the centrifugation step repeated. Subsequently, the pellet was suspen-
ded again in 10 ml ice-cold CaCl2 solution and incubated on ice for 30 min. Following 
another centrifugation as described, bacteria were suspended in CaCl2 solution and 
aliquoted into 250µl samples. Subsequently, aliquots were snap frozen in an ethanol/ 
dry ice bath and stored at -80°C. The exposition with calcium ions led to a better 
transformation capability. Bacteria thus were called “competent”.  
For transformation of competent E. coli DH5α bacteria, 1/10 of an entire ligation 
reaction (ca 50-100ng DNA) were used. After rapidly thawing the bacteria, 50μl of 
suspension were added to the DNA. After incubation on ice for 10 min, bacteria were 
transformed by heat shock at 42°C for 45 sec and immediately cooled on ice again. 
The transformed bacteria were suspended in 1 ml LB medium and incubated for  
45 min at 37°C and 250 rpm on a thermoshaker. Afterwards the mixture was plated 
onto agar plates, containing antibiotics for selection of successfully transformed 
colonies, and incubated over night at 37°C. On the next day, single colonies were 
picked and transferred into 5ml LB liquid cultures in order to prepare plasmid DNA. 
They were incubated 12 hrs on a shaker at 37°C. 
2.2.3.4. Purification of up to 20µg plasmid DNA  
DNA was extracted using the Qiagen MiniPrep Kit plasmid according to the 
manufacturer´s instruction from the cultures prepared in 2.2.3.2. The final elution was 
performed with 50µl injection grade water, which usually yielded a DNA concentration 
of 300ng/µl. A diagnostic restriction digestion followed the purification and pre-
parations were ana-lyzed on a 0.6% or 2% agarose gel. Three successful pre-
parations were chosen to be sequenced and one correctly sequenced sample cho-
sen for further expansion.   
2.2.3.5. Purification of up to 10mg plasmid DNA  
After validation of the DNA sequence, plasmid DNA was expanded further by picking 
respective colonies again and incubation a liquid culture of 100ml LB medium for 
12hrs on a shaker at 37°C. DNA was isolated and processed using the endofree 
plasmid maxi kit from Qiagen after the manufacturer’s manual. The elution step was 
performed with 100-300µl injection grade water depending on DNA pellet size. Thus, 
the process yielded about 200-500µg DNA. Preparations were analyzed again on 
0.6% or 2% gels and sequenced.  
2.2.4. Molecular biology 
2.2.4.1. Restriction digestion of DNA 
For restricted digestion of DNA using restriction enzymes, one unit of enzyme per µg 
DNA was used in combination with the enzyme´s respective buffer. The enzyme 
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solution did not exceed 1/10 of the mixture based on water. Digests were incubated 
at appropriate temperature and time on a thermoshaker (37°C, 1 hr). 
2.2.4.2. Separation of DNA fragments by agarose gel electrophoresis 
Agarose gels, containing between 0.6 and 2% agarose, were used to analyze DNA 
fragments. Electrophoresis was performed in 0.5xTBE buffer. DNA samples were 
mixed with 6x agarose gel electrophoresis loading buffer prior to loading into the gel. 
Additionally, 200-400ng of the size standard were loaded into the gel electrophoresis 
was performed at approx.120V (depending on band size and room temperature) until 
optimal separation (approx. 1 hr). Photos of the gels were taken under UV light for 
documentation. When separating DNA fragments, desired bands were cut out under 
UV light. Extraction out of the gel was performed with the QIAquick gel extraction kit 
from Qiagen after the manufacturer’s protocol. The elution step was performed with 
injection grade water instead of included buffer.  
2.2.4.3. Determination of DNA and RNA concentrations 
DNA concentrations were measured fluorometrically with the „Qbit Fluorometer” from 
Invitrogen. The concept of „Quant-IT Technology” is based on a weak fluorescent 
intercalating color, which was added to a standardized volume of DNA or RNA. When 
binding to nuclear acids a fluorescent signal was emitted. It was linearly dependent 
on the amount of DNA or RNA. Through comparison with two standards, DNA 
concentration could be determined. For DNA concentrations between 0.2 and 100 
ng/ml the „Quant-IT dsDNA HS Assay Kit” from Invitrogen was used. For higher 
concentrations between 2ng/ml to 1000ng/ml the „Quant-IT dsDNA BR Assay Kit” 
from Invitrogen was used. All steps were performed according to manufacturer’s in-
structtions. Measuring of RNA concentrations was performed similarly with the 
„Quant-iT RNA” assay.  
2.2.4.4. Ligation of DNA fragments 
Three different reactions were prepared when ligating vector and insert DNA. Two 
reactions used a molar ratio of 3:1 and 10:1 (insert vector). As control a third reaction 
only contained vector. The total volume of each reaction was 20μl containing 400 U 
(~1μl) T4 DNA ligase and 2μl 10x T4 DNA ligase buffer. Ligation was incubated for 1 
hr at room temperature. 
2.2.4.5. DNA sequencing 
Sequencing of plasmid DNA was performed by Entelechon, Bad Abbach through 
cycle sequencing after the described termination of chain reaction (Sanger et al. 
1992). All plasmids used within the scope of this thesis proved to contain the correct 
sequence.  
2.2.4.6. Analysis of gene expression 
2.2.4.6.1. Isolation of RNA  
Cells cultured and stimulated (2.2.1.8.) in 6cm2 plates were lysated using the 
“PureLink RNA Mini Kit” after the manufacturer´s instructions including the optional 
DNase digestion step. The homogenization step was performed when necessary. 
RNA was eluted from the columns using 35μl RNase free water and the RNA con-
centration was determined (2.2.4.3.).  
2.2.4.6.2. Reverse transcription 
The following mixture (RTplus) was prepared for reverse transcription of RNA into 
cDNA: 
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Component Amount (concentration) 
 RNA 2µg (0.05µg/µl) 
First strand buffer (5x) 8µl (1x) 
DTT (0.1M) 2µl (0.5mM)  
RNAsin (40U/µl) 1µl (1U/µl) 
Acrylamide (15µg/µl) 0.5µl (0.1875µg/µl) 
Hexanucleotide (dNTPs, 2µg/µl) 0.43µl (0.0215µg/µl) 
Superscript II reverse transcriptase 
(200U/µl) 
0.86µl (4.3U/µl) 
RNase free water Ad 40µl 
Table 2: Reaction mixture for reverse transcription of 2µg RNA 
As control for contaminations with genomic DNA, a second reaction containing 0.2μg 
RNA was prepared in which the reverse transcriptase was replaced by RNase free 
water (RTminus control). The reaction mixtures were incubated for 90 min at 42°C and 
350 rpm and subsequently stored at -20°C or used immediately for qPCR. 
2.2.4.6.3. Quantitative real-time-PCR (qRT-PCR) 
The qRT-PCR determines the amount of amplification products of a specific PCR-
reaction. The method is based on fluorescent signals that are caused by amplification 
of the sample and their detection with laser technology. There are two main 
concepts; the Taqman method and SYBRgreen assay. For this thesis, both methods 
were used as explained below.  
All assay reagents were designed not to amplify genomic DNA (e.g. intervening 
introns). All controls, containing H2O instead of RNA, were negative in the performed 
experiments as expected.  
Taqman method 
Taqman assays use primers and a double marked probe that hybridizes to the cDNA. 
The probe is marked with a fluorescent dye [FAM (6-Carboxyfluorescein) or VIC] and 
a quencher. Only when primer and probe attached to the cDNA and the Taq 
polymerase amplified the strand, fluorescent dye and quencher were separated by 
the 5‘-3‘-exonucleaseactivity of the polymerase producing a fluorescence signal. This 
signal could be detected. Sequences of assay primers are listed in 2.1.7. (qPCR, 
taqman).  
Component Amount (concentration) 
cDNA 2µl (1:10 diluted RTplus-sample and undiluted 
RTminus sample) 
Taqman Universal PCR Mastermix 10µl (1x) 
Taqman Assay (primer probe mix) 1µl  
RNase free water Ad 20µl 
Table 3: Reaction mixture used for qRT-PCR using premixed Taqman assay 
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A variant of this experiment included separate forward and reverse primers instead of 
one complete assay. The mixture was prepared as outlined below:  
Component Amount (concentration) 
cDNA 2µl (1:10 diluted RTplus-sample and undiluted 
RTminus sample) 
SYBRgreen mastermix  10µl (1x) 
Target  0.4µl (100nM) 
FW-primer 0.6µl (300nM) 
RV-primer 0.6µl (300nM) 
RNase free water Ad 20µl 
Table 4: Reaction mixture used for qRT-PCR with separate forward and reverse primers 
The components were plated onto 96 well plates with a total volume of 20µl per well.  
For qRT-PCR ABIPrism7000 Sequence detection system and a heat activated Taq-
polymerase were used. After an initial incubation for 2 min at 50°C and for 10 min at 
95°C samples were cycled 40 times for 15 sec at 95°C and for 60 sec at 60°C. For 
each sample RTplus, RTminus and NTC (no template control, no cDNA, primer control) 
in duplicates were examined. Due to the genes of interest being involved in the 
HIF1α biology, no GAPDH- or HIF1α-driven genes were used as reference genes. 
Therefore, expression of target genes was normalized to ubiquitously expressed 
reference genes rRNA. For quantification of the PCR product kinetics of the reaction 
have to be taken into consideration. To do so the threshold cycle was determined for 
each sample (CT-value). Low CT-value stands for a signal detection in an early cycle 
and thus for a higher amount of mRNA in the sample, opposite is true for high CT-
values. Quality criteria for good PCR reaction were negative NTC controls a 
difference of 5 cycles in between RTplus and RTminus samples. Amount of the target 
PCR product was calculated using the reference gene after the following formula: 
ΔCT = CT (target gene) – CT (reference gene). As cDNA doubles each cycle of the 
exponential phase, values were expressed as 2ΔCT. Negative samples were given 
the value 40, as this was the maximum number of cycles.  
SYBRgreen method 
SYBRgreen-based detection works if a gene-specific amplicon is generated during 
the PCR. SYBRgreen causes green fluorescence after intercalation in double 
stranded DNA at low temperatures. Fluorescence is linearly dependent on the 
amplification of template DNA. Melting temperatures were analyzed to check the 
specificity of the amplicons. Increasing of assay temperature from 50 to 95°C lead to 
dissociation of double stranded DNA and decrease of fluorescence at a specific 
temperature. This temperature is characteristic for each amplicon as it depends on 
length and base content. Only wells with a single melting point (fluorescence drop off) 
at expected temperature were included. Primers are listed in 2.1.7. (qPCR, 
SYBRgreen).   
The components were plated onto 96 well plates with a total volume of 20µl per well.  
After an initial incubation for 10 min at 95°C, samples were cycled 40 times for 15 
sec at 95°C and 1 min at 60°C.  
For each sample RTplus, RTminus and NTC (no template control, no cDNA, primer 
control) in duplicates were examined. Due to the genes of interest being involved in 
the HIF1α biology no GAPDH- or HIF1α-driven genes were used as reference genes. 
Therefore, expression of target genes was normalized to reference gene 18S rRNA. 
Quantification using CT values was performed as described above. In addition, a one 
peaked melting curve ensured a specific amplicon product. 
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Component Amount (concentration) 
cDNA 2µl (1:10 diluted RTplus-sample, undiluted 
RTminus-sample) 
SYBRgreen mastermix 10µl (1x) 
SYBRgreen FW-primer 0.6µl (300nM) 
SYBRgreen RV-Primer 0.6µl (300nM) 
Taq DNA polymerase  0.12µl (U/µl) 
RNase free water Ad 20µl  
Table 5: Reaction mixture used for qRT-PCR using SYBRgreen method 
2.2.5. Cloning strategies for luciferase reporter constructs 
The constructs used to evaluate reporter gene activity were based on the basic pGL3 
luciferase reporter vector [by Promega (USA)]. The pGL3 basic vector does not 
contain eukaryotic promoters or enhancer elements, while the pGL3-SV40 promoter 
vector contains a minimal SV40 promoter. The pGL3-SV40 vector is used to study 
enhancer-like activity of cloned sequences. For selection in bacteria, the plasmid 
contains an ampicillin resistance gene. The RANTES/CCL5 construct was cloned in 
house by Sabine Fessele (AG Klinische Biochemie, Prof. Nelson) (Fessele 2001). It 
contains 971 nucleotides of the human RANTES/CCL5 immediate upstream region 
driving firefly luciferase (Figure 15A). To characterize MSC hypoxia response HIF1α -
responsive elements were inserted in front of the SV40 minimal promoter as well as a 
blasticidin selection controlled by a CMV promoter downstream from the firefly 
luciferase to allow stable cell transfection [modification in house by Anna Hagenhoff 
(AG Klinische Biochemie, Prof. Nelson)]. (Figure 15B) 
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A) 
 
B) 
    
Figure 15: pGL3-based luciferase reporter vectors: A) RANTES/CCL5 promoter (pGL3-RFL) dri-
ving firefly luciferase reporter versus B) HIF1α-responsive promoter (pGL3-6xHRE-luc-Blasti_clock-
wise) driving firefly luciferase reporter. 
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2.2.6. Protein biochemical methods 
Western blotting was used to determine the intracellular level of HIF1α protein in 
MSCs and HUH7 cells under different conditions. As first step, a protocol was 
established to reach an optimal protein yield. Therefore, different extraction buffers 
and a time course of different extraction time points were evaluated. Primary cells did 
not yield enough protein for large-scale analyses. Therefore, preliminary experiments 
were performed using immortalized MSCs.  
2.2.6.1. Protein extraction 
Cells were plated into 6cm2 culture vessels and incubated with stimulants for 12 hrs 
as described in 2.2.1.8. Afterwards cells were rinsed with ice-cold PBS and protein 
extraction was performed using RIPA lysis buffer (2.1.3.1.) to gain a whole cell lysate. 
For hypoxic samples PBS and RIPA were equilibrated in a hypoxic incubator. Cells 
were scraped off the plate and the lysate was transferred into 1.5ml tubes on ice 
where the lysate was incubated for 1 hr and stirred lightly from time to time. 
Afterwards lysate was centrifuged for 15 min at 16000rpm and 4°C in a refrigerated 
centrifuge. The supernatant was aliquoted and frozen at -20°C immediately.  
In addition to the RIPA lysis buffer, we also tested a buffer separating nuclear from 
cytosolic proteins (Kumar 2009) and a self-designed buffer based on buffers for HIF 
protein extraction in different publications (Srinivasan et al. 2011). For separating 
nuclear and cytosolic proteins cells were washed with ice-cold PBS, collected in 
buffer A and incubated on ice for 15min. Suspension was centrifuged for 15 min at 
2000 rcf and 4°C. The supernatant contained the cytosolic protein fraction. The pellet 
was suspended in 200µl buffer B, incubated on ice for 1 hr and centrifuged at 16000 
rcf and 4°C for 15min. Supernatant was aliquoted and immediately frozen at   -20°C. 
The buffer based on Srinivasan et al. served for cell collection as well. Suspension 
was rotated upside down for 1 hr at 4°C, centrifuged for 10 min at 10000 rcf and the 
supernatant frozen at -20°C.  
After a preliminary experiment comparing all three buffers we decided to carry out all 
further experiments with the RIPA buffer as described above.  
After evaluating different protein extraction buffers a time course from 12 to 72 hrs 
was performed in order to optimize the best time point for extraction and maximum 
expression. 12 hrs proved to yield sufficient protein concentrations for analysis. Thus, 
RIPA buffer and 12 hrs incubation time were used for all further experiments. For 
normoxic conditions, the cells were incubated in 21% O2, whereas for hypoxic 
conditions either incubation in 1% O2 atmosphere or treatment with 100µM CoCl2 was 
used for stabilization of HIF1α. 
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Figure 16: Establishment of western blot conditions for analysis of MSC hypoxia response: 
N=21%O2, H=1%O2, C=100µM CoCl2. Extracts were run on 6-8% gradient gels under non-denaturing 
conditions. α-tubulin antibody was used as internal control to ensure equal protein amount in samples. 
A) Evaluation of different protein extraction buffers for HIF1α protein: 1. Self-designed buffer, 
whole cell lysate 2. RIPA buffer, whole cell lysate 3.”Dual buffer”, cytosolic and nuclear fraction. 
Results show increase of HIF1α protein after 12 hrs exposure with 1%O2 and 100µM CoCl2 in 
comparison to normoxic exposure (21%O2); RIPA buffer proves to be most effective. Extraction with 
“Dual buffer” shows that HIF1α protein is located in the cytosol as well as the nucleus. B) Extraction 
at different time points to find maximum expression of HIF1α: Protein was extracted using RIPA 
buffer from cells treated with 100µM CoCl2 at four different time points: 12, 24, 48 and 72 hrs. 12 hrs 
proved to be optimal. C) Optimal assay conditions: HIF1α protein level increases under hypoxic 
conditions after 12 hrs in MSCs. 
2.2.6.2. BCA-Assay Protein quantification 
The measurement of protein content in samples was performed with Pierce™ BCA 
Protein Assay Kit. This assay from Thermo Scientific™ is a detergent-compatible 
formulation based on bicinchoninic acid (BCA) for the colorimetric detection and 
quantification of total protein. This method combines the well-known reduction of 
Cu+2 to Cu+1 by protein in an alkaline medium (the biuret reaction) with the highly 
sensitive and selective colorimetric detection of the cuprous cation (Cu+1) using a 
unique reagent containing bicinchoninic acid. The purple-coloured reaction product is 
formed by the chelation of two molecules of BCA with one cuprous ion. This water-
soluble complex exhibits a strong absorbance at 562nm that is nearly linearly 
dependent on increasing protein concentrations over a broad working range (20-
2000μg/ml). The BCA method is not a true end-point method; that is, the final colour 
continues to develop. However, following incubation, the rate of continued colour 
development is sufficiently slow to allow large numbers of samples to be assayed to-
gether.  
Protein concentrations generally are determined and reported with reference to 
standards of a common protein such as bovine serum albumin (BSA). A series of 
dilutions of known concentration are prepared from the protein and assayed along 
side the unknown before the concentration of each unknown is determined based on 
the standard curve. If precise quantification of an unknown protein is required, it is 
advisable to select a protein standard that is similar in quality to the unknown.  
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Measurements were performed according to manufacturer’s instructions in the 
Microplate Procedure. This protocol affords the sample handling ease of a microplate 
and requires a smaller volume (10-25μL) of protein sample; however, because the 
sample to working reagent ratio is 1:8 (v/v), it offers less flexibility in overcoming 
interfering substance concentrations and obtaining low levels of detection. 
2.2.6.3. SDS-Page and western blot 
 Western blotting was performed as previously described (Towbin et al. 1979).  
 
 
 
 
 
 
 
 
 
 
Table 6: Recipe for 6-8% resolving gel. 
For each sample, an appropriate amount of protein was determined. For normoxic 
samples 40µg, samples from primary MSCs 60µg, samples from HUH7 and hypoxic 
samples 20µg. As antibodies typically recognize a small portion of the protein of 
interest (epitope) and this domain may reside within the 3D conformation of the 
protein access needs to be enabled by denaturing the protein. To denature, a loading 
buffer with the anionic denaturing detergent sodium dodecyl sulfate (SDS) was used 
as described by Laemmli (Laemmli 1970). It was added to corresponding amounts of 
the different samples and the mixture incubated for 5 min at 95°C in order to reduce 
and denature samples. For resolving the proteins, a SDS-polyacrylamide gel electro-
phoresis was performed on a 6% and 8% resolving gel according to the expected 
sizes of HIF1α (120kDa) and α-tubulin (52KDa). Resolving gels with a final volume of 
20ml were prepared as summarized in Table 6.  
Following polymerization, a 5% stacking gel was placed above two layers of resolving 
gels (6% and 8 %). Gels were stored in humidified atmosphere at 4°C for no longer 
than one week. Samples were mixed with Laemmli buffer. 0.5-1.5µl MagicMark size 
standard for molecular weight estimation was loaded into one well and subsequently 
samples were loaded into separate wells. Electrophoresis was performed in electro-
phoresis buffer at 80V until samples had entered the stacking gel and subsequently 
at 120V. 
Proteins were electro-blotted onto PDVF-membranes in a wet blot with NuPage 
transfer buffer for 1 hr at 30V. Then the membranes were blocked at least for 1 hr at 
room temperature or overnight at 4°C with 5% skim milk powder in TBST [0,5 g skim 
milk powder added to 10 ml TBST (1x TBS + 0,05% (v/v) Tween 20)]. Then 
membranes were washed three times with water and incubated over night at 4°C on 
a roller with the Anti-Human HIF-1α antibody diluted (ratio 1: 1000) in TBST. 
On the next day, membranes were washed four times with TBST at room tem-
perature for 10 min. Subsequently membranes were incubated for 1 hr with the 
second antibody (Polyclonal Rabbit Anti-Mouse Immunoglobulin HRP) diluted (ratio 
1:5000) in 5 % skim milk powder in TBST on a roller. Finally, membranes were 
washed four times with TBST at room temperature for 10 min and then rinsed two 
times for 5 min with PBS before evaluation using the ECL Kit from Perkin Elmer 
according to manufacturer´s instructions. For developing membranes were trans-
Reagent Gel 6% Gel 8% 
H
2
O  10.6 ml 9.3 ml 
30% Acrylamide  4 ml 5.3 ml 
Tris-HCl (1.5 M, PH 8.8)  5 ml 5 ml 
10% SDS  200 μl 200 μl 
10% APS 
(Ammoniumpersulfate) 
200 μl 200 μl 
TEMED  
(Tetramethylethylendiamine)  
20 μl 20 μl 
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ferred into dark chamber in TBS and immersed in 4ml ECL substrate solution for 1 
min. Excess substrate was wiped off and an autoradiography film (Amersham 
Hyperfilm ECL) was exposed to the membrane. Film was incubated 1 hr for detection 
of HIF1α and 10 sec to 5 min for α-Tubulin expression. The film was developed using 
a developing machine. 
2.2.7. Chemotaxis assay 
Chemotaxis experiments were performed with the 3D chemotaxis assay from Ibidi 
using their µ-slide chemotaxis 3D. These slides are a tool used to observe the active 
movement of cells (chemokinesis) and directed movement towards a chemo attract-
tant (chemotaxis) of cells embedded in 3D gel matrix. The general principle of this ex-
periment is a slide with two large-volume (60µl) reservoirs connected by a small gap 
(=observation area=1000x2000 µm2). If the two reservoirs contain different chemo 
attracttants or different concentrations of the same chemo attractant, then there is a 
lin-ear concentration drop inside the gap. Cells placed in the gap are ex-posed to this 
gradient.  
For 3D experiments as conducted for this thesis, cells were embedded in a collagen 
gel matrix. The cell number inside the channel was chosen according to the cell´s 
size so that each cell could move freely without touching other cells.  
 
 
               
Figure 17: Principle of µ-slide chemotaxis  3D: After stimulation, MSCs in collagen I gel solution 
were seeded into the observation channel and reservoirs were filled on the left side (red) with assay 
medium and  on the right side (blue) with HUH7 conditioned medium as chemo attractant. (ibidi GmbH 
2012) 
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2.2.7.1. Chemotaxis assay preparation 
The chemotaxis assay was used to examine the MSC response to HUH7 conditioned 
medium as chemoattractant with or without prior thyroid hormone/Tetrac treatment. In 
addition, the influence of continuous stimulation with the hormones during the assay 
was examined. At first, optimal assay conditions were evaluated with the help of 
Alexandra Wechselberger (MTA, AG Klinische Biochemie, Prof. Peter Nelson). The 
final choice was a 3D assay with a gel concentration of 1mg/ml and tumor 
conditioned medium (HUH7 cell line) as chemo attractant. Primary MSCs showed the 
highest migratory capacities in comparison to immortalized primary or L87 MSCs.  
Cells were prestimulated in 6cm2 cell culture dishes for 24 hrs as described in 
2.2.1.8. For all cell lines, this was conducted in respective growth medium, except for 
primary MSCs. Here thrombocytes and heparin were removed 24 hrs prior to 
stimulation. Continuous hormone treatment was performed inside the chemotaxis 
slide. The µ-slide Chemotaxis 3D was prepared according to manufacturer´s 
instructions (see application note 17+23+26, Ibidi) with the modification that all 
reagents had to be buffered with 15mM HEPES as recommended alternative for CO2 
fumigation that was not possible while performing the assay. Three different 
conditions could be examined per slide and four slides could be run at the same time. 
Assay medium was prepared by adding 1%BSA and 15mM HEPES to DMEM or 
RPMI medium depending what medium had been used as gel medium. Chemotaxis 
slide was unpacked, reservoir ports were closed using the plugs provided and 
afterwards placed inside a wet chamber (15cm cell culture dish with wet tissues). 
Subsequently, wet chamber, tumor conditioned medium and freshly prepared gel 
medium were transferred into the cell culture incubator for at least 30 min to ensure 
gas equilibration to culture atmosphere. For primary MSCs 1mg/ml DMEM gels, for 
L87 cells 1mg/ml RPMI gels were used: 
reagents manufacturer final concentration in gel ingredients 
RPMI 10x or 
DMEM 10x 
Sigma R1145 
Sigma D2429 
1x  
200mM L-
Glutamine (30g/l) 
Biochrom 
K0283 
RPMI-Gel 0,3g/l          
DMEM-Gel 0,584g/l 
 
 
 
7,5% NaHCO3  
(75g/l) 
GIBCO 25080 RPMI-Gel 2g/l              
DMEM-Gel 3,7g/l 
gelmedium 
1M NaOH Roth 6771 For pH7,3 
VolumeNaOH  =  VolumeCollagen x 
0.025 
 
HEPES GIBCO 15630 15mM  
Collagen I  
5mg/ml 
GIBCO  
A10644-01 
1 mg/ml Collagen 
Table 7: Basic recipe for collagen I gel matrix 
Stimulated cells were detached and suspended in assay medium at a concentration 
of 0.6 Mio primary MSCs /ml and for L87 at 0.9 Mio cells/ml. 
To prepare a suspension of cells in collagen I gel three parts of gel medium and two 
parts of collagen were mixed thoroughly by pipetting on ice followed by adding five 
parts of cell suspension. After thoroughly mixing by pipetting, 6µl were put on one 
side of the observation channel. By aspiration on the other side, the channel was 
filled. In order to obtain a regular fiber structure the pipetting had to be performed on 
ice and terminated within 2-3 min, as the formation of collagen fibers is pH- and tem-
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perature-dependent. Subsequently, channel ports were closed and reservoir ports 
opened. After checking the observation channels for air bubbles, cell number and cell 
distribution the slide was incubated vibration-free for 30min inside the wet chamber in 
the cell culture incubator in order to let the gel matrix get firm. After channels were 
checked for homogeneous fiber structure, reservoirs were filled with 65µl assay 
medium on the left and 65µl HUH7 conditioned medium on the right. After closing all 
ports slide was checked again and put into the heated incubation chamber for time-
lapse microscopy. 
2.2.7.2. Video microscopy 
The slide was placed inside a four channel chamber heated to 37°C, under an 
inverted Leica DMIL microscope with CCD Camera ProgRes®CF. With the ImageJ 
based MicroManger program, pictures were taken every 12 min over 24 hrs at 50x 
magnification. 
2.2.7.3. Chemotaxis analysis using Image J (plugins: Manual tracking, Chemo-
taxis tool) 
Cells were tracked with the “Manual tracking” plug in from ImageJ. The pixel size 
(X/Y calibration) was 2.0901 µm and was determined with a known distance in a 
Neubauer counting chamber. 20-30 randomly distributed living cells were tracked 
manually in all 120 pictures. The tracks were analyzed with the ImageJ plug in 
“Chemotaxis tool” for distance, directionality, velocity. FMI (forward migration index) 
and distribution (Rayleigh test for vector data) were calculated. Tracks were 
visualized in a vector plot. Values for each track were exported to Microsoft excel as 
well as GraphPad Prism and visualized graphically.  
2.2.7.4. Chemotactic and chemokinetic parameters 
Chemotaxis is the directed movement of cells toward a certain stimulus, whereas 
chemokinesis is characterized by distance traveled and velocity. I analyzed the 
chemotactic and chemokinetic response of MSCs to thyroid hormone treatment. MSC 
migration can be characterized by the following parameters:  
 Chemokinesis: 
 Accumulated and Euclidean distance: The accumulated distance displays the 
length of the cell´s actual path in µm and considers all direction changes. 
Opposed to that, the euclidean distance (in µm) only displays the net 
distance between the cell´s starting and end point. 
 Velocity is the quotient of time and travelled distance in µm/min. 
 Directionality describes the directness of the cell trajectories. It is however not 
taking into account the direction of the cell´s movement. It can be calculated 
by dividing euclidean through accumulated distance. A directionality of D = 1 
equals a straight-line migration from start to endpoint regardless of the 
direction. 
 Chemotaxis:  
 Forward migration index (FMI) represents the efficiency of the forward 
migration of the cells in relation to the chemical gradient (x or y-axis 
depending on experimental set up). The larger the index on one axis the 
stronger the chemotactic effect on this axis. In some experiments, the x-axis 
lies perpendicular to the chemotactic gradient; whereas the y-axis lies 
parallel to the gradient for other experiments so that the distribution is vice 
versa. Therefore, the ratio of the cell´s net distance travelled along the x/y-
axis to the cell´s accumulated distance is of interest. A positive FMI means a 
movement toward higher concentrations of chemo attractant; a negative FMI 
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means a movement toward lower concentrations of chemo attractant. This 
means the shorter the accumulated distance in relation to the axis endpoint 
the more straight forward the cell´s pathway and the higher the FMI value.  
 Center of mass (CoM) describes the averaged movement of all cells from the 
starting point. It is also a general indicator if the movement tends to be 
toward higher chemo attractant concentrations, lower or neutral.  
 Rayleigh test for vector data can be performed with the Image J plugin 
Chemotaxis and Migration. It is a statistical test of the uniformity of a circular 
distribution of points. The null hypothesis (uniformity) is rejected with p-
values smaller than p=0.05. The test for vector data also takes into account 
the distance from origin, when creating an analysis. (2.2.10.1.) 
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A) 
    
 
Figure 18: Parameters for evaluation of MSC migration: A) Trajectory plot example: Chemo 
attractant gradient from lower to upper reservoir (CM). Red lines indicate movement toward the chemo 
attractant; black lines indicate movements away from chemoattractant. Blue cross indicates the center 
of mass (CoM). B) Chemotactic and chemokinetic parameters: Accumulated distance represents 
the cell´s complete pathway, while euclidean distance represents the distance between cell´s starting 
point and destination. Directionality is the ratio of euclidean distance to accumulated distance. The 
forward migration index in y-direction (y-FMI) indicates movement along the chemical gradient. It is the 
quotient of the cells net distance travelled in y-direction and the accumulated distance summarized for 
all cells. The displacement of center of mass (Mend) calculates the averaged end point of all cell 
endpoints by subtracting the starting from the end coordinates. Not shown: Velocity is the distance 
travelled over time.   
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2.2.8. Tumor spheroid model 
The tumor spheroid model was established in collaboration with Alexandra 
Wechselberger (MTA, AG Klinische Biochemie, Prof. Nelson), Anna Hagenhoff (AG 
Klinische Biochemie, Prof. Nelson) and Svenja Rühland (bioimaging Zentrum, Prof. 
Dr. Uhl and AG Klinische Biochemie, Prof. Nelson). After preliminary experiments, 
shown in this thesis, the method was developed further to a quantifiable MSC 
invasion assay (Ruhland et al. 2015). Tumor spheroid models are a sufficient means 
to mimick in vivo tumor biology in vitro. Especially aspects of intervascular tumor 
microenvironments as well as tumor growth and physiology can be easily examined 
in this well manageable model.  
2.2.8.1. Spheroid formation 
Many tumor cells tend to attach to each other when lacking the possibility to grow in 
monolayers. Cell attachment was inhibited by coating the culture flasks and dishes 
with polyHEMA (poly-2-hydroxyethyl methacrylate). They were covered with 2% 
polyHEMA in 95% Ethanol and allowed to dry completely. This step was repeated 
once to create an even layer. To obtain hepatocellular carcinoma (HCC) spheroids, 
HUH7 cells were cultivated in polyHEMA-coated dishes at 37°C and 5% CO2. After 
seven to ten days, spheroids had grown to an appropriate size of 200 to 500μm. At 
this size, spheroids began to show central necrosis. To ensure uniform size 
spheroids were filtered through a nylon filter with 300μm and 400µm pores. The 
experiment was conducted likewise for HT29 cells. 
 
Figure 19: Example of 5-day-old HUH7 tumor spheroid in vitro: HE stained, formalin fixed 16µm 
frozen section of one HUH7 tumor spheroid measuring approximately 300µm in diameter. The 
spheroid center shows fewer, condensed nuclei that lie further apart depicting necrosis whereas highly 
proliferating outer layers show tightly packed nuclei.  
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2.2.8.2. Frozen section of HUH7 tumor spheroids 
Spheroids were transferred to cryomoulds and embedded in TissueTek OCT 
mounting medium (Sakura). They were shock-frozen on dry ice and stored at -20°C. 
Frozen section was performed with refrigerated microtome Cryostat Jung CM 3000 at 
-20°C. Serial section into 16µm layers was performed on each spheroid. Complete 
samples were placed on Superfrost™ Plus microscope slides and were allowed to 
dry for app. 1 min at room temperature. 
2.2.8.3. HE staining of HUH7 tumor spheroids 
Before HE staining, sections were fixed in formalin for 10 min and afterwards rinsed 
with PBS. Haematoxylin stains acidic structures e.g. nuclei with DNA blue. Eosin 
stains acidophil structures in cytoplasm red. Sections were placed in hematoxylin 
solution for 3 min and afterwards rinsed with tap water for 5 min. The slide was 
placed in eosin solution for 20 sec and then dehydrated using ethanol baths with 
increasing alcohol concentration (70%, 96%, 100%) and xylol. Mounting medium was 
applied and cover glass placed on top. Samples were examined with inverted 
fluorescence microscope DMIL.  
2.2.8.4. Staining of necrotic and hypoxic areas in HUH7 and HT29 tumor 
spheroids 
To visualize hypoxic and necrotic areas of in vitro tumor spheroids, further stainings 
were performed. Hoechst 33342 is a cell permeable nucleic acid stain, which binds 
especially to adenine-thymine-rich regions of DNA in living cells. Thus, living cells 
show blue color in fluorescence microscopy. PI is a membrane impermeant, 
intercalator dye suitable for fluorescence microscopy. It can only penetrate the cell 
membrane of dead cells, which appear red in fluorescence microscopy.  
For visualization of necrosis a live/dead staining with both chemicals was performed. 
19-day-old HUH7 spheroids were cultured for 24 hrs with 1µg/ml Hoechst 33342 and 
10µg/ml PI in the cell culture incubator in respective culture medium 2. Afterwards 
spheroids were examined with inverted fluorescence microscope DMIL.  
The stain for hypoxia was performed using the Hypoxyprobe™-1 Kit. The chemical 
pimonidazole is activated in hypoxic cells and forms stable adducts with thiol groups 
in proteins. The antibody MAb1 (mouse IgG1 monoclonal antibody) contained in the 
kit binds to these adducts allowing their detection by immunochemical means. This 
method allows accurate measurement of oxygen gradients at the cellular level. DAPI 
binds especially to AT-rich regions of DNA staining cell nuclei with blue fluorescence.  
Seven-days-old HUH7 tumor spheroids were cultured with 100µM pimonidazole for 
24hrs. Serial section was performed as described in 2.2.8.2. Sections were fixed in 
formalin for 20 min. After three rinses with PBS they were permeabilized for 10 min 
with 0.5% Triton X100 and blocked with 5% donkey serum in PBS for 1 hr at RT. 
Afterwards samples were incubated over night at 4°C with MAb1 (1µg/µl) in 0.1% 
donkey serum-0.1%Tween20-PBS. After three 5 min-rinses with PBS secondary anti 
mouse antibody conjugated with AF594 from Jackson Immunoresearch (715-585-
151) was applied (7.5µg/µl) in PBS with 0.1% donkey serum. Subsequently, nuclei 
were stained blue with 200ng/ml DAPI in PBS for 10 min and finally slides rinsed with 
PBS three times for 5 min. Slides were covered with mounting medium consisting of 
0.2% NPG, 50% glycerol and PBS and examined with inverted fluorescence 
microscope DMIL. 
As this stain did not work in HUH7 tumor spheroids, possibly due to inadequate 
uptake of pimonidazole, it was performed in 20-day-old HT29 tumor spheroids.  
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2.2.8.5. CMFDA staining of MSCs 
MSCs were grown to 70-90% confluency in 6cm2 cell culture dishes. After rinsing 
them once with PBS, they were incubated with DMEM and 1µM CMFDA for 30 min at 
37°C and 5% CO2 for dye uptake. Subsequently, dye was removed and MSCs 
incubated in DMEM with 10% sFCS for another 30 min to allow conversion of the dye 
to fluorescence product.  Afterwards cells were detached using Trypsin-EDTA.  
2.2.8.6. Invasion of CMFDA stained MSCs 
A single spheroid was rotated horizontally in 50µl culture medium containing 2.5x104 
stained MSCs at 36rpm for 2 hrs. To wash away redundant MSCs the spheroid was 
rinsed three times with 0.5ml culture medium. For further culture, spheroids were 
transferred into a polyHEMA coated 96well plate with 100µl culture medium. After 
24hrs spheroids were fixed in 4% formalin for 2 hrs at room temperature and sub-
sequently rinsed once with PBS.  
Frozen serial section was performed and TissueTek OCT was removed by washing 
in PBS for 5 min at RT. For nuclei staining 200ng/ml DAPI were added to the 
mounting medium consisting of PBS with 50% glycerol and 0.2% propyl gallate. 
Samples were examined with inverted fluorescence microscope DMIL. 
2.2.9. MTT-Assay 
Cell proliferation was evaluated using the MTT-Assay as previously described 
(Mosmann 1983). With this assay, thyroid hormones, different oxygen conditions and 
HUH7 cell supernatant were tested for influence on MSC growth rate. The underlying 
principle is an indirect approach using a chromogenic indicator in this particular case 
the conversion of water soluble MTT ((3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl-
tetrazolium bromide) to insoluble formazan by living cells. Solubilized formazan can 
be detected at 570nm. The chromogenic signal is linearly dependent on the cell 
number allowing exacting evaluation of growth rates.  
Cells were subcultured in 96 well plates at a ratio allowing the cells to reach 100% 
confluence on the last day of the assay. All values were evaluated in triplets. Acidified 
isopropyl was prepared by adding 1N HCl to Isopropyl at a ratio of 1:24. MTT-solution 
was prepared by adding 50ml of RPMI without phenol red to 250mg of MTT powder 
and sterile filtrating the solution through a 0.22µm filter. To start the assay 
supernatant of adherent cells was removed and 50µl of MTT solution added per well. 
Cells were incubated for 3 hrs at 37°C and 5% CO2. Subsequently plates were 
centrifuged for 5 min at 750rcf (ca 2000 rpm), supernatant was removed and 100µl 
acidified isopropyl were added per well. After solubilization of the color crystals, 
emission was measured with an ELISA plate reader at 570nm (reference 690nm). If 
growth rate was evaluated over several days, different plates for each time point had 
to be prepared.  
2.2.10. Statistical analysis 
Statistical analysis was performed with Graph Pad Prim 6. Results were analyzed 
with two-tailed Student´s t-test. Unless stated differently means and standard 
deviation (SD) are reported for n ≥ 3 independent experiments. For qPCR ex-
periments mean fold change is reported. P-values < 0.05 were considered as 
significant (p<0.05 *, p<0.01 **, p<0.001***, p<0.0001****).  
For the chemotaxis assay, Rayleigh Test for vector data was performed in addition 
with Image J Plugin chemotaxis tool.  
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2.2.10.1. Rayleigh test for vector data 
The p-value calculated by Rayleigh-test for vector data describes the distribution of 
all tracked endpoints in the chamber. It is a statistical test for the uniformity of a 
circular distribution of points (cell endpoints). With p-values above 0.05, the null 
hypothesis (= uniformity) is rejected. Like all statistical tests, it strongly depends on 
the number of cells being analyzed. It was originally designed to describe circular 
distributions of data points. The calculated p-value (significance) describes if the cells 
are rather homogenously (p>0.05) or inhomogeneously (p<0.05) distributed in the 
trajectory plot. This parameter also describes the cell´s chemotactic response. After a 
directed migration, cells are distributed rather inhomogeneously, more toward the 
side of the chemo attractant. The exact calculation can be found in a publication by 
Moore from 1980 (Moore 1980). 
 
Figure 20: Explanation of p-values in Rayleigh-test: P-value < 0.05 means cells are distributed 
inhomogeneously, p-value > 0.05 means cells are distributed homogeneously. 
 
 
 
 
 
 
 
Results  53 
3. Results  
3.1. Synthetic HIF1α-responsive promoter in MSC-based gene-
therapy of solid cancers 
3.1.1. Utilizing the hypoxia response system in MSCs 
As detailed in 1.3., the goal of this doctoral thesis was to evaluate a potential new 
means of targeting transgene MSCs within tumor settings by making use of the 
hypoxia response system. The first step was to characterize the influence of different 
oxygen levels on HIF1α protein expression in MSCs (3.1.2.). Subsequently, HIF1α-
dependent reporter gene activation in MSCs was studied. In parallel, the potential 
activation of HIF1α-responsive elements within human RANTES/CCL5 gene 
promoter, the promoter currently used in the suicide gene system under clinical trial, 
was assessed. (3.1.3.) 
As a next step, cell viability, hypoxia and necrosis were characterized in a HCC tumor 
spheroid model. The final step was an evaluation of the invasion of engineered 
MSCs into the spheroid model, and the subsequent activation of HIF1α-driven 
reporter genes.  
3.1.2. HIF1α protein level in MSCs increases under hypoxic conditions  
Western blot experiments were used to measure HIF1α protein levels in MSCs under 
various oxygen conditions. This was performed to characterize the MSC response to 
hypoxia. As a first step, protein extraction conditions were optimized as described in 
2.2.6.1. RIPA buffer was eventually found to work well and was used to extract 
protein from MSCs after 12 hrs of normoxic (21% O2) or hypoxic (1% O2 or 100µM 
CoCl2) stimulation. Results showed an increase of intracellular HIF1α protein under 
hypoxic conditions, in comparison to incubation with 21% O2 thus providing a base-
line for further experiments.  
 
                                    
Figure 21: Increased intracellular HIF1α protein level under hypoxic conditions in MSCs after 
12 hrs: Whole cell protein extracts (RIPA extraction buffer) from MSCs, incubated in respective culture 
medium with 21%O2 (N), 1%O2 (H) or 100µM CoCl2 (C) for 12 hrs, were run on 6-8% gradient gels 
under non denaturing conditions. α-tubulin antibody was used as internal control to ensure equal 
protein amounts in samples. HIF1α protein level was significantly increased after 12 hrs incubation in 
hypoxia in comparison to normoxic incubation. The results are representative of three independent 
experiments.  
3.1.3. Hypoxic activation of synthetic HIF1α-responsive promoter and its com-
parison to the human RANTES/CCL5 gene promoter  
As shown above, MSCs exhibit a stably inducible response to hypoxia. Most solid 
tumors, such as HCC, contain hypoxic areas of reduced cell viability due to tumor 
growth outpacing vascularization (Gammon et al. 2013). We sought to determine, if 
the hypoxic response could potentially be used for tumor-specific transgene MSC-
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based therapy by using synthetic HIF1α-responsive promoters to drive effector gene 
transcription.  
 
Figure 22: Principle of promoter induced reporter gene activity: A synthetic promoter (A) 
consisting of six HIF1α-responsive elements (blue) linked to a SV40 minimal promoter (orange) was 
used to drive firefly luciferase as reporter gene. Its activation was compared to human RANTES/CCL5 
gene promoter [(B), (green)] containing HIF1α-responsive elements (blue) driving firefly luciferase.  
Immortalized primary MSCs were transiently transfected with a reporter construct 
based on a pGL3 luciferase reporter vector. This plasmid contained a synthetic 
HIF1α-responsive promoter driving the firefly luciferase and a blasticidin selection 
gene [modification in house by Anna Hagenhoff (AG Klinische Biochemie, Prof. 
Nelson)]. Transfection was performed chemically using lipofectamine transfection 
reagent.  Cells were exposed to 1% O2 or 100µM CoCl2 for 48 hrs after transfection. 
Luciferase assays were then used to quantify the potential activation of the 
transgene. MSCs showed efficient induction of firefly luciferase driven by the HIF1α-
responsive promoter (Figure 23) under hypoxic conditions in comparison to 21% O2. 
Repeating the experiment and replacing 20% of the respective culture medium during 
hypoxic incubation with HUH7 tumor cell conditioned medium (CM) provoked no 
further induction of reporter gene activity.  
Suicide gene therapy using human RANTES/CCL5 gene promoter activated 
transgene expression has advanced to clinical trials. The potential response of the 
human RANTES/CCL5 gene promoter to hypoxia was unknown. Human 
RANTES/CCL5 gene promoter controlled reporter gene constructs were then 
examined with regards to their activation by hypoxia. This promoter has been 
reported to contain potential HIF1α-responsive elements (Yeligar et al. 2009), but to 
date no data is available showing that these elements are functional under hypoxic 
conditions. The construct used was based on a pGL3 luciferase reporter vector with 
971 nucleotides of the human RANTES/CCL5 immediate upstream region driving 
firefly luciferase [established in house by Sabine Fessele (AG Klinische Biochemie, 
Prof. Nelson)]. The plasmid was transiently transfected into immortalized primary 
MSCs using Lipofectamine transfection reagent, followed by exposure to 1% O2 for 
48 hrs. The results showed that the human RANTES/CCL5 promoter could not be 
induced by hypoxia-like conditions and thus tumor hypoxia is probably not efficiently 
targeted by the current RANTES/CCL5-driven gene therapy. For more detailed 
information about the constructs, please see 2.2.5. 
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Figure 23: Significant induction of HIF1α-responsive promoter in MSCs after 48 hrs of hypoxic 
exposure, with and without additional exposure to HUH7 conditioned medium (CM). No 
induction of RANTES/CCL5 promoter driven luciferase in hypoxia after 48 hrs: A) Significant 
(p<0.0001) induction of HIF1α-responsive promoter driven luciferase activity in transfected MSCs 
incubated with 1% O2 for 48 hrs, in comparison to incubation with 21% O2 for 48 hrs. No induction of 
RANTES/CCL5-driven luciferase activity under the same conditions. B) Significant (p<0.001) induction 
of HIF1α-responsive promoter driven luciferase activity in transfected MSCs exposed to 100µM CoCl2 
for 48 hrs with and without 20% CM in comparison to MSCs exposed to 21% O2 for 48hrs. Experiment 
performed in triplicates, repeated three times; statistics calculated with two-tailed Student´s t-test, 
reported as mean +/- SD, p<0.05 *, p<0.01 **, p<0.001***, p<0.0001****. 
3.1.4. Hypoxia in HUH7 and HT29 tumor spheroids 
After establishing a reporter gene assay to model the MSC response to hypoxia, the 
next step was to perform similar assays using experimental tumor spheroids. To this 
end, a HUH7 (HCC derived) tumor spheroid model was developed. By preventing the 
adherence of HUH7 cells in polyHEMA coated culture dishes the cells form spheroids 
of approximately 300-500µm diameter after five to seven days of culture. The 
spheroids were then characterized by fluorescent staining. Necrotic areas were 
visualized using a live/dead staining. Hoechst 33342 is a cell permeable nucleic acid 
stain, which stains DNA of living cells with blue fluorescence.  PI is a membrane 
impermeant, intercalator dye, which can only penetrate the cell membrane of dead 
cells. It exhibits red fluorescence. Results show a red fluorescent center in HUH7 
tumor spheroids showing a minimum diameter of 300µm. Smaller spheroids contain 
single dead (red) cells but no necrotic center.  
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Figure 24: Necrotic center of 19-day-old HUH7 tumor spheroid: Inverted fluorescence microscopy 
of approximately 500µM large HCC tumor spheroid with living cells stained blue (Hoechst 33342) and 
dead cells stained red (PI). Center of HUH7 spheroid appears necrotic in spheroids at least 300µm in 
diameter.  
The second step was to establish an immunochemical method to make hypoxia 
visible. HydroxyprobeTM-1Kit (red) was used in combination with DAPI (blue) staining 
of nuclei. Cells take up Pimonidazole, which is added to the culture medium. In 
hypoxic cells it forms stable adducts with thiol groups in proteins. The antibody MAb1 
(mouse IgG1 monoclonal antibody) binds to these adducts allowing their detection by 
immunofluorescence. This way the oxygen gradient at the cellular level can be made 
visible. Though several attempts were made, hypoxia staining was problematic in 
HUH7 cells probably due to cell specific enzymes that metabolized pimonidazole. 
Therefore, hypoxia was evaluated in another in vitro tumor spheroid system estab-
lished in house showing a similar growth type.  Nineteen-day-old, 500µm large HT29 
cell spheroids (derived from colorectal adenocarcinoma) showed tightly packed 
proliferating outer layers. Due to reduced proliferation, nuclei were less densely 
packed deeper into the spheroid. The red fluorescence showed a gradient of hypoxia 
increasing the closer the center of the spheroid. The center of the spheroid showed 
no red fluorescence, as the staining process did not work in necrotic cells. DAPI 
staining confirmed necrosis showing condensed nuclei of dead cells in the spheroid 
center surrounded by the red, hypoxic belt.  
The results correlate with published data about centrifugally spreading necrosis in 
HCC and HT29 tumor spheroids with simultaneously occurring hypoxia (Waleh et al. 
1995, Lee et al. 2015, Pomo et al. 2016). The established visualization of hypoxic 
and necrotic areas in HUH7 and HT29 tumor spheroids was subsequently used to 
correlate the distribution and transgene expression of MSCs within these areas.  
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Figure 25: Hypoxic belt around the necrotic center of HT29 tumor spheroids: Inverted 
fluorescence microscopy of 16µm, formalin fixed frozen sections, of approximately 500µM (A) and 
approximately 700µm (B) large colorectal adenocarcinoma tumor spheroids. Nuclei stained blue 
(DAPI), hypoxic cells stained red (Pimonidazole). Spheroid shows proliferation in outer layers with 
tightly packed nuclei. When proliferation slows down in inner layers cells start becoming hypoxic. 
Hypoxia increases centripetally toward the necrotic center. The center consists of necrotic cells (con-
densed nuclei) due to oxygen lack.  
3.1.5. MSCs show a strong tropism for the center of HUH7 tumor spheroids  
As a next question, we determined if HIF-engineered MSCs were capable of invading 
tumor spheroids and if they would then activate the HIF1α-responsive promoter as 
they entered the hypoxic core of the experimental tumor. To answer these questions 
CMFDA stained MSCs were incubated with eight-days-old 300µM large HUH7 tumor 
spheroids. The results showed MSC invasion into the center of the spheroids 
matching the area characterized as hypoxic and necrotic. 
                      
Figure 26: CMFDA stained MSCs show strong tropism for HUH7 tumor spheroid center: Inver-
ted fluorescence microcopy of 16µm frozen sections of eight-days-old HUH7 tumor spheroids (nuclei 
stained blue with DAPI) incubated with CMFDA-stained MSCs (green). MSCs show invasion into the 
center of the HUH7 tumor spheroid. This location matches the areas characterized as necrotic and 
hypoxic in 3.1.4. 
In a parallel set of experiments, an additional HIF1α reporter construct [established in 
house by Anna Hagenhoff (AG Klinische Biochemie, Prof. Nelson)] was used to 
examine the activation of the hypoxia responsive promoter inside the experimental 
tumor microenvironment. The plasmid comprises the HIF1α-responsive promoter dri-
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ving red fluorescent protein. A pilot experiment by Anna Hagenhoff (AG Klinische 
Biochemie, Prof. Nelson) showed activation of the RFP inside the hypoxic/necrotic 
center. (data not shown) 
In summary, MSCs showed clear tropism for HUH7 spheroid and invasion into its 
necrotic and hypoxic center. HIF1α-responsive promoter is activated inside the tumor 
spheroid setting; however, gene activation within this setting needs to be evaluated 
further. 
3.2. Unresponsiveness of the HUH7 tumor cell line to non-genomic 
thyroid hormone effects. 
The HCC cell line HUH7 does not express integrin αβ3 (Schmohl et al. 2015). 
Therefore, it should be possible to eliminate integrin αβ3-mediated effects on the 
tumor. Using western blots and a luciferase reporter gene activity assay genomic 
(nuclear) effects of thyroid hormones on HUH7 cells were evaluated.  
HIF1α protein levels were evaluated under different oxygen conditions using western 
blot. A stable response of HUH7 cells to hypoxia after incubation with 2.5% O2 or 
100µM CoCl2 for 24 hrs was seen. Thyroid hormones (100nM T3, 1000nM T4) did 
not alter this response.  
 
Figure 27: HIF1α western blot in HUH7 cells shows no effect of thyroid hormone treatment on 
HIF1α protein levels under different oxygen conditions: After 24 hrs incubation with 21% O2 (N), 
2.5% O2 (H) or 100µM CoCl2 (C) with 100nM T3, 1000nM T4 or without thyroid hormone, proteins were 
extracted using RIPA buffer. Western blots showed a stable response of HUH7 cells to hypoxia after 
incubation with 2.5% O2 (H) or 100µM CoCl2 (C) for 24 hrs. Thyroid hormones could not alter this 
response. The results are representative of three independent experiments.  
Furthermore, thyroid hormone treatment did not influence HIF1α-dependent reporter 
gene activation in HUH7 cells. The reporter construct was transiently transfected by 
electroporation. After incubation in either 21% or 2.5% O2 with simultaneous thyroid 
hormone treatment (1-100nM T3; 10-1000nM T4), reporter gene activity was 
measured using a luciferase reporter assay. 2.5% O2 were chosen as this was the 
lowest oxygen concentration tolerated by HUH7 cells. Hypoxia induced a significant 
reporter gene activation (p=0.009). Thyroid hormones did not alter reporter gene 
activity under normoxic or hypoxic conditions. No significant changes in HUH7 
biology could be detected. 
The results of these experiments show that the HUH7 cell line is unresponsive to 
integrin αβ3-mediated thyroid hormone effects and specifically, the hypoxia 
response system is not affected. This makes HCC the optimal model cancer for 
evaluation the hypoxia targeted MSC-based gene therapy and non-genomic thyroid 
hormone effects on this therapeutic approach.  
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Figure 28: HIF1α-dependent reporter gene activity in HUH7 cells not influenced by thyroid hor-
mones under hypoxic or normoxic conditions: HUH7 cells were transiently transfected with HIF1α-
responsive promoter driven luciferase reporter construct and incubated in 21% O2 or 2.5% O2 for 48 
hrs. For the latter 24 hrs additionally 1/10/100nM T3 or 10/100/1000nM T4 were applied. Hypoxia 
produced a significant (p=0.009) increase of reporter gene activity, thyroid hormones did neither alter 
reporter gene expression in normoxia nor in hypoxia. Experiment performed in triplicates, repeated 
three times; statistics calculated with two-tailed Student´s t-test, reported as mean +/- SD, p<0.05 *, 
p<0.01 **, p<0.001***, p<0.0001****. 
3.3. Non-genomic thyroid hormone effects on MSC hypoxia res-
ponse 
As outlined in the introduction, when using the NIS gene to treat non-thyroid tumors, 
it becomes necessary to pretreat experimental animals (or human patients) with 
thyroid hormones to reduce the endogenous expression of NIS by the thyroid gland 
and thereby shield the gland from damage by the administration of radioactive iodine. 
Importantly, thyroid hormones can influence cells through genomic (nuclear receptor-
mediated) or through non-genomic pathways mediated by extracellular receptors 
found on integrin αβ3. It has been previously reported that thyroid signaling through 
integrin αβ3 could possibly influence the hypoxia response system by activation of 
the PI3 kinase. We then sought to test this in our system. To this end, HIF1α protein 
expression, HIF1α-dependent reporter gene activation, and the mRNA expression of 
known HIF1α-driven genes were tested under various oxygen conditions with and 
without thyroid hormone treatment. Thyroid hormone concentrations between 1 and 
100nM for T3 and 10 to 1000nM for T4 with and without the presence of 100nM of 
αβ3-binding inhibitor Tetrac were applied. To exclude confounding effects of thyroid 
hormones present in FCS, dextran coated charcoal was used to strip small organic 
molecules (such as thyroid hormones) from the FCS (sFCS) used in the subsequent 
in vitro experiments. 
3.3.1. Thyroid hormones increase normoxic HIF1α protein level in MSCs in a 
Tetrac dependent manner 
The effects of thyroid hormones on HIF1α protein expression in MSCs were 
examined in western blots performed with the experimental conditions established in 
3.1.2. After 12 hrs incubation with either normoxia, or hypoxia, as well as T3 and T4, 
cellular proteins were extracted with RIPA buffer. Tetrac was used to establish if any 
effects were potentially integrin αβ3-mediated. The results show that thyroid 
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hormone treatment increased normoxic HIF1α protein levels (Figure 29). However, a 
Tetrac dependency could not be reliably established (data not shown). Under 
extreme hypoxic activation with 1% O2 or 100µM CoCl2, thyroid hormones could not 
increase the level of HIF1α protein expression (data not shown).  
 
Figure 29: Thyroid hormones increase normoxic HIF1α protein levels in MSCs after 12 hrs:  
Western blot analysis of whole cell lysates of MSCs for HIF1α expression after 12 hrs of normoxic 
(21%O2) incubation with different concentrations of T3 and T4 (T3: 1/10/100nM; T4 10/100/1000nM). 
Co = Control without hormone stimulation. A) 12 hrs normoxic exposure with simultaneous application 
of 1000nM T4 increases HIF1α protein levels. B) 12 hrs normoxic exposure with simultaneous 
application of 1nM T3 increases HIF1α expression. Higher hormone concentrations show no further 
additive effect. The results are representative of three independent experiments.  
As a next step, the effect of thyroid hormone treatment on a medium/hypoxic 
stimulation was examined by using 50µM CoCl2 in combination with HUH7 
conditioned medium (CM). These experimental conditions were selected to better 
mimic potential effects of the tumor environment. 50µM CoCl2 alone and in 
combination with CM increased HIF1α protein levels in comparison to the normoxic 
control. These experimental conditions in combination with physiological concen-
trations of 10nM T3 led to a Tetrac dependent stable increase of HIF1α protein 
stabilization (Figure 30). Physiological concentrations of 100nM T4 did not produce 
the same effect (data not shown). However, this may be explained in part by a direct 
T3 activation of the PI3K with downstream effects on HIF1α.  
The influence of thyroid hormones on the hypoxia response of MSCs under tumor 
milieu conditions was further evaluated on the level of reporter gene expression.   
 
Figure 30: T3 increases HIF1α protein levels in MSCs in a Tetrac dependent manner under 
tumor milieu conditions: Incubation with 50µM CoCl2 alone and even more in combination with 20% 
HUH7 conditioned medium (CM) increases HIF1α level in MSCs after 12 hrs. 10nMT3 increases 
HIF1α protein level further under these conditions in a Tetrac dependent manner. Effect not 
reproducible with T4 (no direct PI3K activation). Whole cell lysates of MSCs analyzed by western blot 
for HIF1α expression after 12 hrs of normoxic (21%O2) or hypoxic (50µM CoCl2) exposure combined 
with 20% HUH7 conditioned medium, thyroid hormones (T3: 10nM; T4:100nM) and 100nM Tetrac. N = 
21%O2, C = 50µM CoCl2, T = 100nM Tetrac, H = 20% HUH7 CM. The results are representative of 
three independent experiments.  
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3.3.2. Thyroid hormones increase activation of synthetic HIF1α-responsive pro-
moter in normoxia in a Tetrac dependent manner   
The next step in elucidating possible stimulatory effects of thyroid hormones on the 
hypoxia response system in MSCs, examined potential thyroid hormone effects on 
HIF1α-dependent reporter gene expression in MSCs. To this end, promoter-reporter 
constructs comprised of six HIF1α-responsive elements were transiently transfected 
into L87 and primary human MSCs. Reporter gene expression was measured 48 hrs 
after transfection. This time period included 24 hrs of incubation in normoxia (21% 
O2) or hypoxia (1%O2) and an additional 24 hrs with thyroid hormone stimulation. 
Tetrac, integrin αβ3-inhibitor, was used to determine if provoked effects were 
integrin αβ3-mediated. In parallel, RANTES/CCL5 promoter-studies were used to 
determine if agents mentioned could also influence this transgene. Promoter acti-
vation after 48 hrs hypoxic/normoxic and 24 hrs thyroid hormone incubation was exa-
mined. As detailed in 3.1.3. RANTES/CCL5 promoter was not induced by hypoxic 
conditions. 
Under normoxic conditions (21% O2) 10 and 100nM T3 (p=0.04; p=0.009) as well as 
10, 100 and 1000nM T4 (p=0.01; p=0.007; p=0.01) significantly increased HIF1α-
dependent reporter gene activity in comparison to normoxic controls. 1nM T3 did 
show an increase in reporter gene activity as well, however not significant (p=0.06). 
No significant differences could be detected between the different thyroid hormone 
concentrations. (Figure 31A)   
This increase in HIF1α-driven reporter gene activity was reversible with 100nM 
Tetrac (Figure 31B).  
 
Figure 31: Significant Tetrac dependent increase of HIF1α-driven reporter gene activation 
through thyroid hormone treatment in MSCs under normoxic conditions: A) Significant increase 
of HIF1α-driven reporter gene activity under normoxic (21% O2) conditions through 24 hrs thyroid 
hormone treatment with 10/100nM T3 (*/**) and 10/100/1000nM T4 (*/**/*). B) Increase of HIF1α-
driven reporter gene activity is reversed by 24 hrs treatment with 100nM Tetrac. Experiment performed 
in triplicates, repeated three times; statistics calculated with two-tailed Student´s t-test, reported as 
mean +/- SD, p<0.05 *, p<0.01 **, p<0.001***, p<0.0001****. 
Hypoxic incubation (48 hrs; 1% O2) led to an increase in HIF1α-dependent reporter 
gene activity as described in 3.1.3. Additional thyroid hormone treatment (24 hrs) 
appeared to enhance the HIF1α-driven reporter gene activity further (Figure 32). 
However, due to larger variability between single experiments no significant induction 
or Tetrac dependency could be established (data not shown).  
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Figure 32: Increase of HIF1α-driven reporter gene activation through thyroid hormone treat-
ment in MSCs under hypoxic conditions: 24 hrs treatment with 1/10/100nM T3 (p=0.39; p=0.32; 
p=0.34) and 100/1000nM T4 (p=0.07; p=0.14 increases of HIF1α-driven reporter gene activation after 
48 hrs hypoxia (1% O2) in comparison to corresponding hypoxic control (Co). Experiment performed in 
triplicates, repeated three times; statistics calculated with two-tailed Student´s t-test, reported as mean 
+/- SD, p<0.05 *, p<0.01 **, p<0.001***, p<0.0001****. 
To examine potential effects of thyroid hormones on the HIF1α-dependent reporter 
gene activation in the context of tumor-derived signals, the following experimental 
setup was used: Normoxic (21% O2) or hypoxic (1% O2) stimulation was performed 
for 48 hrs. At the same time, 20% of the culture medium was replaced with HUH7 
conditioned medium (CM). Thyroid hormone was then added during the last 24 hrs. 
CM in combination with T3 or T4 did not increase the HIF1α-driven reporter gene 
activation further under hypoxic or normoxic conditions. (data not shown).  
3.3.3. Influence of thyroid hormones and HUH7 tumor cell conditioned medium 
(CM) on the steady state mRNA expression of known HIF1α target genes  
To assess potential effects of thyroid hormones on MSC hypoxia response further, 
the effect of thyroid hormone on the steady state mRNA expression of known 
hypoxia-target genes was examined. The genes tested included the tumor-promoting 
growth factors FGF2, IL6, TGFβ, HGF, TIMP1, CTGF and CXCL12, and the 
angiogenesis-related markers ID1 and VEGFa. HIF1α, MMP2, MMP9 and CCL5 
expression was also assessed. MMP2 and MMP9 showed almost no steady state 
expression at all in the experiments performed.  
MSCs were incubated with thyroid hormones under normoxic (21% O2) conditions for 
36 hrs. After preliminary experiments, 100nM T3 and 1000nM T4 were found to 
produce the strongest results and were used in subsequent experiments with Tetrac 
to determine, if the effects were integrin αβ3-mediated. Under normoxic conditions, 
thyroid hormones (100nM T3, 1000nM T4) led to increased mRNA levels of HIF1α 
and CCL5 genes in a Tetrac dependent manner (Figure 33). In the other genes 
evaluated (IL6, VEGFa, MMP2, MMP9, CTGF, CXCL12, ID1, TGFβ, HGF) no stable 
induction of mRNA levels could be established under normoxia. (data only shown for 
IL6; Figure 33) 
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Figure 33: Steady state mRNA level of HIF1α and CCL5 genes in MSCs increases in a Tetrac de-
pendent manner through thyroid hormone treatment under normoxic conditions: A) MSCs 
incubated with 100nM T3 with or without 100nM Tetrac in normoxia express increased levels of HIF1α 
and CCL5 mRNA compared to untreated MSCs (black line). B) MSCs incubated with 1000nM T4 with 
or without 100nM Tetrac in normoxia express increased levels of mRNA of HIF1α compared to 
untreated MSCs (black line). Results are expressed as mean fold change toward untreated MSCs. 
Experiments were performed in duplets and repeated three times.   
As next step, the potential additional effects of tumor-derived signals were evaluated. 
To this end, hypoxic stimulation was mimicked using 50µM CoCl2 and 20% of the 
culture medium was replaced with HUH7 conditioned medium (CM). MSCs were also 
treated with thyroid hormones for 36 hrs with or without Tetrac. Under these 
experimental conditions, 10nM T3 and 100nM T4 treatment yielded significant and 
reproducible results.  
The trend toward induction of select mRNA species expression by treatment with 
50µM CoCl2 and enhanced induction in combination with CM is shown exemplary for 
the VEGFa gene (Figure 34A).  
Treatment with 10nM T3 and 100nM T4 with simultaneous addition of 50µM CoCl2 
did lead to a Tetrac dependent increase in HIF1α and FGF2 mRNA levels (Figure 
34B). Adding 20% CM led to enhanced mRNA expression of HIF1α, CCL5, IL6, 
VEGFa, FGF2 and CXCL12 (Figure 34C). Other genes (TGFβ, HGF, ID1, TIMP1, 
MMP9) did not show increased mRNA levels. Tetrac dependency can be seen in 
both set ups (Figure 34B, 34C).  
Expanded experiments performed in collaboration with Prof. Spitzweg from Groß-
hadern yielded statistically significant results showing that CM stimulation for 24 hrs 
in combination with 1nM T3 or 1000nM T4, with or without 100nM Tetrac under norm-
oxic conditions induces the mRNA level of CAF-associated markers in treated MSCs 
(Schmohl et al. 2015).  
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Figure 34: Induction of mRNA expression of HIF1α, CCL5, IL6, VEGFa, FGF2 and CXCL12 genes 
in MSCs through thyroid hormone treatment in a Tetrac dependent manner under tumor milieu 
conditions: A) VEGFa mRNA expression increased after 36 hrs treatment with 50µM CoCl2 in 
comparison to untreated cells (black line). Increase is enhanceable through addition of 20% HUH7 
conditioned medium (CM). B) MSCs treated with 50µM CoCl2 and 100nM T4 show increased 
expression of HIF1α and FGF2 mRNA in comparison to MSCs incubated with 50µM CoCl2 alone 
(black line). Tetrac reverses this effect. C) MSCs treated with 50µM CoCl2 in combination with 20% 
CM and 10nM T3 show increased expression of HIF1α, CCL5, IL6, VEGFa, FGF2 and CXCL12 
mRNA in comparison to MSCs incubated with 50µM CoCl2 and 20% CM alone (black line). Tetrac 
reverses this effect. Results are expressed as mean fold change toward A) untreated MSCs B) MSCs 
treated with 50µM CoCl2 C) MSCs treated with 50µM CoCl2 and CM. Experiment performed in duplets, 
repeated twice.   
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3.4. Thyroid hormones enhance chemotaxis and chemokinesis of 
MSCs in a Tetrac dependent manner  
Tumor-specific migration is an important component of MSC-based therapy. A 
chemotaxis chamber assay was developed to study the directed migration of MSCs 
in collaboration with Alexandra Wechselberger (AG Klinische Biochemie, Prof. 
Nelson). Prior to this assay, the primary human MSCs were incubated for 24 hrs with 
thyroid hormones, with and without Tetrac. Subsequently, cell migration was 
observed for 24 hrs in ibidi assay chambers, which provide easy in vitro assessment 
of travelled distances, velocity and distribution of cells exposed to a gradient of 
chemoattractant. Furthermore, effect of continuous stimulation 24 hrs before and 
during the chamber assay was examined.  
In a second model, MSC invasion into experimental HCC tumor spheroids was 
studied (described in 3.1.5.) with support from Alexandra Wechselberger, Anna 
Hagenhoff and Svenja Rühland (AG Klinische Biochemie, Prof. Nelson). MSCs were 
incubated the same way as for chemotaxis chamber assay, dyed with CMFDA and 
then coincubated with HUH7 spheroids. Preliminary results are shown in 3.1.5. 
In both assays, MSCs showed a large variability of basic migratory capacities. HUH7 
conditioned medium (CM) was used as chemoattractant. The migration of MSCs 
along a CM gradient was straightforward (Figure 35). This migration was charac-
terized relative to controls representing no gradient (culture medium or CM on both 
sides).  
While MSCs showed slightly elevated levels of basic movement, when adding the 
chemoattractant to both assay chambers, this effect did not occur when both sides 
were filled with respective culture medium. When comparing the chemotaxis and 
chemokinesis of MSCs exposed to the chemical gradient with the two controls the 
increase of directed migration in gradient exposed MSCs was significantly elevated 
above the controls for all parameters assessed (Figure 35). 
MSCs showed significantly increased FMI (p=0.0002), in comparison to non-gradient 
exposed MSCs. Rayleigh test for vector data proved a significantly inhomogeneous 
cell distribution of gradient exposed cells in comparison to both controls (p<0.05). 
The displacement of center of mass (CoM) was increased for gradient exposed 
MSCs in comparison to both controls. All chemokinetic parameters were significantly 
increased above the culture medium control level in gradient exposed cells 
(directionality p<0.0001, accumulated distance p=0.0044, Euclidean distance 
p<0.0001 and velocity p=0.004). Only directionality (p=0.0017), accumulated 
distance (p=0.0071) and Euclidean distance (p=0.0241) reached significance when 
comparing to the CM control without gradient.  
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Figure 35: Stable directed migration of MSCs along a gradient of HUH7 conditioned medium 
(CM): - /- culture medium/culture medium, +/+ CM/CM, -/+ culture medium/CM (gradient) A) FMI was 
significantly (p=0.0002 and p=0.0681) increased when a CM gradient was applied in comparison to 
application of culture medium or CM alone. B) Rayleigh test for vector data showed a significantly 
(p<0.05) inhomogeneous cell distribution when applying CM gradient. (dotted line represents p=0.05) 
C) The center of mass (CoM) was furthermost away from starting point when applying CM gradient. 
Application of CM without gradient showed a displaced CoM, too. D) Directionality was significantly 
(p<0.0001 and p=0.0019) increased when applying CM gradient. E) Accumulated distance was 
significantly (p=0.0044) increased when applying CM gradient or applying CM without gradient 
(p=0.0071). F) Euclidean distance was significantly (p<0.0001 and p=0.0241) increased when 
applying CM gradient. G) Velocity was significantly (p=0.004) increased when applying CM gradient or 
applying CM without gradient (p=0.0066). The results are representative of three independent 
experiments. Statistics calculated with two-tailed Student’s t-test and Rayleigh test for vector data. * 
p<0.05, **p<0.01, *** p<0.001, ****p<0.000. Results expressed as mean +/- SD.  
MSCs are integrin αβ3-positive. Other cells positive for this integrin have been 
reported to alter their migration when stimulated via thyroid hormones (Cohen et al. 
2014). Therefore, in the next step we sought to determine if thyroid hormones could 
increase the established tumor directed migration of MSCs. Thyroid hormones 
(1/100nM T3 and 10/1000nM T4) were added to the cells 24 hrs prior to the assay. 
The results showed that 1nM T3 and 1000nM T4 increased FMI and displacement of 
CoM best. Rayleigh test for vector data showed significantly increased chemotaxis 
for 1nM and 100nM T3 (p=0.002; p=0.008) as well as 1000nM T4 (p=0.007) (Figures 
36, 37). Velocity and accumulated distance showed higher values with 100nM T3 or 
1000nM T4. Subsequent studies performed in collaboration with Schmohl et al were 
able to demonstrate statistically significant effects of T3 and T4 prestimulation on the 
directed migration of primary human MSCs (Schmohl et al. 2015).  
Subsequently, the results were validated with Tetrac. Stimulation of chemotaxis (FMI 
and displacement of CoM) by 1nM T3 and 1000nM T4 could be reversed with 100nM 
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Tetrac (Figures 38, 39). These results suggest that the mechanism of the stimulation 
is integrin αβ3-mediated. For chemokinetic parameters no clear Tetrac dependency 
could be established (data not shown).  
As a further step, 24 hrs prestimulation were compared to continuous stimulation 
lasting throughout the chamber assay (thyroid hormones were included in all assay 
components) to get an idea of how different thyroidal statuses in vivo would influence 
MSC tumor directed migration. Results showed no conclusive trend that continuous 
stimulation alters MSC chemotaxis in comparison to prestimulation (data not shown).  
In the second model, MSC invasion into HCC tumor spheroids preliminary results 
(described in 3.1.5) show that MSCs are attracted by tumor-derived factors in vitro. 
The set-up was evaluated with thyroid hormone treatment by Svenja Rühland (AG 
Klinische Biochemie, Prof. Nelson) in collaboration with Prof. Spitzweg at Groß-
hadern. The published results substantiated findings of this thesis as well as further 
in vivo experiments in a mouse model (Schmohl et al. 2015). 
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Figure 36: T3 increases tumor directed chemotaxis of MSC: A) Exemplary trajectory plot of un-
treated MSCs showing moderate tumor directed migration. B) and C) Exemplary trajectory plots of 
MSCs treated with 1nM or 100nM T3 for 24 hrs showing increased chemotaxis compared to 
unstimulated MSCs. D-F) Quantification of chemotaxis parameters: Rayleigh Test for vector data (F) 
proved significant chemotaxis for 1nM and 100nM T3 treated MSCs (p=0.002, p=0.008).  FMI (D) and 
displacement of CoM (E) showed no significant but consistent trends substantiating the Rayleigh test. 
Red pathways along the chemical gradient, black pathways against the chemical gradient; blue cross 
represents the CoM. CM stands for HUH7 conditioned medium. The results are representative of three 
independent experiments. Statistics calculated with two-tailed Student´s t-test and Rayleigh test for 
vector data. * p<0.05, **p<0.01, *** p<0.001, ****p<0.000. Results expressed as mean +/- SD.  
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Figure 37: T4 increases tumor directed chemotaxis of MSCs: A) Exemplary trajectory plot of un-
treated MSCs showing moderate tumor directed migration. B) and C) Exemplary trajectory plots of 
MSCs treated with 10nM or 1µM T4 for 24 hrs showing increased chemotaxis for 1µM T4 compared to 
unstimulated MSCs. D-F) Quantification of chemotaxis parameters: Rayleigh Test for vector data (F) 
proved significant chemotaxis for 1µM T4 treated MSCs (p=0.007). FMI (D) and displacement of CoM  
(E) showed no significant but consistent trends indicating most effective chemotaxis for 1µM T4 
treated MSCs. Red pathways along the chemical gradient, black pathways against the chemical 
gradient; blue cross represents the center of mass. CM stands for HUH7 conditioned medium. The 
results are representative of three independent experiments. Statistics calculated with two-tailed 
Student´s t-test and Rayleigh test for vector data. * p<0.05, **p<0.01, *** p<0.001, ****p<0.000. 
Results expressed as mean +/- SD.  
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Figure 38: T3 and T4 increase tumor directed chemotaxis of MSCs in a Tetrac dependent 
manner: A) Exemplary trajectory plot of untreated MSCs showing little tumor directed migration. B) 
Exemplary trajectory plot of MSCs treated with 100nM Tetrac showing a trajectory plot comparable to 
untreated MSCs. C) and D) Exemplary trajectory plots of MSCs treated with 1nM T3 with or without 
100nM Tetrac for 24 hrs showing increased chemotaxis for 1nM T3 compared to unstimulated MSCs 
and unaffected chemotaxis for MSCs treated with T3 and Tetrac. E) and F) Exemplary trajectory plots 
of MSCs treated with 1µM T4 with or without 100nM Tetrac for 24 hrs showing increased chemotaxis 
for 1000nM T4 compared to unstimulated MSCs and unaffected chemotaxis for MSCs treated with T4 
and Tetrac. Black pathways along the chemical gradient, red pathways against the chemical gradient; 
blue cross represents the center of mass. CM stands for HUH7 conditioned medium. The results are 
representative of three independent experiments. 
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Figure 39: T3 and T4 increase tumor directed chemotaxis of MSCs in a Tetrac dependent 
manner characterized by FMI, displacement of CoM and Rayleigh test for vector data: FMI (A) 
and displacement of CoM (C) indicate increased chemotaxis for MSCs treated with 1nM T3 or 1000nM 
T4. This effect was reversible through treatment with 100nM Tetrac. Rayleigh Test for vector data (B) 
proved significant chemotaxis for 1nM T3 and 1000nM T4 treated MSCs in a Tetrac dependent 
manner as well. CM stands for HUH7 conditioned medium. The results show one of three independent 
experiments.  Statistics calculated with Rayleigh test for vector data. p<0.05 indicating significant che-
motaxis. Results expressed as mean. 
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3.5. Effects of thyroid hormones, HUH7 tumor cell conditioned me-
dium (CM) and oxygen level on MSC viability 
Thyroid hormones, CM and oxygen levels can alter MSC biology, specifically their 
growth rate and viability. It was therefore necessary to exclude major effects of the 
stimulants on MSC growth and viability. To test the potential effect of thyroid 
hormones on these parameters, MTT-assays were used to assess effects on MSC 
mitochondrial activity as a means of measuring cell proliferation. MSCs were plated 
into 96 well plates and stimulated for 24, 48 and 72 hrs. Changes in viability were 
detected by colorimetric quantification using an ELISA reader. After 72 hrs significant 
changes in proliferation were seen.  
When looking at the effects of CM on MSC growth, replacing 10% or 20% of the 
respective culture medium with CM increased MSC viability after 24 and 48 hrs as 
well as significantly after 72 hrs (p=0.0162) above control level. As next step, the 
effects of various oxygen concentrations on MSC growth with and without 20% CM 
were tested. Anoxic incubation significantly (p=0.0388) decreased the replication of 
MSCs after 72 hrs with reduced cell viability after 24 hrs. The addition of CM 
appeared to have adverse effects on cell growth in the absence oxygen (p=0.0232).  
However, MSCs showed significantly (p=0.025) increased viability when incubated 
with 2.5% O2 for 72 hrs. This increase could be enhanced by addition of CM 
(p=0.0384). (Figure 40) 
Results  73 
               
Figure 40: Stimulation with HUH7 conditioned medium (CM) and hypoxia leads to significant 
increase in MSC viability after 72hrs: A) Differences in optical density after 24, 48 and 72 hrs 
incubation with 21%, 2,5% and 0% O2 as well as 10% and 20% CM. B) Significant differences in 
optical density after 72 hrs incubation with  20% CM  (p=0.0162) or 2,5% O2  (p=0.025) alone as well 
as 2,5% O2 in combination with 20% CM (p=0.0384). Anoxia significantly (p=0.0388) decreased 
MSC proliferation, even more (p=0.0232) when combined with CM. Dotted line represents 72 hrs 
unstimulated control level. Experiment performed in triplicates, repeated three times; statistics 
calculated with two-tailed Student´s t-test, reported as mean +/- SD, p<0.05 *, p<0.01 **, p<0.001***, 
p<0.0001****. 
The potential effects of thyroid hormones on MSC viability in normoxia were then 
evaluated with and without addition of CM. In the absence of CM, thyroid hormones 
significantly increased MSC viability after 72 hrs above control level (1nM T3 
p=0.011; 100nM T3 p=0.0487; 1000nM T4 p=0.0031). Tetrac dependency could not 
be established for all concentrations. Stimulation with CM alone increased MSC 
viability above the unstimulated control level (p=0.0162). In the presence of CM only 
1000nM T4 increased MSC viability significantly (p=0.0403) above the CM stimulated 
control. Comparing thyroid hormone effects in the absence and presence of CM 
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results showed enhanced thyroid hormone and Tetrac effects for all samples. 
Significantly higher MSC viability was found for stimulation with 100nMT3 (p=0.0205), 
10nMT4 (p=0.0191) and 1000nM T4 (p=0.0482) in the presence of CM. Suggesting 
that the tumor microenvironment may enhance thyroid hormone effects. A significant 
Tetrac effect was only detected for 10nM T4 (p=0.0462).  
         
Figure 41: Stimulating effects of thyroid hormones and HUH7 conditioned medium (CM) on 
MSC proliferation: Differences in optical density (MSC viability) after 72 hrs incubation with 1/100nM 
T3, 10/1000nM T4 with and without 100nM Tetrac and 20% CM.  
Thyroid hormones increase MSC proliferation significantly after 72 hrs in the absence of (CM) 
(1nM T3 p=0.011; 100nM T3 p=0.0487; 1000nM T4 p=0.0031). (light grey bars)  
CM increases MSC proliferation significantly (p=0.0162) after 72hrs. (control) 
CM enhances thyroid hormone and Tetrac effects on MSC proliferation after 72 hrs. In the 
presence of CM 1000nM T4 increased MSC proliferation significantly (p=0.0403) above the CM 
stimulated control. Comparing thyroid hormone effects in the absence and presence of CM results 
showed enhanced thyroid hormone and Tetrac effects for all samples. Significantly higher MSC 
proliferation was found for stimulation with 100nM T3 (p=0.0205), 10nM T4 (p=0.0191) and 1000nM 
T4 (p=0.0482) in the presence of CM.  
Tetrac dependency could not be established for all conditions. 10nM and 1000nM T4 increased 
MSC viability above control level as well in combination with 100nM Tetrac. For 10nM T4 a significant 
(p=0.0462) reverse of the stimulation through Tetrac could only be detected in the presence of 
CM.  
Dotted lines represent control levels with (upper) and without (lower) addition of CM. Experiment 
performed in triplicates, repeated three times; statistics calculated with two-tailed Student´s t-test, 
reported as mean +/- SD, p<0.05 *, p<0.01 **, p<0.001***, p<0.0001****. 
In conclusion, both the tumor microenvironment and thyroid hormones have viability-
increasing effects on MSCs in general. 
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4. Discussion 
4.1. New targeting strategies for MSC-based cancer gene therapy 
Despite advances in our understanding and therapy of tumors, there is still an 
obvious need for new approaches of therapeutic intervention. Various methods using 
MCS-based cancer therapy have advanced to clinical trials, but the technology is still 
in an early stage of development (Niess et al. 2015).  Based in part on their unique 
biology, MSCs have been adapted as therapy vehicles for the treatment of solid 
tumors. MSCs are immunoprivileged, and are easy to grow and engineer. These cells 
have a natural tropism for solid neoplasias, which has been used to adapt them to 
act as potential therapy vehicles - something akin to a “trojan horse” that delivers 
therapeutic agents into tumors (Bao et al. 2012). 
MSCs have been evaluated in diverse animal models for a variety of clinical 
applications including therapy of bone segmental defects, osteogenesis imperfecta, 
brain insults, infarcted myocardium, muscle defects and graft versus host disease 
(Fritz et al. 2008). Other groups have evaluated the use of antitumor agents in MSC-
based cancer therapy. Among the therapy genes tested, are antitumor proteins such 
as interferon-β or TRAIL (Studeny et al. 2004, Keung et al. 2013) or suicide gene 
systems encoding for enzymes acting on prodrugs (Knoop et al. 2011, Bao et al. 
2012). MSC-based therapy may not be free of side effects, as MSCs can naturally 
home to normal tissues as a consequence of tissue homeostasis (Hagenhoff et al. 
2016). The tumor-specificity of MSC therapy can be enhanced by using genetically 
engineered MSCs that express their therapeutic transgenes in response to tumor-
derived signals. This has been achieved through the use of specific gene promoters 
for transgene expression, that respond to tumor signals, thus restricting transgene 
expression to the tumor milieu. The promoters tested to date include the Tie2 
promoter/enhancer and the RANTES/CCL5 promoter. The Tie2 promoter is activated 
by angiogenic signals delivered to the tumor-recruited MSCs (Bao et al. 2012), while 
the RANTES/CCL5 promoter is induced as MSCs response to inflammatory factors 
released into the tumor microenvironment (Zischek 2011). Both promoters have been 
shown to enhance tumor-specificity of the MSC-based therapy. Generally, the 
outcome in various mouse tumor models was shown to be more effective using the 
RANTES/CCL5 promoter, which targets metastases as well the primary tumor 
(Knoop et al. 2015).  
A central goal of this thesis was to evaluate in more detail, a new potential promoter 
targeted approach, and to compare its induction to existing protocols. Solid tumors 
can have large regions of hypoxia, and necrosis. This occurs when tumor growth 
outpaces the generation of new vessels, which happens in most solid neoplasias. For 
example, HCC is a fast growing tumor that generally contains large regions of 
hypoxia and necrosis (Forner et al. 2012, Liu et al. 2014). Due to its aggressive 
growth, this cancer is largely chemo resistant especially in more advanced stages 
(Yang et al. 2011). In addition, this tumor is highly dependent on its supporting 
stromal microenvironment to sustain growth rates, making the tumor stroma a 
promising target (Yang et al. 2011, Heindryckx et al. 2015). These observations led 
to the idea of targeting hypoxic areas in tumor microenvironment.  
4.1.1. Existing protocols do not target hypoxic tumor stroma 
The concept of MSC-based cancer gene therapy discussed here makes use of two 
important principles. The first is the directed recruitment (homing) of MSCs into the 
tumor environment, and the second, is the induced expression of therapeutic 
transgenes within the tumor stroma. MSCs migrate to sites of tissue damage. Cancer 
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is thought to resemble, in many ways, a chronic wound as it shows hypoxia, necrosis, 
inflammation, and new vessel growth (Dvorak 2015). MSCs can act as progenitors 
for many of the cell types that form the tumor stroma. MSCs are attracted by local 
inflammatory chemokines and growth factors (Knoop et al. 2013). However, as was 
previously discussed, MSCs also naturally migrate into other tissues like the lung, 
spleen, thymus, lymph nodes, liver, mucosa of the small intestine, skin and salivary 
glands as a part of normal tissue homeostasis (Fritz et al. 2008, Bao et al. 2012). The 
results described in this thesis show that the RANTES/CCL5 promoter does not 
become activated in response to hypoxic conditions (Figure 42), even though the 
promoter contains potential HIF1α-responsive elements (Yeligar et al. 2009). This 
may be clinically relevant as hypoxic regions are largely resistant to chemotherapy. 
For this reason, it was important to identify an approach that targets these tumor 
regions more effectively. 
4.1.2. Establishing tools to target hypoxic solid tumors 
Hypoxia has been proposed to help fuel tumor progression, and to drive metastasis 
formation and therapy resistance. Thus, targeting the hypoxia response system 
represents an attractive new concept (Casazza et al. 2014). Other research groups 
have explored the potential of hypoxia for cancer treatment by employing HIF1α 
inhibitors (Patiar et al. 2006), HIF1α stability suppressors (Kim et al. 2013a) or  a 
hypoxia activated prodrug called Q6. This drug significantly reduces proliferation-
induced apoptosis (Liu et al. 2014). Oxygen levels also play an important role in MSC 
biology. It has been reported that hypoxia contributes to MSC homing as it promotes 
inflammatory signals emitted by the tumor stroma (Spaeth et al. 2008). In addition, 
the circulating pool of MSCs increases under hypoxic conditions (Salem et al. 2010). 
The main regulators of the hypoxia response are the hypoxia induced transcription 
factors such as HIF1α (Benita et al. 2009). HIF1α levels in MSCs under different 
oxygen concentrations were characterized using western blot. Hypoxic (1-2.5% O2 or 
50-100µm CoCl2) conditions led to increased levels of HIF1α (3.1.2.) in comparison 
to normoxia (21% O2). This serves as basis for gene activation in hypoxic tumor 
areas.  
The next step in this characterization was comparison of HIF1α-responsive reporter 
gene activation under hypoxic conditions (1-2.5% O2 or 100µM CoCl2), to the 
potential hypoxic activation of the RANTES/CCL5 promoter. In contrast to the 
RANTES/CCL5 promoter, the synthetic hypoxia responsive promoter efficiently 
induced reporter gene expression in response to hypoxia in vitro (3.1.3.). These 
findings suggest that the HIF1α-responsive promoter, or related promoters, could be 
suitable for transgene-based therapy of hypoxic tumor areas.  
To study the potential activation of the HIF1α-responsive promoter in a tumor model 
system, HUH7 and HT29 (HCC and colorectal adenocarcinoma derived) tumor 
spheroids were used as in vitro tumor models. These spheroids showed central 
necrosis and hypoxia (3.1.4.). Transgenic MSCs showed invasion into this central 
area. Anna Hagenhoff (AG Klinische Biochemie, Prof. Nelson) has shown activation 
of HIF1α-driven reporter genes in the center of these experimental tumors. Andrea 
Müller et al. subsequently provided in vivo proof of this concept in subcutaneous and 
orthotopic HCC xenograft mouse models (Muller et al. 2016). 
Evaluation of MSC proliferation under tumor conditions showed significantly 
increased MSC proliferation in response to hypoxia (2.5% O2), and after addition of 
HUH7 conditioned medium. These results suggest that MSCs may survive, replicate 
and differentiate in the hypoxic tumor microenvironment, but they may not be as 
active in areas of normoxia. These findings are supported by reports discussing that 
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MSCs can directly stimulate tumor growth (Torsvik et al. 2013), and the cells normally 
reside in hypoxic niches in the human bone marrow (Palomaki et al. 2013). 
 
Figure 42: Principle of hypoxia targeted MSC-based cancer gene therapy in comparison to 
RANTES/CCL5 targeted approach: MSCs engineered with RANTES/CCL5 or HIF1α-responsive 
promoter are applied systemically and naturally home into the tumorous site. Hypoxia driven trans-
genes activate inside the hypoxic tumor center whereas RANTES/CCL5 does not activate in this area.  
The results of this thesis provide sufficient in vitro evidence that hypoxia targeting is a 
promising strategy for MSC-based cancer therapy that should be pursued further. 
4.2. Non-genomic thyroid hormone effects on MSC biology in the 
context of Hepatocellular Carcinoma (HCC) 
The current MSC-based therapy approach under development in our laboratory 
makes use of the sodium iodide symporter (NIS). NIS is a theranostic gene that can 
be used for specific, non-invasive imaging using 123I scintigraphy, 123I SPECT/CT and 
124I PET or even MRI as well as efficient therapy through application of radionuclides 
(131I or 188Re) (Knoop et al. 2015). 131I plays a dual role as therapeutic β-emitter and 
detectable γ-emitter. Both radionuclides cause a substantial bystander effect on 
surrounding tissue surpassing that of other effector genes like the HSV-
TK/Ganciclovir system. Recent reports by our laboratory and collaborators have 
shown that NIS dramatically improves the effectiveness of MSC-based cancer 
therapy (Knoop et al. 2011, Knoop et al. 2013, Knoop et al. 2015). To date, MSC-
based NIS therapy has been successfully demonstrated in experimental liver cancer 
using the constitutive CMV promoter or the tumor milieu-induced RANTES/CCL5 
promoter. The latter also showed a robust therapeutic effect for experimental 
metastatic colon cancer. The NIS gene is strongly expressed in the thyroid gland. It is 
a transmembrane glycoprotein that helps bring iodine into the thyroid for the 
generation of thyroid hormones. The use of diverse methods for transcriptionally 
targeted gene transfer of NIS has subsequently opened the door for a wide range of 
extra thyroidal tumor applications (Knoop et al. 2011, Knoop et al. 2013, Knoop et al. 
2015). Importantly, when using NIS-based approaches for the treatment of non-
thyroid tumors, it becomes necessary to protect the thyroid gland against radioiodine-
mediated damage, by pre-treatment of patients with the thyroid hormones T3 and T4. 
Hyperthyroid levels of these hormones lead to the loss of NIS from the cell surface of 
the thyroid cells. These hormones can have other physiologic effects that are 
relevant in the context of MSC-NIS-based therapy. We have previously shown that 
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T3 and T4 can have direct effects on the migratory capacity of MSCs (Schmohl et al. 
2015).  These hormones can also have effects on HIF1α (Otto et al. 2008). Further-
more thyroid hormones have been shown to play a key role in the tumor stroma 
formation (Davis et al. 2011). In the context of this thesis work, these hormones may 
also thus directly influence hypoxia response in MSCs.   
Approximately 20 years ago, a non-genomic pathway of thyroid hormone action was 
identified. It was found to influence various effects including angiogenesis (Bergh et 
al. 2005, Davis et al. 2014b, Cayrol et al. 2015), proliferation, (Lin et al. 2009, Davis 
et al. 2011) tumor cell growth and inflammation (Sharma et al. 2014, Straub 2014). 
The pathway initiates at the cell surface receptor integrin αβ3, which has binding 
sites for both T3 and T4 (Davis et al. 2011). Upon binding to its site, T4 can influence 
angiogenesis via activation of the mitogen-activated protein kinase (MAPK) and 
ERK1/2 (Davis et al. 2005). At the second binding site, T3 can activate 
phosphatidylinositol 3-kinase (PI3-K). It also influences angiogenesis, but stimulates 
tumor cell division and possibly stabilization of HIF1α in addition (Hiroi et al. 2006, 
Patiar et al. 2006, Davis et al. 2009). 
Interestingly, integrin αβ3 is already a target for antitumor therapies. Tetrac, an 
inhibitor of integrin αβ3, leads to disordered cell defensive pathways and inhibition 
of neovascularization (Davis et al. 2009, Davis et al. 2014b, Lin et al. 2015). 
Treatment with Tetrac also alters the steady-state levels of mRNAs including VEGFa, 
EGFR, MMP9 and HIF1α genes. Additionally, Tetrac was found to increase 
radiosensitivity of cancer cells (Davis et al. 2014b). 
Integrins are involved in the adhesion and migration of cells. MSCs and fibroblasts 
use these cell surface molecules (De Wever et al. 2003, Fox et al. 2007, Salem et al. 
2010). Thyroid hormones have been shown to influence the invasiveness, adhesion 
and migratory capacities of different tumor cells via the integrin αβ3 (Cohen et al. 
2014). We have recently shown that thyroid hormone stimulation through αβ3 can 
also dramatically alter the tropism of MSCs for experimental tumors (Schmohl et al. 
2015). 
Within the scope of this thesis work, it was important to investigate possible 
interactions between hypoxia and thyroid hormones as both influence the tumor 
microenvironment and MSCs. Additionally, the effect of the thyroid hormones on 
MSC growth and differentiation were evaluated to round up the investigation. 
MSC biology was examined in the context of a specific tumor model, in this case 
HCC. The HCC derived cell line HUH7 served a model cancer. Importantly, this cell 
line allows a distinction between effects on MSCs and potential confounding effects 
on the tumor, as the HUH7 cell line lacks expression of integrin αβ3. 
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Figure 43: Influence of thyroid hormones on MSC-based hypoxia targeted cancer gene therapy: 
Thyroid hormones enhance MSC homing into tumors in vitro as well as in vivo. They also enhance 
hypoxia regulated gene activation in the tumor milieu under normoxic and hypoxic conditions. More-
over, MSC proliferation and differentiation can be influenced. 
4.2.1. Potential effect of thyroid hormones on MSC proliferation 
Thyroid hormones can stimulate cell proliferation (Davis et al. 2009). The results 
described here show that thyroid hormones can also increase MSC proliferation 
significantly after 72 hrs, as can treatment with HUH7 conditioned medium. 
Combining both stimuli enhances MSC proliferation even further. The stronger 
effector appears to be tumor conditioned medium, but thyroid hormones show 
additive effects. 10nM and 1000nM T4 increased MSC viability above control level. 
Tetrac dependency could not be clearly established in this experiment. This could be 
due in part to the formulation of Tetrac used. It has been shown to travel into the 
cell´s interior and cause intrinsically stimulating effects itself leading to further 
stimulation instead of inhibition. These effects could be avoided by using 
nanoparticulate version of Tetrac, which is covalently bound to poly-lactic-coglycolic 
acid and cannot penetrate the cell membrane (Davis et al. 2014b). However, this 
agent was not available for the experiments shown here.     
In conclusion, MSCs showed increased proliferation in response to tumor-derived 
signals and under thyroid hormone treatment. These observations suggest that 
thyroid hormone treatment may enhance the use of MSCs as cancer therapy 
vehicles. 
4.2.2. Potential effects of thyroid hormones on MSC differentiation 
The tumor microenvironment can drive MSC differentiation to TAFs or pericyte-like 
cells. Thyroid hormones can also influence MSC differentiation. They have been 
described to enhance MSC differentiation into chondrocytes or oligodendrocytes 
(Mackay et al. 1998, Kaka et al. 2012, Karl et al. 2014). Moreover, MSCs can also 
influence tumor growth by their secretion of growth factors such as VEGF, CXCL12, 
EGF, IL6 and CCL5 (Knoop et al. 2013). We have shown that thyroid hormones and 
tumor-conditioned medium may enhance the differentiation of MSCs into TAF-like 
cells via the integrin αβ3 pathway as demonstrated by an upregulation of respective 
markers (Schmohl et al. 2015). Davis et al. also showed a non-genomic regulation of 
angiogenesis via VEGFa as well as FGF and EGFR (Davis et al. 2014b). 
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Neovascularization is stimulated by hypoxic conditions via stabilization of the HIF1α 
transcription factor. The stabilization of HIF1α is also enhanced by T4, which occurs 
in a Tetrac dependent manner (Mousa et al. 2014). Hypoxia also leads to an 
upregulation of CXCL12, FGF, HGF, IL6 and TGFβ by MSCs (Hagenhoff et al. 2016). 
Moreover, integrin αβ3-controlled MAPK has been linked to increased MMP9 
expression (Cohen et al. 2014). In conclusion, thyroid hormones can influence gene 
regulation and differentiation in MSCs. 
In the context of this thesis, mRNA levels of a series of HIF1α regulated genes were 
examined. Under normoxic conditions, thyroid hormones increased mRNA levels of 
HIF1α and CCL5 genes in a Tetrac dependent manner. Other genes evaluated (IL6, 
VEGFa, MMP2, MMP9, CTGF, CXCL12, ID1, TGFβ, HGF) showed no induction of 
mRNA levels. Treatment with hypoxia increased mRNA levels of all genes examined. 
This increase was even higher when adding HUH7 conditioned medium (CM) 
simultaneously.  
When applying thyroid hormones, a Tetrac dependent increase in mRNA levels could 
be established for HIF1α and FGF2 genes, and for HIF1α, CCL5, IL6, VEGFa, FGF2 
and CXCL12 genes when stimulating MSCs with tumor conditioned medium in 
addition. T3 produced higher levels of induction, which could be possibly be due in 
part to the different binding sites for the thyroid hormones on the integrin αβ3 
receptor. Only T3 has been shown to activate PI3K (with downstream effects on 
HIF1α). Steady state mRNA levels of other relevant genes (TGFβ, HGF, ID1, TIMP1, 
MMP9) did not increase through stimulation with thyroid hormones. The mentioned 
results described in Schmohl et al. (2015) substantiate this data. The tumor 
microenvironment enhances MSC differentiation as evidenced by the changes in 
specific mRNA levels. Thyroid hormones enhance and modulate the response of the 
cells to tumor-derived signals. The Tetrac dependency of the effects is indicative of a 
non-genomic thyroid hormone pathway mediated effect.  
These findings suggest that thyroid hormones play an important role in the growth of 
the tumor stroma. They may enhance MSC differentiation and thus possibly indirectly 
promote growth of the cancer. Hypoxia stimulates MSC differentiation as well. 
However, the additive effects seen between the three general stimulants (hypoxia, 
CM and thyroid hormones) still have to be better defined. The general findings 
support the potential use of a hypoxia targeting strategy as a promising candidate for 
in vivo experiments.  
4.2.3. MSC hypoxia response: HIF1α protein level and HIF1α-driven reporter 
gene activation   
Signaling through PI3K and MAPK can influence HIF1α expression (Moeller et al. 
2005). Both pathways can be activated through stimulation of the integrin αβ3 
(Davis et al. 2009) suggesting that non-genomic thyroid hormone effects may also 
influence HIF1α metabolism and HIF1α regulated gene expression in MSCs. Under 
“maximum” hypoxic activation, no increase in HIF1α protein levels in response to 
thyroid hormones could be detected. However, under normoxic conditions, thyroid 
hormones, especially T3, were found to increase HIF1α protein levels. This effect 
was not strongly influenced by Tetrac treatment. Tumor milieu conditions (medium 
hypoxic stimulation with 20% HUH7 conditioned medium) also increased HIF1α 
protein levels. Adding T3 in this setting produced a Tetrac dependent increase of 
HIF1α protein levels.  
In addition, the results described here showed a significant Tetrac dependent 
induction of HIF1α-associated reporter genes under normoxic conditions. Under 
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hypoxic conditions (1% O2) the increase in hypoxia controlled gene activation was 
not statistically significant.  
In conclusion, thyroid hormones, especially T3, were found to stimulate the hypoxia 
response system in MSCs leading to a more efficient hypoxia driven transgene 
expression. As detailed above, thyroid hormones can increase mRNA levels of 
hypoxia regulated genes in MSCs, especially under tumor milieu conditions. The 
discrepancy between T3- and T4-mediated effects could again be in part possibly 
due to the different binding sites for the thyroid hormones on the integrin αβ3 
receptor. Only T3 has been shown to activate PI3K (with downstream effects on 
HIF1α). 
4.2.4. MSC chemotaxis 
Local concentrations of inflammatory chemokines and growth factors can be 
chemotactic attractants for MSCs (Knoop et al. 2013). This is especially true for the 
chemokine CXCL12, which is thought to play an important role in MSC migration 
(Spaeth et al. 2008, Penzo et al. 2014). This chemokine is upregulated during tissue 
damage or injury, and is linked to the response of a tissue to hypoxia (Semaan et al. 
2017). In addition, growth factors like EGF can stimulate MSC chemotaxis (Lourenco 
et al. 2015). 
Thyroid hormones can regulate the adhesion and migration of certain cells, e.g. 
multiple myeloma cells, via integrin αβ3 (Cohen et al. 2014). In chemotaxis assays 
HUH7 conditioned medium efficiently attracted MSCs. 24-hrs-prestimulation of MSCs 
with 1nM T3 and 1000nM T4 could increase this basic tumor directed migration in a 
Tetrac dependent manner. Thus, the results suggest that integrin αβ3-mediated 
stimulation can increase the general chemotaxis of MSCs.  
Continued stimulation with thyroid hormones during the chemotaxis assay produced 
integrin αβ3-mediated stimulation of MSC chemotaxis as well suggesting that the 
thyroidal status of a patient treated with MSC-based gene therapy should be taken 
into consideration to maximize therapeutic efficiency.  
4.2.5. MSC tumor spheroid invasion, in vivo homing and activation of trans-
genes in tumor stroma 
A lab colleague, Svenja Rühland has extensively evaluated the effects of thyroid 
hormones on MSC invasion in vitro. The HUH7 tumor spheroid model used is the 
same as described in 3.1.5. MSCs showed significantly deeper and more frequent 
invasion into 3D HUH7 spheroids upon 1nM T3 and 1000nM T4 treatment in a Tetrac 
dependent manner (Schmohl et al. 2015), which substantiates the findings of the 
chemotaxis assays described in this thesis (3.4.).  
Moreover, Schmohl et al found out the thyroidal status influences MSC recruitment 
into experimental tumors in vivo significantly (nude mice harboring HUH7 xenografts). 
MSCs were recruited increasingly to perivascular regions of the tumor and invaded 
the surrounding tumor tissue in hyperthyroid mice as compared to euthyroid mice. 
Both recruitment and invasion were reduced in hypothyroid mice, and even further 
reduced in Tetrac treated mice. Neither alteration of the thyroidal status nor Tetrac 
treatment had an effect on tumor growth (HUH7) in these experiments. (Schmohl et 
al. 2015) 
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4.3. Hypoxia targeting and thyroid hormones during MSC-based 
cancer gene therapy  
MSCs and thyroid hormones are key players in the formation of tumor stroma 
(Barcellos-de-Souza et al. 2013). Therefore, the interaction of this biology imposes 
important consequences for the therapeutic efficiency of MSC-based therapy 
approaches. MSC biology has been exploited to treat solid malignancies. Thyroid 
hormones influence both MSC migration into the tumor as well as tumor-specific 
activation of antitumor transgenes.  
4.3.1. Using hypoxia targeting for MSC-based cancer gene therapy  
Hypoxia targeting as a MSC targeting strategy, especially for fast growing solid 
tumors like HCC, represents an interesting new therapeutic approach. These tumors 
can be resistant to conventional therapies (Liu et al. 2014). The established MSC-
based therapeutic protocol using RANTES/CCL5 promoter to drive transgene 
expression shows no activation under hypoxic conditions. The activation of the 
HIF1α-responsive promoter was shown to upregulate the NIS transgene in vivo 
(Muller et al. 2016). However, the experiments showed that for general tumor 
reduction and in vivo survival the synthetic HIF1α-responsive promoter was not yet 
as effective as the RANTES/CCL5 promoter while it’s in vitro effectiveness was 
significantly higher. This may be linked in part to the use of a synthetic promoter 
here. These promoters reach specific targets very efficiently while native promoters 
respond to a wider range of signals, which leads to reduced specificity (Muller et al. 
2016). Limiting promoter activation to one specific pathway requires a promoter 
structure built of tandem repeats (in this case HIF1α-responsive elements).  
However, this structural built up also enhances in vivo recombination due to the 
multiple repeats, which limits in vivo promoter function. Furthermore, the potential 
targeting of tumor metastases using hypoxia driven approaches remains to be 
evaluated (Knoop et al. 2015). While at present, the RANTES/CCL5 promoter is the 
most efficient tumor-specific promoter in vivo, new native promoters strongly 
associated with inflammation and hypoxia represent very promising approaches for 
future experiments.  
To enhance in vivo therapeutic effectiveness of hypoxia targeting, the current focus is 
to identify native gene promoters that are responsive to a wider range of tumor 
signals. RANTES/CCL5 is not activated by hypoxia, but is activated by other tumor-
associated signals allowing effective MSC-based tumor reduction and prolongation of 
survival. Potential native promoter candidates may be found among the hypoxia 
regulated genes identified in this thesis. HIF1α, CCL5, IL6, VEGFa, FGF2 and 
CXCL12 genes are all activated in part by hypoxia, in combination with tumor derived 
signals. Angiogenesis associated gene promoters (VEGFa) are interesting targets for 
tumor therapy. Angiogenesis has been used to target MSC-based therapy 
successfully using the Tie2 gene promoter/enhancer to drive tumor-specific suicide 
gene expression (Niess et al. 2011). VEGFa contributes to MSC tropism for glioma 
and pancreatic cancer (Barcellos-de-Souza et al. 2013). Another interesting option is 
the IL6 gene. It is among the cytokines that are associated with attracting MSCs to 
breast cancer (Barcellos-de-Souza et al. 2013). The potential efficacy of these native 
promoters are currently being evaluated.  
Importantly, the above-mentioned genes were also inducible by thyroid hormone 
treatment. Therefore, in the context of NIS-based therapy, the hyperthyroid status 
used to limit damage to the thyroid gland, could also enhance therapeutic 
effectiveness, when using one of these gene promoters. 
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Figure 44: Effective tumor-specific promoters for MSC-based cancer gene therapy – synthetic 
versus native promoters: The synthetic HIF1α-responsive promoter evaluated in this thesis has the 
disadvantage of potentially being unstable in vivo due to the tandem repeat structure. Moreover, it did 
not reduce tumor load in vivo as effectively as the RANTES/CCL5 promoter did due to limited 
activation through only one pathway (hypoxia). One advantage of this approach is the induction of the 
system by thyroid hormones. The goal now is to find a stable native promoter activated by hypoxia, 
thyroid hormones and other tumor signals to reach a higher therapeutic efficiency than RANTES/CCL5 
promoter provides. Among the potential candidates are the gene promoters for VEGFa and IL6. 
4.3.2. Influence of thyroid hormones on MSC-based cancer gene therapy  
Thyroid hormone treatment enhances tumor directed MSC chemotaxis in vitro, as 
well as MSC invasion into tumor spheroid models. A hyperthyroid status in vivo 
enhances MSC homing into HUH7 xenograft tumors. Tetrac treatment and 
hypothyroid status reduced the effectiveness of MSC homing dramatically in vivo 
(Schmohl et al. 2015). These findings suggest that for any MSC-based cancer 
therapy, it may be important to assess the patient´s thyroidal status. Indeed, the 
patient´s thyroidal status may be relevant when considering the general use of 
engineered MSCs for tumor therapy.  
A survey of the literature shows that hypothyroidism has been associated with cancer 
outcome. It has been linked to tumor invasiveness and metastatic development and 
has been shown to influence the course of glioblastoma multiforme, breast cancer 
and renal cell carcinoma negatively (Martinez-Iglesias et al. 2009, Mousa et al. 
2014). A potential tumor promoting effect of thyroid hormones has to be taken into 
account as well.  
4.3.3. Tetrac as antitumor agent 
Tetrac is undergoing testing as an anticancer agent. In a nanoparticular formulation, 
it exclusively binds to the surface receptor integrin αβ3 (Davis et al. 2014b). For 
αβ3 expressing tumors, Tetrac has been shown to alter proliferation and apoptosis 
and sensitize the tumor to conventional treatment (Lin et al. 2016). This is in addition 
to indirectly reducing angiogenesis (Davis et al. 2014b).  
Most of the in vitro and in vivo effects of thyroid hormones shown in this thesis were 
found to be Tetrac dependent. In vivo Tetrac mimics a hypothyroid status, which 
leads to reduced MSC-based tumor stroma growth (Schmohl et al. 2015). This 
occurs by reducing the migration and differentiation of MSCs (Schmohl et al. 2015). 
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Tetrac may limit angiogenesis, and in αβ3-expressing tumors, directly limit growth. 
The results shown here suggest that Tetrac may also show therapeutic efficacy for 
integrin αβ3-negative solid tumors as well (Schmohl et al. 2015). 
4.3.4. Possible therapeutic improvements by prestimulation of MSCs with thy-
roid hormones 
Another possible amendment to MSC-based gene therapy is the prestimulation of 
exogenously administered MSCs with thyroid hormones. As shown in this thesis 
pretreatment of MSCs with thyroid hormones enhanced their tumor directed 
chemotaxis in vitro. It has to be established if prestimulation of MSCs enhances 
tumor migration in vivo. Furthermore, other effects of prestimulation remain to be 
evaluated, including increased viability and resilience. Integrin αβ3-mediated 
pathways have to be examined in more detail to discover the full potential of thyroid 
hormone effects on MSC biology.   
4.4. Outlook 
MSC-based cancer gene therapy is still in its early stages. We still need to better 
understand general MSC and tumor stromal biology. The applicability and effect-
tiveness of MSC-based cancer gene therapy can also be enhanced by the 
identification of better tumor-specific promoters for each tumor entity. Furthermore, 
possible immunosuppressive and cancer promoting abilities of MSCs should be 
addressed in parallel. 
Finally, MSC-based cancer gene therapy represents a next generation therapy for 
solid cancers. Due to the complicated nature of the biology at work, and the many 
steps needed for effective therapy, further optimization is required to advance the 
approach into the clinic.  
4.4.1. Effects of chronic tumor disease on patient´s thyroidal status and rele-
vance for MSC therapy 
When the NIS gene is used as theranostic transgene, patients need to be treated 
with thyroid hormones in order to reduce NIS expression in the thyroid gland. This 
helps protect the organ from treatment with radioiodine. As detailed earlier, 
hypothyroidism can influence cancer outcome (Nelson et al. 2006, Martinez-Iglesias 
et al. 2009). Hyperthyroidism has also been linked to the prevalence of certain cancer 
types (Lin et al. 2016). How then to interpret T4 substitution need for MSC/NIS-based 
cancer therapy? Transient T4 substitution in cancer patients needs to be better 
evaluated.  
4.4.2. Current limitations and risks of MSC-based cancer therapy and appli-
cation of thyroid hormones 
While MSC-based cancer therapy is a promising new approach, it is also important to 
keep risks and challenges in balance with the advantages. The isolation and 
expansion of MSCs is still challenging, and the isolated cells are fragile and 
heterogeneous. The best source for MSCs for cancer therapy has yet to be 
determined. MSCs can be isolated from bone marrow, umbilical cord blood, cord 
blood and adipose tissue (Brown et al. 2014, Hagenhoff et al. 2016). Generally, 
MSCs isolated from the bone marrow of patients or healthy donors are used. 
Immortalization, safety and the general characteristics of the modified cells need to 
be examined further. Targeting metastases also imposes further challenges in finding 
appropriate tumor-specific promoters. Possible tumor promoting effects of exogenous 
MSC application have to be considered, which have proven to be minor in 
comparison to the therapeutic effect so far (Schmohl et al. 2015). However, several 
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studies showed enhancement of tumor growth through MSC application. One 
explanation for tumor promotion could be MSCs’ immunosuppressive functions. 
Innate and adaptive immune system are influenced likewise altering the endogenous 
antitumor immunity.  
However, for transient application all these alterations seem to be of minor relevance. 
(Knoop et al. 2011). To date, clinical trials have shown mild or no adverse effects 
from MSC treatment (D’souza et al. 2015). 
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5. Addendum 
5.1. Abbreviations and Symbols 
5-FU   5-fluorouracil 
ADP   adenosine diphosphate 
AG   research group 
ARNT   aryl-hydrocarbon receptor nuclear transporter  
ATP   adenosine triphosphate 
BCA   acid 
BSA   bovine serum albumin 
°C   degree Celsius  
C57BL/6 mice C57 black 6 mice 
CAF   cancer associated fibroblasts 
CCL3 chemokine ligand 3 
CCL5 chemokine ligand 5 
CCL19 chemokine ligand 19 
CCL21 chemokine ligand 21 
CD14 cluster of differentiation 14 
CD19 cluster of differentiation 19 
CD34 cluster of differentiation 34 
CD45 cluster of differentiation 45 
CD73  cluster of differentiation 73 
CD90 cluster of differentiation 90 
CD105 cluster of differentiation 105 
cDNA   complementary DNA 
CE/CPT-11  carboxyl esterase with irinotecan 
CM HUH7 conditioned medium 
CMDA 4-[(2-chloroethyl) (2-mesyloxyethyl) amino] -benzoyl-L-glutamic 
acid 
CMFDA 5-chloromethylfluorescin diacetate 
CMV cytomegalovirus 
CO2 carbon dioxide 
CoCl2 cobalt-(II)-chloride 
CoM center of mass 
CPG2/CMDA carboxypeptidase G2/4-[(2-chloroethyl) (2-mesyloxyethyl) amino] 
-benzoyl-L-glutamic acid 
CT   cycle threshold 
CTGF   connective tissue growth factor 
CX3CL1  CX3 chemokine ligand 1 
CXCL12  chemokine (C-X-C Motif) Ligand 12 
CXCL16  chemokine (C-X-C Motif) Ligand 16 
CXCR4  chemokine receptor type 4 
DAPI   4',6-diamidino-2-phenylindole 
dl   deciliter 
DMEM  Dulbecco´s modified eagle medium 
DMSO  dimethyl sulfoxide 
DNA   deoxyribonucleic acid  
DTT   dithiothreitol 
EDTA   ethylenediaminetetraacetic acid 
EGF   epidermal growth factor 
EGFP   green fluorescent protein 
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EGFR   epidermal growth factor receptor 
ELISA   enzyme-linked immunosorbent assay 
EMT   epithelial mesenchymal transition 
ERK1/2  extracellular-signal regulated kinases 
FACS   fluorescence-activated cell sorting 
FCS   fetal calf serum 
FGF2   fibroblast growth factor 2 
FMI   forward migration index 
hBMSC  human bone marrow derived mesenchymal stem cell 
HCC   hepatocellular carcinoma 
HCl   hydrochloric acid 
HE   haematoxylin-eosin 
HEMA  2-hydroxyethyl methacrylate 
HEPES  (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid ) 
HGF   hepatocyte growth factor 
HIF1α   hypoxia inducible factor 1α 
HIFs   hypoxia induced transcription factors 
HLA-DR  human leukocyte antigen - D related 
HRE   hypoxia responsive element 
hrs   hours 
HSV-TK  herpes simplex virus thymidine kinase 
HUH7   human hepatoma cell line 7 (HCC derived) 
I   iodine 
ID1   DNA-binding protein inhibitor 1 
IGF-2   Insulin-like growth factor 2 
IL6   interleukin 6 
kDA   kilodalton 
L   liter 
M   molar 
MAPK   mitogen-activated protein kinase 
MHC II  major histocompatibility complex II 
Min   minute 
ml   mililiter 
MMP9/2  matrix metalloprotease 9/2 
Mio   million 
MRI   magnetic resonance imaging 
mRNA  messenger RNA 
MSCs   human mesenchymal stem cells 
MTA   medical-laboratory assistant 
mTOR  mechanistic target of Rapamycin 
MTT   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
n   number  
NaOH   sodium hydroxide 
ng   nanogram 
NIS   sodium iodine symporter  
nM   nanomolar 
NTC   no template control 
NTR/CB1954 nitroreductase Nfsb with 5-(aziridin-1-Y1)-2 4-dinitrobenzamide 
O2   oxygen 
p   probability value 
PBS   phosphate buffered saline 
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PCR   polymerase chain reaction 
PET   positron emission tomography 
Pg   pikogram 
PI3K   phosphatidylinositol 3-kinase 
PIPES  piperazine-N,N′-bis(2-ethanesulfonic acid) 
PLB   passive lysis buffer 
µF   microfarad 
µl   microliter 
µM   micromole 
qPCR   quantitative polymerase chain reaction 
qRT-PCR  quantitative real time polymerase chain reaction 
rcf   relative centrifugal force 
Re   rhenium 
RNA   ribonucleic acid 
Rpm   rounds per minute 
rRNA   ribosomal RNA 
RT   reverse transcriptase  
SD   standard deviation 
SDF1   stromal cell-derived factor 1 
SDS   sodium dodecyl sulfate 
Sec   second 
sFCS   stripped fetal calf serum 
SPECT  single photon emission computed tomography 
SV40   simian virus 40 
T3   3,3´,5-triiodo-L-thyronine 
T4   L-thyroxine 
TAF   tumor associated fibroblasts 
Tetrac   tetraiodothyroacetic acid 
TGFβ   transforming growth factor β 
Tie2   angiopoetin receptor 
Timp1   metallopeptidase inhibitor 1 
TPP   techno plastic products 
TR   thyroid hormone receptor 
TRAIL   tumor necrosis factor related apoptosis inducing ligand 
UV   ultraviolet 
V   volt 
VEGF   vascular endothelial growth factor 
Vzvtk/Aram  varicella zoster virus thymidine kinase with 6-methoxypurine  
arabinonucleoside 
WB   western blot 
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